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High-throughput synthesis and screening of chiral stationary phase 
media 
By Phillip Mimes 
Libraries of peptide based chiral stationary phases (CSPs), on silica-supports, were 
synthesised, packed into columns and tested for their ability to resolve racemates 
using a range of test analytes. Research focused on varying the CSP end group and 
results showed that the most important capping group was 3,5-dinitrobenzoyl. On 
the basis of initial results, CSPs were developed that used 3,5-dinitrophenylalanine; 
an amino acid variant of the 3,5-dinitrobenzoyl group, in the peptide core. 
However, these CSP were found to be unsuccessful in separating test analytes. 
Possible protein chiral stationary phase ligands were screened using a surface 
plasmon resonance biosensor (Biacore S5 1 0), using pharmaceutical enantiomers as 
analytes, to analyse possible binding characteristics, giving results that correlated 
well with the analogous screenings carried out by HPLC. 
A reciprocally designed CSP based on a single enantiomer of anthryl ethanol was 
synthesised, the key synthetic step involving the use of Sharpless asymmetric 
dihydroxylation which incorporated the key chiral centre into the molecule. This 
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HOBt 1 -hydroxybenzotriazole 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectrometry 





J coupling constant 




M multiplet, metres 
M moles per litre 
Me methyl 
Mem methoxyethoxyl methyl ether 
Mom methoxy methyl ether 
min minutes 
MIP molecular imprinted polymer 
mol moles 
mp melting point 
MS mass spectrometry 
mw molecular weight 
NHS N-hydroxysuccinimide 
NMR nuclear magnetic resonance 
Ph phenyl 
Phe phenylalanine 
ppm parts per million 
Pr propyl 





Rf retention factor (movement of compound/solvent front) 
RP-HPLC reverse-phase high performance liquid chromatography 
Rs resolution factor 
rt room temperature 
S singlet, seconds 
Ser serine 
SFC supercritical fluid chromatography 
SM starting material 
V 
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SPR surface plasmon resonance 
t triplet 
TLC thin layer chromatography 
TEA triethylamine 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
tic thin layer chromatography 
tR elution time of compound on HPLC 
Tyr tyrosine 
UV ultraviolet (EM spectrum) 
Vis visable (EM spectrum) 
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1.1 	Chiral separations 
1.1.1 	Introduction 
In 1815 the French physicist Jean-Baptiste Biot reported that he found a-quartz 
rotated plane polarized light 1  This was the first report of a molecule displaying 
what is now known as chirality. However, the initial ideas of stereochemistry 
didn't really begin until 1848, when Louis Pasteur reported hemihedral facets on 
the crystals of racemic sodium ammonium tartrate. He was able to separate the 
mirror image crystals of the isomers by the use of a magnifying glass and 
tweezers2' , the first reported chiral separation! - - 
Pasteur found that the physical properties of individual enantiomers differed from 
one another only in the rotation of a plane polarized light. This led to the 
postulation that the enantiomers had different three-dimensional arrangements of 
atoms/groups which at a molecular levels are mirror-images of each other 4 . 
Following this, the Dutch chemist Jacobus Hendricus van't Hoff5 and the French 
chemist Achille Le Be1 6, both independently hypothesised in 1874 that the 
molecular basis of chirality that Pasteur observed was due to an asymmetric 
carbon. The asymmetric carbon proposed by Van't Hoff had the correct tetrahedral 
shape, whereas Le Be!, proposed a square pyramid 3 . 
The chirality 7 of a molecule can in fact be attributed to any of the following: 1) by 
virtue of a chiral center, e.g., an sp 3 -C covalently bonded to four different groups of 
atoms; 2) restricted rotation giving rise to perpendicular disymmetric planes, such 
biaryl antroisomers and unsymmetrically substituted allenes; 3) due to a helical 
shape, such as helicenes and trans-cyclooctene; 4) restricted rotation cause by 
covalent bonding conformation, such as substituted paracyclophanes; 5) other 
special cases, such as adamantanes with differing substitutes at the bridgehead 




enantiomer. Enantiomers have the same internal energies and their physical and 
chemical properties are tantamount in an achiral environment. 
The importance of chirality in the pharmaceutical industry has been recognised for 
many years, because the pharmacological and pharmakinetic activities may vary 
between different enantiomers of the same drug 8 . Before 1992 only 10% of all 
chiral synthetic drugs on the market were sold as single enantiomers. At that time, 
the Food and Drugs Administration regulations (USA) were changed and stated 
that for any new stereoisomeric drug to be approved, both enantiomers had to be 
treated as separate substances in pharmacokinetic and toxicological profiling 9. In 
response to this in 1998, 80% of all drugs under development were single 
enantiomers 8 . Furthermore, by 2000 the worldwide annual sales of single 
enantiomer products final formulation was $131 billion and by 2005 this had 
grown to $225, representing 37% of the total final formulation pharmaceutical 
market of $602 billion 10,11 
Some pre-existing drugs have been remarketed as single enantiomers, thus 
(S)-(+)-Ibuprofen reaches therapeutic concentrations in blood in 12 minutes versus 
30 minutes for racemic mixture and has now been marketed separately from the 
racemic drug as a fast acting alternative 12, 13 (R)-Fluoxetine for the treatment of 
depression is a pure isomer of Prozac with improved efficacy and also minimizes 
adverse side effects (anxiety and sexual dysfunction). 
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There have also been horrendous examples of enantiomer specific toxicological 
effects. The most well known is that of thalidomide, where R-thalidomide is a 
sedative and S-thalidomide is teratogenic. 3 
However, although enantiomers have different pharmacological profiles, they have 
identical physical and chemical properties rendering their separation difficult as 
conventional techniques of purification cannot be used. As a consequence, 
pharmaceutical companies have had to find new and improved techniques for both 
analytical and semi-preparative chiral separations. 
Chiral compounds are also important in the agrochemical industries7' 14,  where the 
usage of non-active isomers (contained in agrochemical racemates), contribute 
towards environmental pollution and poisoning and are discouraged. 15 . They also 
have various roles of use within synthesis, specifically asymmetric synthesis', such 
as for the preparation of pure optically active compounds. They are also used in 
studies for determining reaction mechanisms, as well as reaction pathways. 
Furthermore enantiomer separations are also important in environmental" ,17 
forensic '8' 19  and nutritional analysis20 . 
1.1.2 	Chiral separation methods 
The market for optically pure products has experienced a huge increase 21  which 
has stimulated the development of asymmetric synthesis and chiral separation. The 
application of chiral technologies for pharmaceutical and agrochemical 
intermediates has been estimated to have generated annual revenues of $8 billion in 
200322 . 
Again it was Pasteur that made the first advancements in the field by studying the 
influence of one chiral compound upon another and introduced the technique of 
resolution via diastereomer formation 4. This separation of enantiomers by 




1. 1.2.1 Chiral Derivatisation 
Early methods of separating enantiomers were based on chiral derivatisation23' 24 
This method involved the reaction of a racemate with an enantiomerically pure 
chiral derivatising agent (usually a cheap natural product) to form two 
diastereomers. The diastereomers having different physical and chemical properties 
could be separated by conventional methods such as chromatography, HPLC and 
crystallisation. This method is a so called an indirect method. However it is often 
less favoured, due to the number of extra steps involved, corresponding to extra 
time, effort and poorer recovery 25 . It is successfully employed by Eli Lilly in the 
resolution-racemisation-recycle synthesis of the serotonin-norepinephrine reuptake 
inhibitor, Duloxetine26  where (S)-Mandelic acid is added to a racemic amine 
intermediate. The (S,S)-diastereomeric salt formed is insoluble, whereas the (S,R)-
diastereomeric salt stays in solution. The (S,S) diastereomer is collected and base 
hydrolysed to remove the Mandelic acid to the give enantiomerically pure (S) 
amine. 
1.1.2.2 Chiral Crystallisation 
Enantiomeric enrichment of racemates from solution or melts through chiral 
crystallisation is possible; however the feasibility of selective crystallization 
depends strongly on the whims of nature, specifically on the solid-liquid 
equilibria27 . Wallach's rule states that racemic crystals are denser than that of the 
pure enantiomer crystal 28  It follows that increased density of a crystal normally 
corresponds to higher crystalline stability and reduced aqueous solubility. 
Therefore, crystallisation of racemic solutions or melts of these materials form 
racemic crystals which are homogenous co-crystallisations of both enantiomers, 
this accounts for 90-95% of molecules29. However, there are a small proportion of 
exceptions to this, where the enantiomer forms more stable crystals than the 
racemate. In this case the crystallisation process forms crystals that contain just one 
enantiomer, but the crystals produced are a mechanical mixture of enantiomers 
giving a so-called racemic conglomerate. 
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The application of crystallization for the separation or purification of enantiomers 
requires detailed knowledge of the corresponding binary (melting point) and 
ternary (solubility) phase diagrams 29 . Figure 2 shows typical ternary diagrams of 
both racemic compounds and conglomerates. Important features of the diagram 
indicate the ternary composition required to give pure enantiomers, which are the 
shaded turquoise areas. A racemic mixture of a conglomerate type material can be 
directly crystallised into enantiomers at the appropriate solvent concentration and 
temperature. In the other case (non-conglomerate type), the racemate can only be 
separated when there is sufficient enantiomeric enrichment in the feed solution. 
The ternary diagram also shows the conditions at which racemic crystals are 
formed (light-blue shading). The one-phase areas are near the solvent corner where 
the solution is too under saturated for crystallisation. The three-phase areas are 
where a mixture of pure enantiomer and racemic compound crystallise. 
Solvent 
()-Ena,liorner E 	Racemic 	E (-)-Fnariomer 
compound  
Solvent 
(+Epnorpr 	 (-)-Enarliornec 
Racemic compound 	 Racemic conglomerate 
Figure 2 Typical ternary phase diagram of enantiomeric systems under isothermal 
conditions. 
1.1.2.3 Chiral Capillary Electrophoresis 
Capillary Electrophoresis is a versatile technique of high speed, high sensitivity 
and low limits of detection. A source vial, destination vial and capillary (20-200 




sample is then introduced to the capillary inlet via capillary action, pressure, or 
siphoning and the migration of the analytes is initiated by an electric field which is 
applied between the source and destination. All ions, both positive and negative, 
are pulled in the same direction through the capillary by electroosmotic and 
electrophoretic flow. The analytes separate as they migrate due to their varying 
electrophoretic mobility. A detector (normally UV/Vis.) placed near the end of the 
capillary determines the electropherogram. 
Chiral recognition mechanisms in capillary electrophoresis are similar to those 
found in chiral HPLC when using chiral mobile phase additives. Resolution takes 
place due to the formation of diastereomeric complexes between the chiral selector 
and the racemate enantiomers. The nature of the interactions between chiral 
selector and enantiomer depends on the type of chiral selector. Chiral separations 
are achieved in one of two ways: 1) indirect resolution is performed by 
diastereomeric complex formation followed by standard resolution by capillary 
electrophoresis; 2) direct resolution involves the use of chiral selectors in the 
background electrolyte. There are various types of background electrolyte chiral 
selectors that have been used, most of which are also used in analogous systems of 
chiral HPLC as chiral stationary phases. The most common are; macrocyclic 
antibiotics, proteins and polysaccharides as well as Pirkle type, alkaloids, crown 
ethers and cyclodextrins. Furthermore, micellular electrokinetic chromatography 
can be used as an adaptation of capillary electrophoresis, with the addition of 
sufficient surfactant, to aid the separation of neutral analytes. The disadvantages of 
this technique are in the scaling up the processes to preparative level and in the 
trouble of selection of appropriate chiral selectors. 
1.1.2.4 Super-critical Fluid Chromatography 
Supercritical fluid chromatography utilises mobile phases that are used above both 
the critical temperature (T a) and the critical pressure (P a) of the eluent 30 . The most 
commonly used fluid for SFC is carbon dioxide, as it is relatively inexpensive, non-
toxic, non-flammable and readily available. The overall setup of a SFC system is 
much the same as used for HPLC. Generally SFC is carried out using packed 
columns, which contain the stationary phase 30' 31  All columns types used for chiral 
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separation on HPLC can also be used in SFC, with the exception of protein based 
CSPs. 
SFC does not give an enhancement in enantioselectivity over chiral HPLC as they 
are analogous techniques in which chiral HPLC separations are achieved on SFC, 
with few exceptions 32, However, the reduced viscosities and increased 
diffusivities of supercritical fluids compared to liquids, mean that the pressure 
drops across the column and increases the efficiency of the column at higher flow 
rates34' . As higher flow rates can be used, separation can be carried out in 
reduced time. Although, screening on SFC can be carried out more rapidly, it does 
not remove the trial and error approach associated with method, development of 
chiral separation carried out on HPLC. SFC is complicated by the possible 
chemical interactions of the carbon dioxide mobile phase with some analytes In 
particular amines can react with the carbon dioxide in situ, therefore altering the 
results observed36' . 
Enantioseparation can also be carried out with pressures above the critical pressure 
(Pa), but keeping the temperature below critical (T a). Although the mobile phase is 
now a liquid, it still retains some of the preferential properties of a supercritical 
fluid, this technique is known as subcritical fluid chromatography. 
1.1.2.5 Simulated Moving-bed Chromatography 
Continuous counter-current chromatography or simulated moving-bed 
chromatography is an adaptation of traditional HPLC. It was first used in 
petrochemical and sugar industries for separating very large quantities of materials. 
The process involves the continuous separation of materials rather than the 






Column 	 Feed 
Mobile phase 
B 
C.oWrrkn 	 Feed 
Mobile - 
Figure 3 Principle of simulated moving bed chromatography; (A) Analyte mixture feed 
into middle of column and compounds move at different speeds along the column with 
mobile phase, (B) Column is moved in the opposite direction to mobile phase with a 
magnitude between of speeds of the compounds. 
A simulated moving-bed system consists of multiple columns connected in series 
with valves between each column which can be individually opened and closed. 
The system has multiple pumps controlling the addition of fresh solvent, injecting 
feed, remove the raffinate and extract used solvent. The valve system between the 
columns allows the operator to open or close the inlet and outlet of each column 
simultaneously. The operation of simulated moving-bed chromatography involves 
many parameters and therefore the design and process optimization are very 
complicated, therefore these systems use sophisticated computer simulations. 
Column 	 eed 0[ 




Extrad 	 ExhW  
E1 t 
 4 Simulated moving bed chromatography. numerous columns (segments) connected 
in series with continuous feed of mixture. The mobile phase inlet, feed inlet and compound 
extract points move each time a column moves from one end to the other. 
As well as the advantage that these techniques have for the separation of large 
quantities of materials; the continuous process also uses less solvent and requires 
less stationary phase. Furthermore, some racemates have small affinity differences 
between enatiomers and CSP, where it is not possible to improve resolution by 
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changing stationary phase or further optimisation of chromatographic conditions. 
In these cases, simulated moving-bed can be separated by allowing their small 
retention time differences to accumulate by utilising multiple column passes. 
However, investment and maintenance cost compared to single column operations 
are much higher; making simulated moving-bed methods generally unnecessary for 
non-large scale separations. Also the higher complexity means that each separation 
has to be extensively simulated. 
1.1.2.6 Molecular Imprinted polymers 
Molecular imprinted polymers can be used as a unique type of chiral selector in 
HPLC38 "°, TLC, SFC and CEC41' 42  Molecular imprintiun is method of 
polymerization to prepare synthetic materials that are able to mimic the molecular 
recognition found in biological systems 435. - 
The technique involves adding a target molecule with a solution of functional 
monomers. The two compounds associate to form a 'complex', which is then 
incorporated by polymerization into a highly cross-linked macroporous polymer 
matrix. Following this the target is removed to leave sites in the polymer with 
specific shape and functional group complementarity to the original print molecule. 
The polymeric material formed can then be used in various chromatographic 
systems as a chiral selector with its special recognition capacity for target 
enantiomers46 . 
As with the conventional techniques of HPLC and CE, initially screenings are 
required for the determination of appropriate CSP or electrolyte additive 
respectively. MIP have the advantage of the made-to-measure approach, where the 
order of elution is always predictable with the imprinted target enantiomer being 
more strongly bound. However, MIP's are not suitable for use with low solubility 
target molecules. There are many other disadvantages to this technique, such the 
requirement of significant quantities of enantiomeric target material 47 , low sample 





1. 1.2.7 Gas Chromatography 
As with HPLC, Gas Chromatography chiral separations are mainly performed on 
chiral stationary phases, although indirect methods are also used; where chiral 
analytes are pre-derivatised with chiral auxiliaries and separated on achiral 
stationary phases. 
The stationary phase of a chiral GC can be formed by a variety of chiral selectors 
most of which are in common with those used in HPLC. The most common are: 
amino acid or, metal coordination based and cyclodextrin inclusion type" which 
are normally covalently bound to polysiloxanes 52. As in HPLC, the analyte 
enantiomers form transient diastereomeric intermediates with the stationary phase 
chiral selector, leading to one enantiomer being more strongly bound to the 
stationary phase and therefore being retained longer on the columnIcapillary.  
The main application of chiral Gas Chromatography is in the precise determination 
of enantiomeric compositions 53, due to the technique being quick and highly 
efficient. Also it has the advantage that volatile enantiomers can be analysed 
directly from the vapour phase of the sample matrix, whereas LC and CE require 
optimization of numerous chromatographic/electrophoretic conditions, such as 
solvents, buffer pH, modifiers and gradients. However, due to the conditions in 
which GC is run, there are many restrictions to the analysis carried out. Most 
importantly the analyte has to have sufficient volatility, but also have sufficient 
thermal stability and stereochemical integrity at elevated temperatures 53 . 
1.1.2.8 Other methods of chiral separation 
Chromatography direct methods of chiral separation are based on the formation of 
transient diastereomeric complexes, rather that derivatisation. One approach called, 
Chiral Mobile Phase Additives consists of adding an enantiomerically pure 
compound to the HPLC mobile phase to generate transient diastereomeric 




this method is not widely used, because of the constant supply of the often 
expensive chiral mobile phase additive required. 
There are many other methods which are currently not routine for chiral 
separations; however they may have specific application in which they are 
appropriate. Potentiometric, amperometric and piezoelectrical enantioselective 
biosensors have been used for enantioselective analysis of chiral drugs on a 
miniaturised sca1e 5557, although, their sensitivity and biosensor lifetime are low 57 . 
Another method focuses on the use of chiral selective membranes in 
electrodialysis, where the chiral selector is a membrane which separates selections 
of the electrodialysis chamber. This is similar to capillary electrophoresis, although 
it also has the potential to be used on larger scale separations, however currently 
58 the optical enrichment provided is poor.	- 	- - 	 -. - - - - 
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1.2 	Chiral chromatography and HPLC 
1.2.1 	Chiral Stationary Phases 
Since 1980 chiral separations have been mainly carried out using a direct method, 
chiral chromatography. Chiral HPLC columns are made by immobilising single 
enantiomers onto a stationary phase. Resolution relies on the formation of transient 
diastereomers on the surface of the column packing. The compound which forms 
the most stable diastereomer will be most retained, whereas the opposite 
enantiomer will form a less stable diastereomer and will elute first. The ability of a 
given CSP to interact differently with enantiomers is called chiral recognition and 
the principles of chiral recognition have been extensively studied. To achieve chiral 
recognition and discrimination between enantiomers there needs to be a minimum 
of three points of interaction, with at least one of these interactions being 
stereochemically dependent 59, the three point rule 60 . 
The forces that lead to this interaction are very weak and require careful 
optimisation by adjustment of the mobile phase and temperature to maximise 
selectivity. Chromatography is a multi-step method where the separation is a result 
of the sum of a large number of interactions. Typically a free energy of interaction 
difference of only 0.03 kJmol' between the enantiomers and the stationary phase 
can lead to resolution. 
The intermolecular forces involved with chiral recognition are polar/ionic 
interactions, pi-pi interactions, hydrophobic effects, hydrogen bonding dipole-
dipole (Keesom), induced dipole-dipole (Debye) and London dispersion forces 1 . 
These can be augmented by the formation of inclusion complexes and binding to 




1.2.2 	Chiral Stationary Phase Types 
Chiral Stationary Phases (CSPs) may be classified according to their interaction 
mechanism with the racemate. A scheme for classification was first proposed by 
Wainer 61 : 
1.2.2.1 Type I CSPs (Pirkie or Brush type) 
These differentiate enantiomers by the formation of complexes based on attractive 
interactions. These may be hydrogen bonds, pi-pi interactions, dipole stacking. The 
columns within this group are mainly the result of the work of Pirkle62' 63  and co-
workers. Pirkle applied work on chiral NMR to HPLC stationary phases in the 
1960's, by a process of reciprocal design, that is immobilising analytes, onto solid-
phases, that had given large 'resolutions' on earlier chiral stationary phases in 
solution. 
Pirkle type CSP's fall into three classes: t-electron acceptorshr-electron donors 
(e.g. Whelk-0, ULMO), t-electron acceptors (e.g. Phenylglycine, f3-Gem 1, a-
Burke 2, Pirkle 1-J) and t-electron donors (e.g. Naphthylleucine). They are 
generally made up of small molecules covalently bound to silica, meaning the 
columns exhibits high durability without the leaching of chiral selector into the 
mobile phase. Chromatography with Pirkle columns is generally run in normal 
phase mode, but is also extensively used in reverse phase mode. Further details of 
synthesis and usage of Type I CSP are in section 1.3. 
1.2.2.2 Type II CSPs 
1.2.2.2.1 Polysaccharide 
Most type II phases are based on polysaccharide derivatives. Polysaccharides can 
be immobilised onto the silica support, via absorption onto the surface of the 
silica 64, 65 The chemically modified polysaccharide can be immobilized onto a 
vinylised silica gel via a radical co-polymerization reaction 66, polycondensation of 
triethoxysilyl groups 67,68  or by covalent bonding using an inert linker to the silica 69 . 
The chiral selector is normally cellulose or amylase based with a large number of 
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Figure 5 Left: a modified cellulose chiral selector found in type II CSPs. Right: a modified 
amylase chiral selector found in type II CSPs; the R groups represent the point of variation 
for many commercialised columns. 
There are many different derivatised polysaccharide based CSP available, each 
with their own specialised uses. These include: 3,5-dimethylphenylcarbamate for 
both cellulose 70, 71 (e.g. Chiralcel-OD®) and amylose 7173 (e.g. Chiralpak-AD(g), 
these columns have good generality use and can separate a large range of racemates 
and are particularly effective for aromatic, amide, carbamate and ester groups as 
well as alkyl amines, and compounds with multiple stereogenic sites; 1-
phenylethylcarbamate for amylase 72  (e.g. Chiralpak-ASS) and 4-methylbenzoate 
for cellulose 74  are particularly effective for 13 lactams, epoxides, acids, natural 
products and heterocyclic compounds. (Chiralpak-OJ(V); acetate for cellulose 
(Chiralcel-OAS), this is a special column suited for low molecular weight 
racemates; 4-chlorophenylcarbamate 73 (e.g. Chiralcel-OF®), which is a very 
retentive column and especially suited for prostaglandins. All of the above column 
phases are produced by coating the polysaccharide onto silica, which renders some 
higher polarity solvents incompatible 75 , due to problems of leaching. Recently, 
Chiralpak IA amylose 3,5-dimethylphenylcarbamate and Chiralpak lB cellulose 
3,5-dimethylphenylcarbamate columns, with polysaccharides immobilized on silica 
gel, were launched onto the market; they can be used with a wide range of 
solvents 76. They also show some amount of complimentarity in comparison with 
similar coated colunms77' 78• 
There are a number of sites in each derivative which may interact with functional 




interactions, dipole—dipole stacking and hydrogen bonding. These interactions are 
relatively weak and are considered to be more effective under normal-phase 
conditions79 . Although, normal-phase conditions are most popular with 
polysaccharide based CSP80' 81,  both reverse phase 79, 81 and polar-organic 8 ' eluents 
have been successfully employed. 
1.2.2.2.2 Synthetic helical polymers 
Helical polymers are another type of CSP that can interact with analytes by 
forming inclusion complexes. However there is limited research into their 
application. Unlike biological macromolecules of proteins and nucleic acid where 
the helical nature is determined by the homochirality of their components, the 
absence of chirality from the building blocks of synthetic helical polymers leads to 
equal preference of right and left-handed helices 82. A predominance of one helix 
can be attained by - the used of chiral monomers or via the use of asymmetric - - - 
polymerisation 82, ". Although certain helical polymers can resolve a range of 
racemates, details of the molecular recognition mechanism are not widely known 
and advantages of these over polysaccharide based CSP seem limited 84 . 
1.2.2.3 Type III CSPs 
This category is for macrocyclic based CSP, with chiral selectors based on 
cyclodextrins, glycopeptides and crown ethers. They rely on the solute entering 
into chiral cavities to form inclusion complexes. 
1.2.2.3.1 Cyclodextrin CSPs 
Cyclodextrins are cyclic oligosaccharides containing six or more 
D-(+)-glucopyranose units, which are bonded through a-(1,4) linkages. They are 
the most widely used type of chiral selector in chiral GC; they are also very 
commonly used in CE. The classic inclusion complex column is the cyclodextrin 
type of column developed by Armstrong 62. Although generally they are not first 
choice in HPLC and SFC, currently there are many commercialised cyclodextrin 
CSP columns which are successful for enantioseparation using all mobile phases 
modes. Hydroxypropyl--cyclodextrin 85 (e.g. Cyclobond I RSP) and aromatic 
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derivatised cyclodextrin 86 (e.g. Cyclobond I DMP) are very widely used and 
effective for many enantioseparations. 
Figure 6from left to right: a, fi and y-cyclodextrin. 
When in reverse phase mode, the interaction mechanism is dominated by formation 
of hydrophobic inclusion complexes (Figure 7) and hydrogen bonding interaction 
at the mouth of the cyclodextrin cavity. In normal and polar organic phase modes 
dipole-dipole forces play a role in the interaction between analyte and the 
immobilised cyclodextrin. 
Figure 7 Formation of inclusion complex between analyte enantiomer and cyclodextrin 
Cyclodextrin based CSPs can be synthesized by immobilization of monoazido 
functionalised Cyclodextrins onto the surface of amino functionalised silica gel via 
stable urea linkages using a Staudinger reaction87' 88,  or by forming a reactive 
siloxane intermediate using hydrosilylation with triethoxylsilane followed by its 
coupling with silica gel 89 . The main advantages of cyclodextrin CSP are their ease 
of preparation, broad applicability and cost. However, the kinetics of host-guest 





1.2.2.3.2 Crown ether CSPs 
Crown ethers are macrocyclic polyethers which form stable inclusion complexes 
with alkali, alkaline-earth and primary ammonium cations. They were first 
synthesised by Pedersen 90  and then adapted into chiral crown ethers by Lehn 9 ' and 
Cram92' It was Cram who used the chiral crown ethers for enantioseparation, 
first using them as a chiral mobile phase additive 94  then later as a CSP 95 . 
Chiral crown ether CSPs are powerful tools for the separation of chiral molecules 
containing primary amino groups in reverse phase mode with acidic additives. 
Chiral recognition is based on the formation of inclusion complexes between the 
primary ammonium ion and the crown. Crown ethers are covalently bound to silica 
in CSP synthesis such as in the commercialised column Sumichiral OA-8000 
(Figure 8)9698.  However, the use of acid in the mobile phase means that the 
durability of a crown ether column is a concern. This problem has been recently 
overcome by the use of phenolic substituents in the CSP (Figure 8)' 100  Phenol in 
the mobile phase is sufficient to form ammonium ions from amine analytes; so it 
can be used in normal phase mode' ° '. The major disadvantage of crown ethers as 
chiral selectors is their limited range of racemates which can be effectively 
separated. Currently a large array of primary amines and secondary amines, 







Figure 8 left: Crown ether CSP by Hirose; right: Sumichiral OA-8000 '° 
1.2.2.3.3 Macrocyclic antibiotics 
In the past decade, macrocyclic antibiotics have proved to be an exceptionally 
useful class of chiral selectors for the separation of enantiomers of biological and 




the use of glycopeptides; avoparcin, teicoplanin, ristocetin A and vancomycin 
(Figure 9) have been used to resolve more racemates than with all the other 
macrocyclic antibiotics combine& 03 . 
Vancomycin-related antibiotics bind to the bacterial cell wall peptide 
D-Ala-D-Ala-OH, thus blocking the process of wall-building of Gram-positive 
bacteria under aerobic and anaerobic conditions' 04' Since the target of these 
antibiotics is the D-Ala-D-Ala group, in 1994 Armstrong used them in the 
separation of amino acid enantiomers' 06 . Macrocyclic antibiotics possess several 
characteristics which allow them to serve as chiral selectors. They posses a number 
of stereogenic centres and functional groups, this allows them to have multiple 
interactions with chiral analytes. Different antibiotics may be acidic, basic, or 
- neutral, and can have little or no UV—Vis absorbance. The macrocyclic antibiotics - 
can interact by hydrophobic, dipole-dipole, it-it interactions, hydrogen bonding, as 




Figure 9 Vancomycin binding to D-Ala-D-Ala. 
Macrocyclic antibiotics CSPs are synthesized by the covalent linkage of antibiotics 
to silica gel using a variety of chemistries. This ensures their stability while 
retaining their chiral recognition properties 110112 As the glycopeptides have 
hydrophobic, hydrophilic and ionisable moieties, this gives them good solubility in 
aqueous solution. Furthermore, unlike protein based CSP, glycopeptide based CSP 
can be used in normal and polar organic mode without irreversible change or 
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denaturation. They can also be derivatised to alter their enantioselectivity"°' 112 
Also, glycopeptide CSPs in general have good complimentarity to each other; 
partial separation of an analyte on one can often be completely resolved on another. 
1.2.2.4 Type IVCSPs 
Type IV CSPs separate by means of diastereomeric metal complexes. This 
technique is also known as Chiral Ligand Exchange Chromatography (CLEC) and 
was developed by Davankov"3' 114  It was the first practical approach for the 
resolution of amino acids on HPLC and is now an especially effective method for 
separation of amino acids, amino acid derivatives and hydroxy acids. 
In ligand exchange chromatography the retention of analytes occurs by the 
reversible formation of metal complexes by the coordination of the analyte 
molecule, which acts as a ligand to the metal ion. In traditional CSP based 
separation, a chiral amino acid-copper complex is bound to silica or a polymeric 
stationary phase. Racemic amino acids may then be separated by the formation of 
diastereomeric copper complexes. Copper ions are also included in the mobile 
phase to ensure there is no loss of copper from the complex. The Cu 2 or other 
metal ions form diastereomeric complexes with the chiral analytes, where the 
complexation is kinetically labile and separation occurs due to differences in the 
thermodynamic stabilities between the enantiomers and the divalent cation 115 
As well as CSP based ligand exchange chromatography, amino acids have also 
been successfully separated using ligand exchange molecules as chiral mobile 
phase additives and as chiral coated phases, where reverse phase silica is coated 
with a hydrophobic derivative of the complexing chiral selector 116 However, 
ligand exchange chromatography is not a widely used technique. Due to the 
constraints in the formation of diastereomeric complexes at the metal binding sites, 
there are strict limitations to which chiral molecules can be successfully separated. 
Only ionisable analytes with hydroxyl or amino substituents a to a carboxylic acid 
are appropriate for the formation of the diastereomeric complexes necessary for 
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resolution' Furthermore, ligand exchange chromatography is further complicated 
by the necessity of UV absorbing copper salts in the mobile phase' '. 
1.2.2.5 Type VCSPs 
Proteins CSPs are defined as Type V CSPs where separations rely on a 
combination of hydrophobic and polar interactions. In 1973, it was first 
demonstrated that protein could be used for chiral resolution, whenStewart" 7 used 
bovine serum albumin on agarose to separate D,L-Tryptophan. Since then, various 
proteins were being used as chiral selectors in HPLC; glycoproteins such as a,-acid 
glycoprotein" 8 ovomucoid' 19,  ovoglycoprotein' 20, avadin' 21 and riboflavin binding 
protein ' 22; albumins such as bovine serum albumin 123  and human serum 
albumin' 24 ; enzymes such as trypsin' 25 , cellobiohyrolase 1126,  lysozyme'27 
pepsin 128,  a-chymotrypsin'  29  and amyloglucosidase' 30; and other proteins such as 
I3-lactoglobu1in'' and ovotransferrin 132 have all been used. 
Enantioseparation of analyte racemates using protein CSPs occurs due to multiple 
possible intermolecular interactions between enantiomer and protein surfaces. 
Some proteins are specifically good for resolution of acid, basic or neutral 
racemates, while others are particularly effective for certain types of analytes' 33 . To 
use proteins as chiral selectors, the protein has to be incorporated into the 
stationary phase whilst also maintaining the protein's natural conformation which 
is essentially for analyte resolution. This has been achieved in a number of 
different ways, the most common of which is immobilisation via covalent 
attachment using silica, agarose or other polymer as the base material. Further 
details of synthesis and usage of Type I CSP are given in section 1.4. 
1.2.3 	Silica 
Although porous polymer and other materials are used as solid-phase supports in 
HPLC stationary phase packings, silica is by far the most used material, due to its 
high mechanical robustness allowing high operating pressures. for long periods 
while displaying low backpressures as well as high column efficiency 134 . Perfusion 




very large pores (4000 to 8000 A) throughout the support and also include a 
network of smaller interconnecting pores (300 to 1000 A) between these large 
through-pores 25 . However, the most appropriate particles are totally porous 
microspheres which are available in various different diameters, pores sizes and 
surface areas. They provide high efficiency, sample loading and durability. They 
can be used for separating small molecules, when particles are 3-15 tim, pore sizes 
are 70-120 A and surface area 150-400 m 2g', but separation of macromolecules 
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Silica chromatographic fJ icaxerol  
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(a) Hydrolysis and polycondensation, (b) Condensation and gelling, (c) Condensation, 
ageing and dehydration, (d) Hydrothermal treatment and sieving. 
Figure 10 Formation of silica particles 
Manufacturing of porous silica is most frequently achieved via the sol-gel ' 35 
process starting from sodium silicate solutions, silicon tetrachloride or 
tetraalkoxysilanes, where the conditions employed can be used to control the 
particle shape, particle diameter, pore size and surface area generated (Figure 10). 
For optimal use in HPLC the silica particles should contain a fully hydroxylated 
layer of silanol groups (SiOH), with a concentration of about 8 .tmo1m2 136  These 
silanol groups can be chemically modified with a wide variety of different 
functiona1ities' 3740; which can be used to alter the polarity of the stationary phase 
or to tether other molecules to the silica particle. Chemical modifiers include alkyl, 
aryl, halogen, hydroxyl, amine, carbonyl and carboxylic acid groups, which can be 
achieved using a number of different methods with the most applicable being 





Si—OH + Z—Si—R 	 Si—O-Si-R + HZ 
Scheme 1 Functionalising silica surface via siloxane formation. 
1.2.4 	Liquid Chromatography Variables 
C) 	 c..1 
tfj > 	tR2 
Figure 11 Standard chromatographic conditions. 
Retention factor 	 k = (tR-tO) I to 
The capacity factor, k, of a sample component is a measurement of the degree to 
which that component is retained by the column relative to an unretained 
component, and to is the elution time of the unretained component representing the 
column void volume. 
Selectivity factor 	 a = k2 I k 1 
The selectivity parameter a, is a measure of the ability of the column to separate 
peaks 1 and 2 due to different affinity and therefore retention. 
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Resolution factor 	R = 2 (tp - tRI) / (W2 + W 1 ) 
W is the peak width of the component, R measures the quality of separation of two 
adjacent peaks, where W 1 and W2 are the peak base widths of peak 1 and peak 2 
respectively. 
Theoretical plates 	N = 16 (tR / W) 2 = 5.54 (tR / WI/2)2 
W 1 '2  is the width at half the peak height, 16 is a factor carried over from distillation 
theory. N is the number of theoretical plates, which represents the efficiency of a 
column. N is the measure of the band spread of a peak throughout the 
chromatographic system. The smaller the band spread, the larger the N and the 




1.3 	Type I CSPs (Pirkie or Brush) 
Low molecular mass selectors linked to a solid support form the type I class of 
stationary phase (also called brush, Pirkle or donor-acceptor type phases), in which 
the individual chiral molecules are evenly distributed onto the surface of the silica. 
fl 	PB ----- PA 
Z1 % ~—Y 
Li 	0H-------Z 2  
fl 	PBX" y 
Li- H"H" Zl %~—PA  Oft------Z 2 
Z' = carbonyl hydrogen bond receptor, Z 2 = hydrogen bond receptor, PB = 7r-base, PA = it- 
acid 
Figure 12 Three-point interaction of Pirkie type CSP with enantiomers 
Work by Pirkie in 1979 using rationally designed chiral columns based on the 
three-point interaction rule was the basis for type I CSPs 145 . Whilst working On 
NMR shift reagents, he observed that chiral fluoroalcohols such as 2,2,2-trifluoro-
9-anthrylethanol interacted with a wide number of solutes to form two 
diastereomeric two-point chelate-like solvates146' 147  There were three points for 
interaction with the third needed to obtain a stereochemically dependent 
interaction; these were hydrogen bonding, carbonyl hydrogen bonding and it-it 
donor-acceptor (Figure 12)148 149 Using this approach Pirkle was able to separate a 
number of 3,5-dinitrobenzoyl derivatised amines, alcohols and mercaptans. From 
this work Pirkle used the principle of reciprocity to design 'second-generation 
CSPs', such as the well known phases of 3,5-dinitrobenzoyl phenyiglycine and 3,5-
dinitrobenzoyl leucine, which were capable of separating a wide range of analytes 










The reciprocity concept was also used in development of other commercially 
available CSP, such as WHELK-O 1 (Figure 13) which was especially designed for 
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Figure 14 DACH-DNB chiral stationary phase 	- 	 - --------- 
Another series of CSP have used the trans-1,2-diaminocyclohexane (DACH) 
molecule as a potential new chiral selector'50' 151,  because of beneficial results 
obtained on using some DACH derivatives as chiral auxiliaries in the field of 
asymmetric induction. This research has lead to the commercially available 
DACH-DNB columns which have been used to separate a large range of racemates, 
further more the DACH was used for a series of hybrid polymeric chiral 
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Figure 15 Amino acid based CSPs 153 ' 55. 
A large number of CSP have been based on the use of amino acids as they 
possesses many qualities which make good chiral selectors ' 53 ' 55 . They inherently 
have chirality with each enantiomer being readily available, and are appropriate for 
the solid-phase synthesis which may be appropriate in synthesizing CSP. In recent 
years there have been extensive examples of totally synthetic chiral selectors being 
used in chiral stationary phases with mixed results' 56159 . 
Type 1 CSPs can separate a wide spectrum of racemic compounds, such as alkyl 
and aryl carbinols, aryl substituted hydantoins, lactams, succinamides, phthalides, 
sulfoxides, sulfides, amides and imides 14. For racemic analytes having amino, 
carboxyl and hydroxyl polar functional groups, they have to be made less polar by 
derivatisation as they interact too strongly with the CSP when underivatised. 
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1.4 	Protein type V chiral stationary phases 
1.4.1 	Introduction 
Protein-based CSPs are of special interest because of their unique enantioselective 
properties and because they are capable of separating a wide range of different 
racemate types" 160  The CSP can be made up of native protein, protein fragments 
or modified protein and rely on many different types of interaction with the analyte 
to achieve resolution. 
1.4.2 	Types of protein CSP 
1.4.2.1 Glycoproteins 
Glycoproteins are proteins that contain oligosaccharide chains (glycans). a 1 -acid 
glycoprotein' 18 ovomucoid' 19 ovoglycoprotein 120, avadin 12 ' and riboflavin binding 
protein 122  are glycoproteins that been used in CSP columns. Human a 1 -Acid 
glycoprotein contains one peptide chain of 181 amino acids and has five 
polysaccharide moieties, whilst it also contains 14 sialic acid residues (a 
monosaccharide containing a nine carbon backbone and acid functionality) which 
gives the protein an acidic character and a isoelectric point of 2.7 16 1  and was first 
used as a CSP by Hermansson 118 AGP based CSP columns have been showed to 
separate a large range of different compounds' 60' 162-164  although the retention and 
enantioselectivity depend greatly on the chromatographic conditions used, 
especially the use of modifiers which can affect the hydrogen bonding properties 165 
as well as pH and temperature which cause a conformational change in AGP 
structure166' 167 
Ovomucoid, ovoglycoprotein and avidin from chicken egg white were first used as 
chiral selector in CSPs by Miwa119' 121  Ovomucoid CSP columns have been 
utilised in separating drug enantiomers and in assaying of enantiomers in biological 
fluids' 169  Avidin which has an isoelectric point of 10 has been applied mainly to 
the separation of acidic and neutral compounds'21' 170, 171 Riboflavin samples from 




reported as separating a small number of racemates in chromatography although 
these are more commonly used for capillary electrophoresis. 
1 .4.2.2Albumins 
Bovine Serum Albumin (BSA) and Human Serum Albumin (HSA) have both been 
used as chiral stationary phases to successfully separate a variety of enantiomeric 
forms. BSA and HSA are closely related and therefore share many binding 
characteristics; both have an isoelectric point of 47174  They have been 
immobilised onto agarose, silica' 75177, hydroxyethylmethacrylate 178, polystyrene 
divinylbenzene perfusion beads 179 and polyethylene hollow fibre membranes' 80 . 
Some CSPs have been based on the use of BSA fragments; Anderson used a 
38000 Da fragment that was obtained by enzymatic cleavage which was adsorbed - - - 
onto silica, but results showed this was poorer than BSA in resolving racemates 181 . 
Kaginaka used an isolated fragment of mass 35236 which gave mixed results 
compared to whole BSA'82' 183  Although BSA and HSA have similar binding 
characters, there are some differences such as with Warfarin, where (S)-Warfarin 
elutes before (R)-Warfarin on a column using an HSA based CSP, but the elution 
order reverses when using a BSA based CSP column 124 . 
1.4.2.3 Enzymes and other proteins 
Trypsin and a-chymotrypsin are serine proteases and were first used as CSP by 
Theolohan 125 and Wainer 129, they have been used to separate amino acids, amino 
acid derivatives and a range of other compounds'25' 184 Cellobiohydrolase I is one 
of four major cellulases produced by the fungus Trichoderma reesei185 and has 
been used to resolve the enantiomers of a range of compounds especially 3- 
blockers, whereas other cellulases were not good186' 187  Marle used fragments of 
cellobiohydrolase I to determine that the majority of the enantiomeric resolution 
was attributed to the core structure rather than the flexible region and binding 
domain' 88 . Lysozyme and pepsin have both been used for the separation of basic 
and uncharged enantiomers'27' 128  although immobilised pepsin has been shown to 
irreversibly denature above pH 7128  Amyloglucosidase, ovotransferrin and 13- 
lactoglobulin have also been used as CSP, but their applicability is limited'30132. 
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1.4.3 	Synthesis of protein chiral stationary phases 
There are two methods for generating CSP by the immobilisation of proteins; either 
by physical adsorption onto the solid phase or by covalent binding. Although chiral 
stationary phases have generally been silica-based, many other materials have been 
used for coating of proteins such as zirconia, anion exchange silica, hollow fibres 
and poly(vinylimidazole) coated silica. Immobilisation by adsorption is a quick 
approach to generating a protein CSP and can be done in situ by passing protein 
solution through a packed column, however as protein molecules are linked to the 
solid-phase by only weak interactions there are significant problems with column 
stability and long term use. 
0 










(a) NN'-disuccinimidyl carbonate, (b) protein, (c) ethanolamine/water, (d) gluteraldehyde, 
(e) protein, (f) NaBH 3CN, (g) N,N'-disuccinimidylsuberate, (h) protein, 
(i) ethanolamine/water, (j)  EDC, HSSI (N-hydroxysulfosuccinimide), (k) protein. 
Scheme 2 Synthesis ofprotein CSP using aminopropyl silica 
The preferred method for immobilisation of proteins is via covalent attachment, 
which uses derivatised silica material for the binding of proteins. The three most 
common types of silica for protein immobilisation are amino-silica (normally as 
aminopropyl silica); diol-silica and epoxy-silica. Each have various means for the 
attachment of the protein which is normally achieved through either terminal or 
amino acid side-chain amine or carbonyl groups. 
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For amino-silica (Scheme 2) the most commonly used method involves the 
activation of aminopropyl silica with NN'-disuccinimidyl carbonate (DSC), 
followed by binding of the protein, through side-chains of Lys, Arg and N-terminal 
amine groups. Another procedure similar to this uses NN'-disuccinimidylsuberate 
(DSC) and leads to an immobilised protein with a six carbon spacer between the 
two amide bonds, which leads to increased flexibility and availability of the 
immobilised protein, but due to the nature of the spacer it may hydrophobically 
interact with the analyte thus reducing the CSPs resolution. Proteins can also be 
bound to aminopropyl silica with the use of glutaraldehyde, by the formation of 
Schiff-bases firstly with aminopropyl silica followed by protein amine groups, the 
imine groups are then reduced using sodium cyanoborohydride. Another method of 
immobilisation is via peptide coupling reaction of protein to aminopropyl silica 
through the proteins carboxyl groups using 1-ethyl-3-(3-dimethylaminopropyl) 









(a) CDI, (b) protein, (c) tresyl chloride, (d) protein, (e) H 5 106 , (f) protein, (g) NaBH4 , 
(h) HCI (0.1 M), (i) protein. 
Scheme 3 Synthesis ofprotein CSP using diol and epoxy silica 
Diol-silica (Scheme 3) also requires activation prior to protein immobilisation; this 
is most commonly achieved in one of three ways. Diol-silica can be activated with 
1,1' -carbonyldiimidazole (CDI), followed by binding of the protein, through side-
chain Lys, Arg and N-terminal amine groups. The diol-group can also be activated 




by reductive amination using sodium borohydride. Protein immobilisation on 
epoxy-silica (Scheme 3) can be achieved either via ring opening with HC1 (0.1 M) 




1.5 	Surface plasmon resonance 
1.5.1 	Introduction 
Surface plasmon resonance is a phenomenon first discovered by Turbadar' 89, when 
polarized light, under conditions of total internal reflection, strikes an electrically 
conducting layer at the interface between media of different refractive index. 
At an interface between two transparent media of different refractive index 
(e.g. glass and water), light coming from the side of higher refractive index is 
partly reflected and partly refracted. Above a certain critical angle of incidence, no 
light is refracted across the interface, and total internal reflection is observed. 
While incident light is totally reflected the electromagnetic field component 
penetrates a short (tens of nanometers) distance into the medium of a lower 
refractive index creating an exponentially detenuating evanescent wave 190 . 
Figure 16 Total internal reflection: n1 and n, are differing refractive index media (ii, > n2). 
The incident ray a Oj (red) is below the critical angle and is refracted and reflected, 
whereas ray at 02 (blue) is above the critical angle and undergoes total internal reflection. 
On a metal surface the collective vibrations of an electron gas/electron density 
surrounding the atomic lattice sites of the metal are called surface plasmons or 
surface plasma polaritons. Surface plasmon resonance can occur when a thin layer 
of the metal (normally gold) is placed at the interface of the two differing refractive 
index media. Using monochromatic and plane polarised light a resonance energy 




and surface plasmon wave vectors match. This produces a reduction in intensity of 
reflected light at a certain angle. The wave vectors of the metal surface plasmon 
which determine the angle at which the reflected light intensity minimum occurs, 
depends on the nature of the metal surface and the medium in close proximity to it. 
Therefore the resonance conditions are influenced by the refractive index of the 
bulk media above the metal (gold)190' '' 
Surface Plasmon 
1.5.2 	Surface Plasmon resonance biosensors 
Surface plasmon resonance biosensors use monochromatic light focused as a 
wedge-shaped beam on the total internal reflection interface and the angle of 
minimum reflectance intensity is determined using a detector. The sensor chips use 
a gold layer as the metal and the surface coating of the sensor chip and the 
surrounding sample solution is the low refractive index medium. Biomolecular 
interactions occurring at the sensor surface change the solute concentration and 
thus the refractive index changes near to the sensor chip and within the evanescent 
wave penetration range. The angle of incidence required to create the SPR 
phenomenon (the SPR angle) is therefore altered and it is this change which is 
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Figure 17 SPR biosensor system measuring interaction. 
Immobilised biomolecules on the sensor chip surface interact with the materials 
flowing over the sensor through a flow channel by binding or dissociation. The 
interaction causes a change in angle, which is proportional to the mass of bound 
material and is recorded in a sensorgram. When sample is passed over the sensor 
surface, the sensorgram shows an increasing response as molecules interact and the 
response remains constant if the interaction reaches equilibrium. When sample is 
replaced by buffer, the response decreases as the interaction partners dissociate. 
There are numerous manufacturers of SPR biosensors; Biacore International AB 
(Uppsala, Sweden) is one of the leading companies in SPR technology and have 
marketed many systems which cover a range of applications{Biacore, Accessed on 
10/12/07 #374}. Of the current systems Biacore A100 and Biacore Flexchip focus 
on automated array SPR measurements, whereas Biacore X100 and Biacore T100 
are automated non-array type. Other varieties; Biacore 3000 has an SPR-MALDI 
interface; Biacore C specialises in determining the active concentrations of protein 
therapeutics and vaccines; and Biacore X for manual single measurement 
usage{Biacore, Accessed on 10/12/07 #374}. Other companies such as Sensata 
Technologies (Attleboro, MA, USA) manufacture the Spreeta model, which can be 
considered a low cost SPR system and Lumera Corp. (Bothell, WA, USA) which 
uses SPR to analyse high-density microarrays in a flow cell in its Proteomic 




1.5.3 	Uses of SPR biosensors 
SPR is a surface sensitive technique which is ideal for studying interactions 
between immobilised biomolecules and a solution phase analyte. A molecular 
interaction can be monitored as long as one of the interaction partners can be. 
immobilised onto the sensor chip. It has many advantages over conventional 
techniques such as fluorescence or ELISA, most significantly because the 
technique uses measurement based on refractive index changes, meaning that the 
analyte does not require labelling such as radioactivity or fluorescence, or special 
characteristics such as scattering bands' 95 . It can also be detected directly rather 
than via multistep detection protocols used in sandwich as5ay'95' 196  SPR also is 
capable of detecting analytes over a wide range of molecular weights and binding 
affinities. 
Data from an SPR biosensor can be used for the determination of many factors: 
Specificity, whether the binding partners have a binding affinity or not; Kinetics, 
rates for complex formation and dissociation; Affinity, the strength of binding 
interaction is determined at equilibrium as a function of sample concentration and 
concentration, this can be determined using a binding calibration curve. SPR 
biosensors can provide data for numerous applications, for example: Drug 
screening, where interactions between small molecules and immobilised proteins 
give details on potential drug candidates binding characteristics' 97 ' 99 ; Kinase 
analysis, where small kinase systems can have affinities, kinetics and 
thermodynamics fully characterised 200, 201; Immunoassay sensing, which can 
provide high sensitivity, selectivity, speed and reliability in carrying out direct 202 , 
sandwich 203 , displacement204 and indirect205 competitive inhibition assays; Cell 
signalling pathways, where kinetic and thermodynamic data can help determine 
inherent pathways 206, 207; Antibody development, in which potentially therapeutic 





1.6 	Reciprocal based chiral stationary phases 
In most cases, the processes of selecting successfully effective chiral selectors have 
been done on the basis of the trial-and-error 209. However, Pirkie and others have 
successfully employed the concept of reciprocity of chiral recognition in designing 
chiral selectors rationally 209215 . Based on the idea that if an immobilised 
enantiomer (+)-A as a CSP could separate a given racemate (+)-B and (-)-B, the 
counter argument should hold that an immobilised enantiomer of (+)-B as a CSP 
will be able to separate racemate (+)-A and (-)-A. 
1.6.1 	Uses of Reciprocal designed CSPs 
Reciprocally designed CSPs have been used for the determination of appropriate 
chiral selectors for a given target molecule. Pirkle used this method to develop a 
CSP for separating the anti-inflammatory drug naproxen 153 ' 216 ' 217 by immobilising 
(S)-naproxen and using it to screen potential naproxen chiral selectors. The 
developed CSP was then also successfully employed in separating other non-
steroidal anti-inflammatory drugs' 53 . Frechet used a combinatorial approach to 
discover new, potentially useful chiral stationary phases 210, 218-222 such as using the 
Ugi multicomponent condensation reaction to create large numbers of analytes and 
screening these as leads for CSPs 220 . 
However, the use of reciprocity in chiral resolution should not be relied on to give 
effective results. In work by Hyan the use of reciprocally designed CSPs gave 
opposing results to what was expected, firstly with CSPs based 3,5-dinitrobenzoyl-
a-amino acid amides and esters 209  and also with proline-3,5-dimethylanilide based 
CSP213 . Reciprocal systems of chiral recognition are not intrinsically mirror images 
of one another, where success of one resolution would not exclude failure of the 
reciprocal arrangement223' 224 As well as this there are numerous other factors 
which can contribute towards non-reciprocal behaviour such as the structural 
changes necessary for immobilisation of the reciprocal CSP. The nature of the 
immobilisation can affect the energies involved in the resolution 153  and differences 




1.7 	Synthesis of non-proteinogenic a-amino acids 
As a-amino acids are the fundamental building blocks of proteins as well as 
peptides there has been enormous amount of research focused on their synthesis. In 
order to modify the physical and biological properties there have been many 
reports on the use of non-proteinogenic a-amino acids 225229 . 
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Scheme 4 Synthesis of a-amino acids: A = alkylation of an acetamidomalonate, 
B = nucleophilic substitution of a-halocarboxylic acid, C = Petasis reaction, D = Strecker 
amino acid synthesis. 
There are five methods for obtaining optically active amino acids, these are: 
Isolation from a natural source; chemical or enzymatic resolution of racemic amino 
acid derivative; asymmetric synthesis; diastereoselective synthesis; and catalytic 
enantioselective synthesis 230. Chemical and enzymatic resolution procedures 
generally require the synthesis of amino acid functionality first, which can be 
achieved in a number of different ways, the most common of which are alkylation 
of an acetamidomalonate 231 , nucleophilic substitution of a-halocarboxylic acid, 
Petasis reaction 232, 233 and Strecker amino acid synthesis {Strecker, 1850 
#313;Strecker, 1854 #3141. These methods are summarized in Scheme 4. 
Depending on the method used to synthesise the amino acid and the substituents 




isomer. When using the alkylation of acetamidomalonate, this can be achieved by 
selective deacetylation of the L-enantiomer using enzymes such an acylase 236 or 
lipase237 . 
We 
BnO OBn a,b 
OMe 	 We 
BnOJOBn c,d BnO L OBn 
OTBDMS 	 OTBDMS 
HO H 2 N 
(a) AD-mix-a, (b) TBDMS-C1, (c) Diphenyiphosphoryl azide (DPPA), DEAD-Ph 3P, (d) 
Ph3P. 
Scheme 5 Section of the synthesis of (R)-(4-methoxy-3, 5-dihydroxyphenyl) 238, 
Asymmetric synthesis of optically pure non-proteinogenic a-amino acids can be 
achieved in a number of ways. For example Boger used Sharpless asymmetric 
dihydroxylation, followed by displacement of the secondary alcohol upon 
Mitsunobu activation and subsequent reduction to an amine functionality, in the 
synthesis of the amino acid (R)-(4-methoxy-3,5-dihydroxyphenyl) glycine from 
Vancomycin238 (Scheme 5). 
Diastereoselective synthesis uses chiral auxiliaries for inducing optical character 
into the amino acid. Important reactions in this class include the use of Evans and 
McDonald auxiliaries 239 and work by Lu, which used a glycine enolate of a (R)-
camphor derivative to give either desired stereoisomer, due to a strong preference 
to form the endo product 211,211  (Scheme 6) 
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(a)(i) LDA, HTvIPA/THF, (ii) R-Br, -78 °C, (b)(i) HCI (8.0 M), 87 °C, (ii) EtOH, propylene 
oxide, (c)(i) LDA, THF, (ii) HMPA, (iii) R-Br, -78 °C, (d) (i) HCI (8.0 M), 87 °C, 
(ii) EtOH, propylene oxide. 
Scheme 6 Chiral Tricyclic Iminolactone Derivedfrom (R) -Camphor 
Enantioselective catalysis and the synthesis of chiral a-amino acids has been the 
subject of extensive research in recent years. There are numerous methods in this 
vast field which have been successfully employed and each of these can be 
categorised by the method of introducing chirality: by a-hydrogen, a-amine group, 
a-side-chain and carbonyl group. The most common is a-hydrogen introduction 
which involves either: the enantioselective hydrogenation of carbon-carbon double 
bonds; hydrogenation or hydride addition onto carbon-nitrogen double bonds; 
protonation of chiral enolates; or by a combined carbonyl hydrogenation-dynamic 
kinetic resolution of racemic (R)-amino-1,3-dicarbonyl compounds. One of the 
most important ideas in this area was by Knowles who developed the DiPAMP 
ligand for use in asymmetric hydrogenation using a rhodium catalyst 242. This 
catalyst was used in Monsanto's synthesis of L-DOPA a non-proteinogenic a-
amino acid that is used in the treatment of Parkinson's disease  243  (Scheme 7). 
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1.8 	Aims of the project 
The development of high-throughput methods to dramatically increase the 
efficiency of column selection for a broad range of chiral separations could be 
enhance our knowledge of interactions occurring in the chiral separation process, 
relating structural changes to the chiral separation observed and by the separation 
of a range of racemates with small structural changes on a large range of different 
chiral stationary phase columns. 
To achieved this, this PhD describes the preparation of silica bead based CSP 
libraries; which including common Pirkle type materials including variation of the 
capping group and peptide composition as well as protein-type CSPs. The 
generation of an array of inexpensive and general chiral stationary phases could 
lead to a candidate CSP for separating a high proportion of current pharmaceutical 
racemates. 
The exploration of other potential high throughput methodologies, such as the 
Biacore biosensors as a quick screening method for the successful selection of 
chiral stationary phase was also investigated. In this process comparative 
screenings of analytes on specific chiral columns and the same chiral selectors 




2 	Dipeptide based type I CSPs 
2.1 	Preliminary Chiral Stationary Phases 
2.1.1 	Introduction 
The dipeptidic amino acid sequence used was developed from the screening of a 
library of potential dipeptidic CSPs previously described  244.  Synthesis of CSP (3) 
was achieved using various aminopropyl silicas (spherically beaded particles of 
3,4,10 and 12 jim), coupled to Fmoc protected amino acids, using 
diisopropylcarbodiimide (DIC) and N-hydroxybenzotriazole (HOBt). Using a 
solvent mixture of DCMIDMF (4:1), the peptide coupling could be forced by 
refluxing for three hours. 
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(a) Fmoc-Tyr(Bu)-OH, DIC, HOBt, DCMIDMF (4:1), (b) Piperidine/DMF (5:95), 
(c) Fmoc-Phe-OH, DIC, HOBt, DCM/DJVIF (4:1), (d) Piperidine/DMF (5:95), 
(e) 3,5-dinitrobenzoyl chloride, NEt3 , DCM. 




This was followed by deprotection of the Fmoc group with 5% piperidine in DMF 
to give (1). The procedure was modified from the standard Fmoc deprotection 
procedure, which uses 20% piperidine in DMF. Larger concentrations of piperidine 
causes a breakdown of the silica bead core structure 244  The modified procedure 
requires shaking of the beads in 5% piperidine in DMF solution (20 mLg') for 30 
mm. Deprotection monitored by UV spectroscopy detecting the fulvene-piperidine 
complex at 302 nm. 
The second amino acid group, Fmoc-Tyr( tBu)-OH, was coupled using the same 
procedure, followed by another Fmoc deprotection to give (2). The primary amine 
group was then capped with 3,5-dinitrobenzoyl chloride to give the desired CSPs 
(33), (34), (310) and (312), with bead sizes of 3,4, 10 and 12 jim respectively. After 
each step in the synthesis, the reaction was checked by a TNBS test, which 
indicates the presence of free primary amine groups and was used for both the 
coupling and deprotection steps. After each step was complete the reaction mixture 
was filtered and washed. For silica particles of 10 jim and 12 jim a microfiltration 
device was used with a 5 jim pore size. For 3 gm and 4 jim particle sized silica a 
centrifuge procedure was used. 
2.1.2 	Screening of the Preliminary CSPs 
CSP materials were packed into columns of 150 mm length by 2.1 mm i.d. using an 
Ailtech Model 1666 slurry packer. The columns were attached to an HPLC for 
screening. All CSP columns were screened using a test racemate; 1 -(anthracen-9-
yl)-2,2,2-trifluoroethanol as it has been shown to separate relatively easily on 
Type I CSPs and therefore would likely provide positive results to compare244' 245 
Initial tests showed that all columns gave a separation of the test racemate into its 
enantiomers, except 3,5-DNB-Phe-Tyr( tBu)-APS using 4 jim silica (34). The 4 jim 
aminopropyl silica used was supplied by Capital HPLC, a different manufacturer to 
that of the 3, 10 and 12 jim aminopropyl silicas (Thermohypersil), which may have 
caused this anomaly. The three CSP columns (33), (34) and (312) were each 
screened under normal phase conditions, using various chromatographic 
conditions. Each of the three columns were used to separate racemic 
1-(anthracen-9-yl)-2,2,2-trifluoroethanol using flow rates of 0.2, 0.3 and 0.4 




Results obtained from these initial screenings indicated that selectivity factors were 
not greatly affected by flow rate or eluent composition for this CSP column type. 
However, the resolution factor was influenced by both flow rate and eluent 
composition. In general, slower flow rates gave better resolution, as did less polar 
eluents, indicating that selectivity factors are a better measure of CSPs inherent 
enantioseparational powers. 
Silica bead size was found to cause negligible differences in the selectivity and 
resolution factor results. For subsequent experiments it was decided that 10 or 
12 p.m beaded aminopropyl silica should be used. However, this was a synthetic 
preference rather than for chromatographic reasons, due to the impracticalities 
involved in the washing steps, when using the smallest (<5 m) silica beads. 
2.2 
	
Variable head group CSPs 
2.2.1 
	
Synthesis of CSPs with varied head groups 
In order to evaluate the role of the CSP head (or end) group in chiral separations a 
library of CSPs was generated. These used the same common core as before (Phe-
Tyr(Bu)-APS), attached to an aminopropyl silica support (spherical beaded, 
10Jim). 
Synthesis of dipeptide (4) attached to a silica support was achieved as previously 
described for (2), except with the sole use of 1 Op.m silica. Free-amino dipeptide (4) 
was then derivatised with a range of different aryl carboxylic acids (Scheme 9 and 
Table 1) to give a library of CSPs (5-23). 
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(a) DIC, HOBt, DCM!DMF (4:1), R02H* 
* R groups used in synthesis of CSPs (5-23) shown in Table 1. 
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Three of the carboxylic acids used were not commercially available and were 
synthesized (Scheme 10). Thus benzene-1,3,5-tricarboxylic acid dimethyl ester 
(25) was synthesized starting from benzene-1,3,5-tricarboxylic acid, which was 
converted into the trimethyl ester (24) using methanol and a catalytic quantity of 
acid (conc. H2SO4), followed by selective saponification (1 eq. NaOH) to give the 
desired mono-carboxylic acid (25). 
3 ,5-Bis(acetylamido)benzoic acid (26) was synthesized directly from 
3,5-diaminobenzoic acid using acetyl chloride and pyridine to acylate the aniline 
groups. Benzene-1,3,5-tricarboxylic acid-bis((1R,2S,5S)-menthol) ester (27) was 
synthesized from benzene-1,3,5-tricarbonyl chloride by the addition of two 
equivalents of (1R,2S,5S)-(-)-menthol in THF. This was then followed by the 
quenching of the remaining acid chloride with water, to give the required acid (27). 
Each CSP was synthesized on a 1.0 g scale and the materials were packed 
separately into empty HPLC columns (150 mm length by 2.1 mm i.d.) using an 
Ailtech 1666 slurry packing device. Each CSP in the library was screened with a 
range of racemates based on the racemate 1 -(anthracen-9-yl)-2,2,2-trifluoroethanol. 
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(a) conc. H2SO4(cat.), MeOH, DCM, Reflux (b) NaOH (leq.), MeOH, (c) AcCI, pyridine, 
Et20, (d)(i) (1R, 2S, 5S)-(-)-Menthol (2eq.), Et 3N, THF, (ii) Water. 
Scheme 10 Synthesis of carboxylic acids end groups (25-2 7) for CSPs (21-23) respectively. 
2.2.2 	Racemic analytes 
To test the separation ability of the new library of CSPs a range of racemates were 
required for screening purposes. A small library of test racemates were synthesised 
based on the structure of 1 -(anthracen-9-yl) ethanol (otherwise known as 
anthrylethanol). A library of racemic analogues based on anthrylethanol was 
chosen as they were likely to give enough positive separation and will allow a 
direct comparison for new CSP columns as well as analysing important structural 
factors of the analyte that contribute towards the ease of its own enantioseparation. 
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Synthesis was carried out to give a collection of racemic compounds (29-31), (33) 
and (35-37) such that each of the three groups attached to the chiral centre of 
anthrylethanol were altered. The synthesis of three of these was achieved by 
nucleophilic addition to 9-anthraldehyde (28) to give the propyl (29), pentyl (30) 
and phenyl (31) anthryl carbinols. 
A Grignard reagent was reacted with 9-anthraldehyde to give compound (29) was 





(a)(i) Magnesium turnings, THY, 12 (cat.), (ii) 9-Anthrylaldehyde, TI-IF, (iii) 10% NI44C1. 
Scheme I  Grignard synthesis of (29). 
Compounds (30) and (31) were successfully synthesised via addition of 'BuLi and 











(a)(i) BuLi (2.5M), THF, 0°C, (ii) Water, (b)(i) PhMgBr (1 .OM), THF, 0°C, (ii) Water. 
Scheme 12 Synthesis of racemates (30) and (31). 
The pyrene (33) analogue of anthrylethanol (34) was synthesized by the addition of 
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Scheme 13 Synthesis of Pyrene analogue to anthryl ethanol (33). 
Three further racemates were prepared by protecting the hydroxyl group of 
anthrylethanol (34) with methyl (35), benzyl (36) and acetyl (37) groups. This was 
achieved by deprotonating anthrylethanol with sodium hydride followed by 











(a)(i) NaH, THF, 0 °C, (ii) methyl iodide (1.4 M), TI-IF, 0 °C—+ rt, (b)(i) NaH, THF, 
(ii) benzyl bromide, TI-IF, 0 °C—+ rt°C , (c) Ac 20, NEt3 , DMAP. 
Scheme 14 Synthesis of anthryl ethanol analogues (35-3 7). 
The final two test racemate analogues were the commercially available 
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Figure 	18 	Nap hihyl 	equivalent 	racemate 	(38) 
	
and 
1-(anthracen-9-yl)-2, 2, 2-trJluoroethanol (39). 
2.2.3 
	
Screening for the varied head group CSPs 
2.2.3.1 Introduction 
Screening of these materials was carried out on an Agilent 1100 HPLC, eluting 
isocratically with 3% 2-propanol in heptane, with a flow rate of 0.3 mLmin'. 
Conditions were not optimized for individual racemates or CSPs, as the total 
number of combinations was already 171 and it was desirable to ensure that all the 
racemates and CSP screening results were directly comparable. 
2.2.3.2 Screening results for varied head group CSPs 
The most important screening results are shown in Table 2, Table 3 and Table 4 
and in Graph 1. These results show that only six of the ten racemates showed 
separation on any of the columns. The racemic series with capped hydroxyl groups 
showed no enantioseparation on any member of the CSP library. Racemates with 
capped hydroxyl groups clearly interact too weakly with the stationary phase and 
are eluted too quickly for sufficient interactions with the immobilized enantiomer 
and therefore no observable enantioseparation occurs. This emphasizes the 
importance of the hydroxyl group in the hydrogen bonding interaction with the 
chiral stationary phase. Also the anthryl group of the racemate seems very 
important to the separation. Naphthyl carbinol (38), showed separation on only two 
of the CSP library, Whereas pyrenyl carbinol (33) was not separated on any of the 
CSP library. Racemates (29)-(32) and (34) which vary at the alkyl position, showed 
very similar separation to one another. 
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k1c 	a b 	 k 1 c 	 a 	k 1 c 
(34) 	Y= Me 	4.64 	1.55 	3.05 	1.19 	3.73 	1.20 
Y=Et 2.81 1.57 3.65 1.08 2.08 1.15 
Y=Bu 	1.79 	1.45 	1.30 	1.19 	1.70 	1.19 
Y=Ph 3.36 1.56 2.86 1.21 3.09 1.21 
Me OZ 
, - - 
(35) 	Z = Me 	0.20 	1.00 	0.10 	1.00 	0.18 	1.00 
(36) ZBn 0.85 1.00 0.75 1.00 0.79 1.00 
(37) 	ZAc 	1.48 	1.00 	0.72 	1.00 	0.58 	1.00 
OH 
(LM 
(33) 	 1.25 	1.00 	3.65 	1.00 	4.68 	1.00 
7- 
Me OH 
(38) 	- 	--.. 	3.61 	1.13 	3.85 	1.11 	2.64 	1.00 
' 7- 7- 
(39) 	 3.22 	1.54 	2.76 	1.18 	3.73 	1.23 
a Mobile phase is heptane/2-propanol (97:3), flow rate of 0. 3mL/min. 
b a = k 27k 'i = enantioseparation factor. 
C  V2 and k ' are the capacity factors for the second offirst eluted enantiorner respectively. 
Table 2 Enantioseparation of racemates (29)-(31), (33)-(39) on CSP (5)-(7). 
Of the nineteen CSP columns screened, eight CSPs showed separation of a least 
one racemate. The 3,5-dinitrobenzoyl (5) end group was generally the best at 
separating the racemate library. When the nitro moietes on the end group were 




substitution with a hydrogen atom; 3-nitrobenzoyl (8), the enantioseparation (a 
value) of the racemates decreased, in some cases to 1.0 (i.e. no observable 
separation). Other 3,5-disubstitued electron withdrawing end groups, such as 3,5-
difluorobenzoyl (18), 3 5 -bis(trifluoromethyl)benzoyl (19) and 3 ,5-disulfobenzoyl 
(20) did not have any of the separational properties of the parent 3,5-dinitrobenzoyl 
end group (5). In fact none of these CSPs showed any separation of any member of 
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Graph 1 Screening results of columns that show separation of at least one racemate. 
The other end groups showed limited success in enantioseparating the racemates. 
CSPs with end groups of: 3,5-dimethoxybenzoyl (10), 
3 ,5-bis(methoxycarbonyl )benzoyl (21), 2-naphthoyl (13) and 2-Benzylbenzoyl (16) 
each gave separation of at least one racemate in the library. Of the CSPs that 
showed no enantioseparation ability, some were due to low sample retention by the 
column, highlighted by low capacity (k') values, notably these were 2-thiophenoyl 
(15) and 3,5-difluorobenzoyl (18). In these cases the low sample retention could 




gave good retention of sample but still without enantioseparation such as 2-
pyridoyl (14) and 3,5-bis(acetylamido)benzoyl (22). 
The 3,5 -bis(methoxycarbonyl)benzoyl (21) capping group gave enantio separation 
of three members of the racemate library. This led us to investigate the possibility 
of using further 3,5-disubstituted ester end groups. 
3,5-bis(mentholoxycarbonyl)benzoyl (23) was derived from this, with the addition 
of further chiral information in the menthol ester side groups instead of the methyl 
ester side groups. However, unlike 3,5-bis(methoxycarbonyl)benzoyl (21), 3,5 
bis(mentholoxycarbonyl)benzoyl (23) CSP didn't show any enantioseparation of 
the racemate library. This could be because the large menthol end group 
substituents may compete for complexation, hindering the racemic analyte's 
normal mode of interaction with the CSP. 
Although the 3,5-dinitrobenzoyl (5) end group, which is used in many 
commercialized CSPs, could not be bettered for enantioselectivity, there were a 
number of interesting results. Notably the positioning of the nitro groups around 
the benzoyl end group greatly affected the enantioseparation observed. In 3,5-
dinitrobenzoyl end group (5), the positioning of nitro groups gives the most evenly 
distributed ic-electron acceptor. However the 2,4-dinitrobenzoyl (6) end group also 
gave some enantioseparation, whereas there was no separation with the benzoyl (9) 
end group. This indicated that the nitro groups in the 2, 4 and 6 positions of the end 
group benzoyl ring can also be involved in generating a successful CSP end group. 
Future work in adding substituents into the 2,4 and 6 positions of the 3,5-
dinitrobezoyl end group could augment the enantioseparation of the CSP. Using 
Alkoxy and alkylester moieties in CSP end groups has been shown to give 
separation. These as well as further nitro groups, could all be substituted into the 2 
and/or 4 and/or 6 positions of the 3,5-dinitrobenzoyl end group, to potentially give 
CSPs with better enantioseparation. However, the stability of all of these types of 
end groups is not well known. 
All attempts at co-crystallisation of the CSP peptide structure and racemic 
1 -(anthracen-9-yl)-2,2,2-trifluoroethanol (39), (R)- 1 -(anthracen-9-yl)-








Graph 2 Separation of 1-anthracen-9-yl,.i-2,2,2-trfiuoroethanol (39) on GSPs: (from top 
to bottom) (5)-(9). 
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k1c 	a b 	 k 1 c 	a 	k 1 c 	 a  
V OH 
, ,- -- 
(34) 	Y= Me 	2.85 	1.00 	3.28 	1.05 	3.79 	1.00 
Y=Et 1.70 1.00 3.80 1.00 4.05 1.00 
Y Bu 	1.26 	1.00 	3.12 	1.00 	3.42 	1.00 
Y=Ph 2.99 1.00 3.09 1.00 3.36 1.05 
Me OZ 
,- - - 
(35) 	Z=Me 	0.01 	1.00 	0.10 	1.00 	0.04 	1.00 
(36) Z=Bn 0.80 1.00 0.72 1.00 0.54 - 1.00 
(37) 	ZAc 	0.50 	1.00 	0.34 	1.00 	0.21 	1.00 
OH 
fl(LMe 
(33) 	 4.44 	1.00 	3.02 	1.00 	3.21 	1.00 
AO 
Me OH 
(38) 	 1.75 	1.00 	1.80 	1.00 	1.93 	1.00 
F3COH 
(39) 	-.. 	-. 	 3.08 	1.20 	3.99 	1.08 	5.61 	1.05 
Mobile phase is heptane/2-propanol (97:3), flow rate of 0.3mL/min. 
b a = k 21k ' = enantioseparation factor. 
C 
 V2 and k 'j are the capacity factors for the second or first eluted enantiomer respectively 




CSP (16) 	 CSP (21) 
	
CSP (23) 
(34) 	Y= Me 	2.19 	1.00 	3.11 	1.13 	3.11 	1.00 
Y = Et 1.13 1.00 2.06 1.00 2.01 1.00 
Y = Bu 	0.84 	1.00 	1.93 	1.00 	1.70 	1.00 
Y=Ph 2.47 1.08 3.54 1.14 3.09 1.00 
Me OZ 
- - - 
(35) 	ZMe 	0.01 	1.00 	0.02 	1.00 	0.10 	1.00 
(36) Z = Bn 0.60 1.00 0.84 1.00 0.50 1.00 
(37) 	Z = Ac 	0.14 	1.00 	0.44 	1.00 	0.41 	1.00 
OH 
• fl(Me 
(33) 	 2.46 	1.00 	4.88 	1.00 	4.21 	1.00 
Me OH 
(38) 	-.. 	 1.95 	1.00 	2.24 	1.00 	2.32 	1.00 
F3COH 
(39) 	 3.75 	1.00 	5.69 	1.22 	3.66 	1.00 
"Mobile phase is heptane12-propanol (97:3), flow rate of 0. 3mL/min. 
b a = k 2/7 ' = enantioseparation factor. 
C  V2 and k ',  are the capacity factors for the second or first eluted enantiomer respectively 
Table 4 Enantioseparation of racemates (29)-(31), (33)-(39) on CSPs (16),(21) and (23). 
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2.3 	CSPs containing two 3,5-dinitrobenzoyl head groups 
2.3.1 	Introduction 
Following the screening of a wide range of head groups, the 3,5-dinitrobenzoyl 
group was found to be by far the most successful. Chiral stationary phases 
containing two 3,5-dinitrobenzoyl head groups, could lead to beneficial 
enhancement of enantioseparation or separation of a broader range of racemates, in 
comparison to that of CSPs with only one 3,5-dinitrobenzoyl head group. 
2.3.2 	Synthesis of CSPs containing two 3,5-dinitrobenzoyl head groups 
Three initial CSPs containing two 3,5-dinitrobenzoyl head groups were synthesised 
(43-45). Each of these head groups used an amino acid backbone attached to the 
aminopropyl derived silica beads. However, in order for the CSP to contain the two 	- - - 
required 3,5-dinitrobenzoyl groups, different amino acids had to be used, compared 
to previous procedures. The backbone was simplified to just one amino acid which 
would then be derivatised with two equivalents of the required 3,5-dinitrobenzoyl 
group, instead of the original dipeptidic sequence of Tyr(tBu)  and Phe as neither 
Phe nor Tyr(tBu)  were suitable for this. 
CSP (43-45) used amino acids Dap (Diaminopropionic acid), Lys and Ser 
respectively. Synthesis was achieved starting with Aminopropyl silica (10 jim) as 
shown in Scheme 15. Following a peptide coupling procedure similar to that used 
before, the appropriately protected amino acid (Ser, Dap or Lys) was coupled to 
aminopropyl silica. Boc-Dap(Boc)-OH, Fmoc-Lys(Fmoc)-OH and Fmoc-Ser( tBu)-
OH, were used to form compounds (40-42) respectively. After successful coupling 
of the amino acid to the solid support, the protecting groups were removed (both 
amine and sidechain). Once all the protecting groups had been removed the amine 
functional group(s) (and hydroxyl for Ser based compound (42) were available for 
coupling. 3,5-Dinitrobenzoic acid was coupled using a similar method. In the case 
of the Ser based compound (42), the formation of the required ester bond, was 
achieved by the addition of catalytic amounts of DMAP to the standard coupling 
reagents. Successful coupling of two 3,5-dinitrobenzoyl groups gave CSPs (43), 
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O L J NO2 
NO2 
(40) and (43) Z = CH2, X = NH, (a) Boc-Dap(Boc)-OH, DIC, HOBt, DCMIDMF (4:1), 
(b) DCM/TFAIWater (50:50:1), (c) 3,5-dinitrobenzoic acid, DIC, HOBt, DCMIDMF (4:1) 
and (44) Z = CH2CH2CH2CH2, X = NH, (a) Fmoc-Lys(Fmoc)-OH, DIC, HOBt, 
DCMIDMF (4:1), (b) PiperidinefDMF (5:95), (c) 3,5-dinitrobenzoic acid, DIC, HOBt, 
DCM/DMF (4:1) 
and (45) Z = CH2, X = 0, (a) Fmoc-Ser('Bu)-OH, DIC, HOBt, DCM!DMF (4:1), 
(b)(i) Piperidine/DMF (5:95), (ii) DCMITFAIWater (50:50:1), (c) 3,5-dinitrobenzoic acid, 
DIC, HOBt, DMAP (cat.), DCMJDMF (4:1) 
Scheme 15 Synthesis of CSPs (43-45). 
2.3.3 	Screening of CSPs containing two 3,5-dinitrobenzoyl head groups 
Three new CSPs were packed into columns (150 mm length by 2.1 mm i.d.) and 
screened using the same racemate library as previously described in section 2.2. 
The screening results obtained (Graph 3) show that CSP columns (43) and (45) 
both separated the same five racemates out of the ten member racemate library. 
These results were similar to the best CSP (5) results from the previous CSP 
library, with the exception that CSP (5) also showed small separation of the 
naphthyl based racemate (38). These results show that within this small library of 
racemates, the new CSPs containing two 3,5-dinitrobenzoyl groups did not increase 










- 	 - 
29 -- 
Racemate 	 4: 
	 45 
3c 	 CSP Column 
Graph 3 Screening results of CSP columns (43-45) with ten member racemate library. 
Separation of the library by CSPs (43) and (45) were very similar to CSP (5) with 
the exception of racemate (38). The hydroxyl capped racemates (35-37), still 
showed no separation, which was not surprising following similarly negative 
results in previous screenings. 
However, the overall chiral selectivity of CSPs (43) and (45) are lower, in all cases, 
compared to CSP (5). CSPs (43) and (45), have selectivity factors between 1.3-1.4, 
whereas CSP (5), showed selectivity factors between 1.5-1.6 (for separated 
racemates). Therefore it was concluded that CSPs (43) and (45), containing two 
3,5-dinitrobenzoyl groups, showed no chiral stationary phase improvement 
compared to CSP (5) which contained only one 3,5-dinitrobenzoyl group. 
CSP (44) showed no separation of any of the racemate library. This was quite an 
intriguing result compared to CSP (45), which showed separation of five of the ten 
member racemate library. CSP (44) and (45) are structurally very similar, with CSP 
(44) (containing Lys) having a four carbon side chain, to which one of the 
3,5-dinitrobenzoyl group was attached, compared to CSP (45) (containing Dap) 
having a one carbon side chain. These comparative results indicated that the extra 
length in the carbon side chain linkage in CSP (44) is responsible for the loss of 




2.4 	CSPs with achiral spacers 
2.4.1 	Introduction 
Placing achiral spacers into the original structural framework of CSP (5), would 
help to confirm the most important structural features of the CSP towards the 
enantio separation of racemates. 
Synthesis of 'spacered' CSP based upon the structure of CSP (5), was carried out 
using very similar procedures involved in the synthesis of previous CSPs. These 
spacers were placed into two positions of the CSP. Group A; spacers between the 
aminopropyl silica bead and the main peptide chain. Group B; spacers between the 
end group and the peptide chain attached to the aminopropyl silica bead. 
To fit well with the peptide chemistry used in the synthesis of the CSPs, the spacers 
were also required to be amino acids. Glycine, the non-side-chain derivatised 
proteogenic amino acid, was used as the 2 carbon spacer. Non-proteogenic amino 
acids aminobutyric acid and aminohexanoic acid were used for 4 and 6 carbon 
spacers. 
2.4.2 	Synthesis of spacered CSPs-group A 
Synthesis was achieved starting with aminopropyl silica. To this was coupled an 
Fmoc protected achiral spacer (Fmoc-Gly-OH, Fmoc-Abu-OH, Fmoc-Ahx-OH). 
Following the coupling and Fmoc deprotection, was the synthesis of the rest of the 
spacered CSPs. This involved coupling the amino acid sequence (Tyr(Bu),  Phe) 
using Fmoc protected amino acid with Fmoc deprotection steps following 
successful peptide couplings. Following this, end group coupling of the 3,5-
dinitrobenzoyl group occurred, which successfully gave three new CSPs (46),(47) 
and (48) with glycine, aminobutyric acid and aminohexanoic acid spacers 










(a) (46) X = CH2, Fmoc-GIy-OH, DIC, HOBt, DCM/DMF (4:1), 
(47) X = CH2CH2CH2, Fmoc-Abu-OH, DIC, HOBt, DCMIDMF (4:1), 
(48)X = CH2CH2CH2CH2CH2, Fmoc-Ahx-OH, DIC, HOBt, DCM!DMF (4:1), 
(b) Piperidine/DMF (5:95), (c) Fmoc-Tyr( tBu)-OH, DIC, HOBt, DCM/DMF (4:1), 
(d) Piperidine/DMF (5:95), (e) Fmoc-Phe-OH, DIC, HOBt, DCMIDMF (4:1), 
(f) Piperidine/DMF (5:95), (g) 3,5-Dinitrobenzoic acid, DIC, HOBt, DCMIDMF (4:1) 
Scheme 16 Synthesis of spacered CSP-group A 
2.4.3 	Synthesis of spacered CSPs-group B 
Synthesis of spacered CSP-group B was very similar to that used for spacered CSP-
group A. This was achieved by following the identical synthetic sequence for that 
of compound (4). The free amino-group of was then derivatised with the selection 
of achiral spacers (Gly, Abu, Ahx) using standard coupling conditions. These three 
peptide compounds were then coupled with the 3,5-dinitrobenzoyl group, to give 
the required three CSPs (49), (50) and (51), which have glycine, aminobutyric acid 
and aminohexanoic acid spacers respectively (Scheme 17). 
NO 
10 H 0 j: H 0 	49-51 
H2N 	
a-g 	
02N LN N 
aoj< 
(a) Fmoc-Tyr(Bu)-0I4, DIC, HOBt, DCMIDMIF (4:1), (b) PiperidinelDMF (5:95), 
(c) Fmoc-Phe-OH, DIC, HOBt, DCMIDMF (4:1), (d) Piperidine/DMF (5:95), 
(e) (49) X = CH2, Fmoc-Gly-OH, DIC, HOBt, DCM/DMF (4:1), 
(50) X = CH2CH2CH2, Fmoc-Abu-OH, DIC, HOBt, DCMJDTVIF (4:1), 
(51) X = CH2CH2CH2CH2CH2, Fmoc-Ahx-OH, DIC, HOBt, DCMJDMF (4:1), 
(0 Piperidine/DMF (5:95), (g) 3,5-Dinitrobenzoic acid, DIC, HOBt, DCMIDMF (4:1) 




2.4.4 	Screening of spacered CSPs 
Screening was carried out on column packed CSPs using the same ten member 
racemate library as previously synthesized and used for screening. 
The CSP-spacered libraries were screened under identical conditions as used 
previously. Chiral selectivity results are shown for the spacered CSP-group A in 
Graph 4 and spacered CSP-group B in Graph 5. 
17 
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Ecemate 
I I::: = CSP (46), Red = CSP (47), Blue = CSP (48), 	 = CSP (5) 
Graph 4 Screening results of spacered CSP -group A. 
The screening results from spacered CSP-group A (46-48), showed that the 
separation of the silica from the peptide chain, or effectively lengthening the CSP, 
had a significant effect on the chiral selectivity of any racemate. Although CSPs 
(46-48) are identical to CSP (5) at the peptide end, they differ markedly with 
respect to silica attachment. With the CSP sequence (46), (47), and (48) comes an 
increasing tether length between the silica bead and the optically active peptide end 
over the original CSP (5). However, such a significant change in the corresponding 
chiral selectivity obtained from screening the CSPs was not expected, as previous 
experiments indicated that the nature of the head group was a key structure feature 
of CSP (5). 
Increasing the distance of the optically active peptide portion of the CSP away 




(47) and (48) with the longer achiral spacers (Abu and Ahx). CSP (47), with the 
intermediate length achiral spacer (Abu, 4 carbon), separated five of the ten 
racemates successfully. However, all of the chiral selectivity values were slightly 
lower than that for CSP (5). CSP (48) had the longest achiral spacer (Ahx, 6 
carbon). Although CSP (48) did still successfully separate five of the ten member 
of the racemates library, the results show that the further increase in achiral spacer 
length causes a further decrease in chiral selectivity aptitude. 
CSP (47) has the shortest achiral spacer (Gly, 2 carbon). This CSP generally 
showed a slightly greater aptitude of chiral selectivity compared to CSP (5) and 
also separated six of the ten member racemate library. However, the racemates 
separated were not all the same. Racemate (33) had a small separation on CSP (47) 
but there was no separation of racemate (38). The results of these two racemates on 
CSP (47) are opposite to those of CSP (5). 
The results of CSP (47) indicate that a small increase in the overall chain length of 
CSP, in comparison to CSP (5), has a small positive effect of the chiral selectivity 
in most cases. This is certainly true for the largest pyrene racemate analogue (33), 
which had a small separation on CSP (47) it compared to zero separation on CSP 
(5). However, CSP (5) gave a small chiral separation of smallest naphthyl racemate 
analogue (38) compared to zero separation of this racemate for CSP (47). 
Overall the CSP (47) with a Glycine spacer shows slightly better chiral separation 
aptitude than the original CSP (5) with no spacer. However, there was a small 
increase in the selectivity of some of the racemates separation, but a complete loss 




= CSP (49), Violet = CSP (50), 	= CSP (51), 	 = CSP (5) 
Graph 5 Screening results of spacered CSP-group B. 
The screening results from spacered CSP-group B are much clearer to interpret. 
Graph 5 shows the chiral selectivity of CSPs (49)-(51), and unspacered CSP (5) for 
the same ten member racemate library. 
CSPs (49)-(51) all showed no separation of any of the member racemate library. 
This clearly indicates that the insertion of the achiral spacer in between the optical 
active peptide part of the CSP and the 3,5-dinitrobenzoyl end-group has a very 
significant effect on the chiral separation ability of the CSP. Even with the smallest 
spacer (Gly, 2 carbon) used in CSP (49), there was complete loss of chiral 
separation compared to CSP (5). 
To conclude, the results show the importance of the CSP end-group's direct 
structural attachment to the optically active peptide part of the CSP. The separation 
of the end group away from the optical active portion removed all detectable chiral 
separation ability. 
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2.5 	CSPs with switched D/L character of the amino acid 
2.5.1 	Introduction 
CSPs synthesized thus far have exclusively used the natural L-configuration amino 
acids. CSP (5), which is a dipeptide, contains two L-configuration amino acids. 
The opposite enantiomer (with both amino acids with the D-configuration) shows 
the same magnitude of chiral selectivity, however, the order of elution of the two 
enantiomers in the racemates will be opposite. 
This phenomenon comes from the inherent mechanism which operates in chiral 
separation. If the CSP-enantiomer, with L-amino acids, forms a stronger transient 
diastereomeric complex with one of the analyte-enantiomers over the opposite 
analyte enantiomer, the opposite enantiomer-CSP, will form a similarly stronger 
transient diastereomeric complex with the opposite analyte-enantiomer, explaining 
the reversal in elution order observed. 
CSP (5) contains two amino acids, which give the possibility for two further optical 
isomers, diastereomeric in relation to the original CSP (5), with each diastereomer 
containing one D and one L-configured amino acid. Screening of these two new 
CSPs will give information towards the comparable importance of each amino acid 
in the CSP. It is also possible that one diastereomer will give an augmented chiral 
separation ability due to different possible three dimensional orientations of 
possible transient diastereomeric complexes formed. This situation arises due to the 
possible non-identical physical nature of diastereomers. 
2.5.2 	Synthesis of differing amino acid D/L character CSPs 
Synthesis was achieved using procedures similar to that for CSP (5), except that 
this time the Fmoc-D-Tyr( tBu)-OH and Fmoc-D-Phe-OH were substituted for the 
L-configured equivalent amino acids where required. The opposite enantiomer to 




0 	 0 	52 









NO2 	 cJ< 
),ji 	




(a) Fmoc-Tyr( tBu)-OH, DIC, HOBt, DCM/DMF (4:1), (b) Piperidine/DMF (5:95), 
(c) Fmoc-D-Phe-OH, DIC, HOBt, DCM/DMF (4:1), (d) Piperidine/DMIF (5:95), 
(e) 3,5-dinitrobenzoic acid, DIC, HOBt, DCM/DMF (4:1), (f) Fmoc-D-Tyr(Bu)-OH, DIC, 
HOBt, DCMIDMF (4:1), (g) Piperidine/DMF (5:95), (h) Fmoc-Phe-OH, DIC, 
HOBt, DCMIDMF (4:1), (i) Piperidine/DMF (5:95), (j) 3,5-dinitrobenzoic acid, DIC, 
HOBt, DCM!DMF (4:1), (k) Fmoc-D-Tyr( tBu)-OH, DIC, HOBt, DCMIDMF (4:1), 
(1) Piperidine/DMF (5:95), (m) Fmoc-D-Phe-OH, DIC, HOBt, DCM/DMIF (4:1), 
(n) Piperidine/DMF (5:95), (o) 3,5-dinitrobenzoic acid, DIC, HOBt, DCMJDMF (4:1) 
Scheme 18 Synthesis of CSP with differing D/L character. 
2.5.3 	Screening of CSP with differing D/L character to determine difference in 
racemic analytes R/S elution order 
The first screening for CSPs (52)-(54) was to determine how the stereochemistry of 
the CSP affected the corresponding order of elution of the enantiomers. For 
screening, the single enantiomers of 1 -(antbracen-9-yl)-2,2,2-trifluoroethanol, (39) 
were used as the analyte, to give retention factor values, so that the chiral 
selectivity factor and elution order could be subsequently be determined. The 




(S)- 1 -(anthracen-9-yl)- 	(R)- I -(anthracen-9-yl)- 
2,2,2-trifluoroethanol 2,2,2-trifluoroethanol 
HO,,. CF3 	 HOCF3 
CSP 	Short CSP structure 
— — — 	 — — — 
k' a 	 k' a ay—
(5) 	3,5DNB-L-L-Si0 2 	 3.22c 
	
4.95 
3,5DNB-D-L-Si0 2 	 7.13 
	 5.69c 	 1. 25e 
3,5DNB-L-D-Si02 	 470C 
	
5.77 	 1•23d 
3,5DNB-D-D-Si0 2 	 5.67 
	 4Ø5C 	 1.40e 
"Mobile phase is heptane/2-propanol (97:3), flow rate of 0.3 mL/min. 
- 	b  a = k ' (largest) 1k '(smallest) = chiral selectivity factor 
Highlighted is first eluted enantiomer for corresponding CSP 
d chiral selectivity where S enantiomer is eluted before R enantiomer 
chiral selectivity where R enantiomer is eluted before S enantiomer 
Table 5 Screening CSPs (52)-(54) and (5) with single enantiomers of 1-(anthracen-9-yl)- 
2,2, 2-trfiuoroethanol to determine elution order. 
Results obtained indicate how each of the amino acid influences the chiral 
separation of the overall CSP. Two of the CSPs screened showed chiral separation 
with S being eluted before R. These are the original CSP (5) and CSP (53), which 
contains D-Phe. The other two CSPs, (52) and (54), had an opposite elution order 
(the elution order using CSP (5) and CSP (54) was also previously examined 244). 
These results show that the Phenylalanine in these CSPs has a greater influence 
over the chiral separation effect, than the Tyrosine residue. 
Comparing CSP (5) with CSPs (52) and (53); where CSP (53) has D-Tyr(Bu) 
replacing LTyr(tBu) as the first amino acid, gives a drop in the magnitude of the 
chiral selectivity, but with the elution order staying the same. However, CSP (52) 
(D-Phe replacing L-Phe as the second amino acid) resulted in a very similar drop in 
the magnitude of chiral selectivity, but with a reversal of elution order. This shows 
for this particular type of dipeptidic CSP, the second amino acid, Phenylalanine has 
a stronger influence over the overall chiral separation compared to the second 
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amino acid Tyr(tBu).  Changing the stereochemistry of Phenylalanine produces the 
overall changing of the elution order, rather than the changing of Tyr(Bu),  which 
gives only a reduction of the overall CSP chiral separation ability. 
Approximate chiral selectivity values are used in Figure 19 to illustrate how the 
changing of amino acid two, Phenylalanine, caused a more dramatic effect on the 
selectivity, than Tyrosine (—twice as much). 
Selectivity 
S before R 
1.2 
Theoretical racerric column point 





R before S 
35DNB-D-D-Si0 2 
 7 
° Diagram shows order of elution above and below zero chiral separation (1.0) 
An elution order of S before R is shown above zero chiral separation arbitrarily. 
'Light green shading shows change offirst amino acid, Tyr(4Bu). 
Light blue shading shows change offirst amino acid, Phe. 
Figure 19 Diagram to show the effect the second amino acid, Phenylalanine, has on chiral 
selectivity. 
2.5.4 	Screening of CSP with differing D/L character to determine chiral selectivity 
Following the screening with I -(anthracen-9-yl)-2,2,2-trifluoroethanol, all of the 
CSP were screened using the standard ten member racemate library. It was 
assumed that CSP (5) and CSP (53) would separate all of the racemates with the 
same elution order. The results are plotted in Graph 6, arbitrarily as positive chiral 
selectivity. Similarly CSPs (52) and (54), were assumed to give identical elutions, 
but this time results were plotted as negative chiral selectivities (Graph 7). This 




The selectivity given as a ratio without consideration of the elution order and 
furthermore, it is known that for CSP (5), the RJS elution orders of racemates 
1 -(anthracen-9-yl)-2,2,2-trifluoroethanol (39) and I -(anthracen-9-yl)ethanol (34) 
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Racemate 
= CSP (5), 	= CSP (54) 
Graph 6 Chiral Selectivity for CSPs (5) and (53) with standard racemate library 
CSP (53) successfully separated five of the ten member of the racemate library. All 
of the separated racemates gave lower chiral selectivity values than CSP (5). This 
trend was anticipated and results from the switching of the configuration of amino 
acid one, from L-Tyr(Bu) to DTyr(Bu).  An almost identical trend was observed 
with CSP (5) compared to CSP (53), similarly caused by the change in amino acid, 











IIhI\ = CSP (54), Pktu = CSP (52) 
Graph 7 Chiral selectivity for CSPs (52) and (54) with standard racemate library 
2.6 	Utilising experimental design to optimize chiral separation 
chromatographic conditions 
2.6.1 	Introduction 
In testing numerous CSPs it is vital that identical chromatographic conditions are 
used for each screen, so that results are directly comparable with each other. 
Although chiral selectivity factors are strongly influenced by the CSP material, 
many other chromatographic conditions can alter these values. The most common 
variables in HPLC were varied using a design of experiments (DOE) approach to 
confirm which chromatographic conditions were most important when considering 
optimization of a chiral separation. 
2.6.2 	The experimental design 
The design of experiment was trialled on CSP (5) with 1 -(9-anthracenyl)-2,2,2- 




factors; temperature (5°C and 35°C), flow rate (0.1 mLmin' and 0.7 mLmin t ), 
injection volume (1 p.L and 11 p.L) and eluent 2-propanol (1% and 5%). These 
factorials were used in a design resolution of IV (level at which the design is 
confounded). This required eight runs along with 3 optional centre point runs. The 
runs are shown in order in Table 6 and Table 7, along with seven responses (to/mm, 
t 1 /min, t2/min, a, R, Solvent usedlmL and total time/mm). This experiment gave 
reliable information on first level effects of the numeric factor on the responses, 
most importantly, the separation factor (a). Additional information on any strong 
second level effects was also generated, although these were not conclusive as the 
combined second level factorials aliases with other equivalent terms, thus making it 
harder to distinguish second level factors responsible for the given effect. 
Nevertheless, the second level factors may be determined by discounting the 
aliased second level factors based on scientific logic 246 . 
Run 
number 







1 35 0.1 11 1 6.21 
2 5 0.7 1 5 0.97 
3 5 0.1 1 1 7.31 
4 5 0.1 11 5 7.48 
5 20 0.4 6 3 1.6 
6 35 0.7 11 5 0.88 
7 20 0.4 6 3 1.52 
8 35 0.7 1 1 0.91 
9 5 0.7 11 1 1.09 
10 20 0.4 6 3 1.6 
11 35 0.1 1 5 6.07 
Table 6 1-(9-anthracenyl)-2,2,2-trjfiuoroethanol (39) separation on CSP (5) using 
experimental design. 
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Run 
number 








1 32.94 39.85 1.26 0.298 6.06 60.62 
2 1.86 2.59 1.52 1.707 2.58 3.69 
3 38.08 65.51 1.89 3.827 7.63 76.27 
4 13.33 19.77 2.1 1.031 3.22 32.22 
5 3.61 5.04 1.71 1.121 3.29 8.23 
6 1.33 1.41 1.18 0.165 1.95 2.79 
7 3.3 4.56 1.71 1.066 2.57 6.42 
8 4.35 6.23 1.55 2.014 5.92 8.45 
9 5.74 9.85 1.88 1.197 10.02 14.32 
10 3.6 5.05 1.73 1.145 7.64 3.06 
11 10.43 13.08 1.61 1.374 1.72 17.19 
Table 7 1-(9-anthracenyl)-2,2,2-trfluoroethanol (39) separation on CSP (5) using 
experimental design. 
2.6.3 	Interpretation of experimental design results 
Results obtained from the DOE showed that many factors affect measured 
responses. The most significant observations come from the separation factor (a). 
Temperature and Flow rate had strong negative effects, meaning as temperature or 
flow rate increases (without changing other factors and irrespective of the other 
factors values) the separation factor will decrease. 2-Propanol concentration only 
had a very weakly negative effect. This result was surprising, but can be explained 
by the relatively small range that the eluent 2-propanol concentration was tested 
over (only between 1-5%). Two important second level effects were also deduced. 
Flow rate/eluent 2-propanol concentration second level term showed a strong 
negative effect on the separation factor (a), as shown in Graph 8. This means that 
higher a values occured when using either high flow rate and low eluent 2-propanol 
concentration or vice-versa. However lower a values occurred when either both 
factor are high or low. Temperature/flow rate second level term also had a positive 
effect on the separation factor (a), as shown in Graph 9. Thus when both 
temperature and flow rate were low, (with other factors constant) the highest a 











Eluent IPA concentration (%) 
a a values determined with constant Temperature of 20 9C and an injection volume of 6 uL. 
Graph 8 An experimental design graph showing predicted separation factors depending on 
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a a values determined with constant injection volume of 6 pL and eluent 2-propanol (IPA) 
of 3%. 
Graph 9 An experimental design graph showing predicted separation factors depending on 
variable flow rate/mLmin' and temperature/°C a  Plotted using Design-Expert®. 
DOE was also used to determine an optimal condition range for the separation of 
(RIS)-l-(9-anthracenyl)-2,2,2-trifluoroethanol on CSP (5). Optimatisation 
('excellent separation'), restricted responses to favourable values: separation factor 
(a) ? 1.7, resolution factor (Rb)? 1.5 and total time ( 30 minutes. Constant actual 
factors: injection volume (6 p.L) and eluent 2-propanol (IPA) concentration (3%) 
















Excellent' separations was restricted to separations factor (à) ? 1. 7 resolution factor 
(1?) ~! 1.5 and total time 30 minutes. 
h Graph determined with constant injection volume of 6pL and eluent 2-propanol (IPA) of 
3%. 
Excelleni ' separation area shaded in gold 
Graph 10 An experimental design overlaid optimization plot, showing the predicted 
excellent separation area using a variable flow rate/mLmin' and temperature/°C  
Plotted using Design-Expert®. 
2.7 	Synthesis of new CSP with two 3,5-dinitrobenzoyl end-groups 
2.7.1 	Introduction 
One further CSP was synthesised following on from work in section 2.3. This CSP 
incorporated the two 3,5-dinitrobenzoyl groups in the structure used in CSP (5). 
2.7.2 	Synthesis of new CSP with two 3,5-dinitrobenzoyl end groups 
This was achieved starting with compound (4). which was derivatised into a 
tripeptidic structure (55), with the coupling of Fmoc-Ser( tBu)-OH, using standard 





then derivatised with two 3,5-dinitrobenzoyl groups using a slight modification of 
standard coupling condition with the addition of a catalytic quantity of DMAP to 
the reagent mixture. 
0 0 4 
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(a) Fmoc-Ser(Bu)-OH, DIC, HOBt, DCMIDMF (4:1), (b)Piperidine/DMF (5:95), 
(c) DCMJTFAIWater (50:50:1), (d) 3,5-dinitrobenzoic acid, DIC, HOBt, 
DMAP (cat.), DCM/DMF (4:1) 
Scheme 19 Synthesis of CSP (56) 
2.7.3 	Screening of new CSP containing two 3,5-dinitrobenzoyl groups 
The standard racemic library was used for screening CSP (56). Chiral selectivity 











3536 	37 Racemate 
Brown = CSP (56), 	 = CSP (43) 
Graph 11 Chiral selectivity of CSP (56) compared to CSP (43) on standard racemale 
library 
Results for CSP (56) were similar to that of CSP (43). Five of the ten member 
racemate library were successfully separated, identical to CSP (43). However, the 
chiral selectivity for all five was slightly higher for the new CSP (56). The new 
CSP, which incorporates both the structural features of CSP (5) (Phe, Tyr peptide 
chain) as well as utilising two 3,5-dinitrobenzoyl end groups, did not enhance the 
enantioselectivity of CSP (5) for the library of racernates tested. 
2.8 	Summary 
A 3,5-dinitrobenzoyl end group is utilised in many commercially available CSPs. 
The importance comes from its ability to interact strongly, mainly through it-it 
forces, with analyte enantiomers. This strong interaction enhances the scale of 
transient diastereomeric energies, thus improving the chances for chiral separation. 
A library of CSPs with alternative end groups was synthesised and screened against 
a small library of racemate analytes. The results were compared to identical 
screenings using a CSP with the 3,5-dinitrobenzoyl end group (5). Although the 
library of CSPs could not improve upon the separation ability of CSP (5), it did 
give an important insight to show how important all the features of the 3,5-
dinitrobenzoyl group were. Removal or movement around the ring of nitro moieties 




For a dipeptidic type CSP, the second amino acid from the silica bead was found to 
have more influence on the overall chiral separation ability of the CSP. This was 
found by switching the optical character of the dipeptidic CSP structure. 
Incorporating two 3,5-dinitrobenzoyl groups into the CSP structure could also not 
improve the CSP's ability over that of CSP (5) containing one 3,5-dinitrobenzoyl 
group. This is possibly because the second 3,5-dinitrobenzoyl a group is competing 





3 	Surface plasmon resonance biosensor screening of chiral 
stationary phase ligands. 
3.1 	Protein based CSPs 
3.1.1 	Introduction 
The determination of appropriate chiral stationary phase media, for the separation 
of a given optically active racemate, is generally a difficult procedure. Historical 
precedent for separation of structurally similar racemates gives ideas to possible 
useful CSPs, however, even the smallest structural differences between analytes 
can show a dramatically different behaviour on the same column. 
Separation of any given novel racemic compound thus firstly requires selection of a 
CSP from hundreds of commercially available CSP columns, sometimes without 
indication which columns may potentially allow successful separation of the 
analyte247 . 
The determination of an appropriate CSP medium requires a faster approach to the 
screening of the racemate analyte on chiral stationary phase materials. Standard 
HPLC setup is limited to the screening of only one CSP at a time therefore, this can 
be very time consuming process. Of all the commercially available CSPs, there are 
approximately twenty to thirty that are regarded as those with the highest possible 
chance of success, with a very high chance that at least one member of these elite 
CSP columns will successfully separate any give racemate 247 . 
Screening of a given racemate on all twenty to thirty CSPs is however itself a very 
time consuming process, without taking into account the infinite number of 
chromatographic changes that are possible. The parallel screening of all CSPs 
simultaneously is possible, but is beyond the fiscal means of all but the largest of 
research budgets and does not overcome the further problems in chromatographic 
optimisation. 
Surface plasmon resonance (SPR) biosensors are primarily used to monitor the 
interaction between an immobilised biomolecule and a flowing solution of another 




material is monitored in real time by the biosensor system utilising the surface 
plasmon resonance phenomena. 
The SPR biosensor has many similarities to that of HPLC. An HPLC trace is the 
resultant of the sum of many thousands of interactions between immobilised-
molecule and analyte-molecule over the whole column. SPR biosensors measure 
instantaneous real-time interactions between a material immobilised onto a sensor 
in the device and a solution of analyte flowing over the sensor's surface. 
3.1.2 	Synthesis of protein CSPs 
As SPR biosensors are used to monitor biomolecule-based interactions. It was 
decided that biomolecule-based CSP materials could be used for initial screenings 
on HPLC. 
There are a small number of biomolecules that have previously been used for CSP 
columns 174 . Some commercially available CSP columns of this type use cheap 
readily available proteins such as Bovine Serum Albumin (BSA) and Human 
Serum Albumin (HSA), and these proteins can be covalently attached to silica to 
give the required CSPs. 
Synthesis was achieved following a literature procedure for synthesising a protein 
CSP 128 . Aminopropyl silica needed to be chemically activated before the protein 
could be immobilised to it. This was achieved using a large excess of 
N,N'-disuccinimidyl carbonate (10 eq.). The silica was then filtered, washed and 
dried to give the aminopropyl silica with a carbo-succinimidyl activating group 
(57). To a solution of activated silica (57) in phosphate buffer (pH 6.8) was slowly 
added the protein, BSA or USA whilst carefully maintaining the pH. The amine 
groups present on the lysine residues of the protein displace the succinimide group 
on the silica to form a strong urea bond, thus immobilising the protein to the silica 
to give the desired CSPs (58) and (59) having immobilised BSA and HSA 













p xNAN € 
(a) NN'-discuccinimidyl carbonate, MeOH, (b) (58) X = BSA, Bovine Serum Albumin, 
phosphate buffer pH 6.8, (59) X = HSA, Human Serum Albumin, phosphate buffer pH 6.8 
Scheme 20 Synthesis ofprotein based CSPs (58) and (59) 
3.1.3 	Screening of protein CSPs 
3.1.3.1 Initial screening ofprotein CSPs 
These protein CSP columns were then screened using commercially available small 
molecule racemic analytes; benzoin, warfarin, ibuprofen, chlorpheniramine, 
bendroflumethiazide. With the nature of the CSPs involved in this screen, the 
HPLC was always used in reverse phase mode and initial screenings used 
phosphate buffer based mobile phases with small quantities of organic modifiers. 
The five analytes were run on both CSP columns (58) and (59), using six different 
chromatographic conditions; two phosphate buffer concentrations (10 mM and 
50 mM) and three buffer pHs (6.5, 7.0 and 7.5) using a ramped gradient of 1-PrOH 
as an organic modifier (2% isocratic for t = 0-10 mm, 2-10% gradient over 
t = 10-30 mm, 10% isocratic for t = 30-40 mm, 10-2% gradient over t = 40-50 mm, 
2% for t = 50-60 mm) at a flow rate of 0.5 mLmin' flow rate. However, the 
screening of the CSPs all showed either no separation or ambiguous results. Both 
the CSPs were resynthesised and screened again using some of the same 
chromatographic conditions. A number of other combinations of gradients, organic 
modifiers (2-PrOH, EtOH) and flow rates (0.2-1.0 mLmin') were also 




3.1.4 	Screening of commercial protein CSPs 
3.1.4.1 Introduction 
Commercially available protein CSP columns were used at GSK, Stevenage. These 
columns could be used for the chiral screening of some small molecule 
enantiomers whilst also gaining valuable knowledge aimed at improving 
chromatographic conditions. 
An immobilised bovine serum albumin column was purchased, from Nagel, 
Resolvosil BSA-7 (100 mm length x 4.0 mm i.d.) was used, along with a human 
serum albumin column and a a 1 -acid glycoprotein (AGP) column, manufactured by 
ChromTech AB (Chiral-HSA and Chiral-AGP respectively; both 50 mm length x 
4.6 mm i.d.). These columns will be known as BSA-CSP, HSA-CSP and 
AGP-CSP. - - - - - - 
Due to this single enantiomers of the analytes will now be used, as this improves 
the clarity of the HPLC spectra results. These single enantiomers will also be 
imperative for the future SPR biosensor screenings. Both Chlorpheniramine and 
Bendroflumethiazide are both deemed unsuitable for the future screenings, as they 
are both commercially unavailable for purchase as discrete single enantiomers and 
suitable semi-preparative chiral separation methods could not be determined. 
Analytes were initially screened using one of two generic gradient methods. Both 
methods used a mobile phase combination of ammonium acetate buffer (pH 7.4) 
(A) and 2-PrOH (B). 
Protein gradient method I 	 Protein gradient method 2 
Time/min Eluent A/% Eluent B/% 
0 100 0 
15 75 25 
25 75 25 
25.1 100 0 
30 100 0 
Time/min Eluent A/% Eluent B/% 
0 100 0 
15 50 50 
25 50 50 
25.1 100 0 
30 100 0 





The time of sample elution in the generic screening was used as a guide for the 
alcohol modifier concentration for an individually tailored isocratic mobile phase 
composition run. 
3.1.4.2 Benzoin 
OH 	 OH 
0 
R-Benzoin 	 S-Benzoin 
Figure 20 R- and S-Benzoin 
Initial screens of R and S-Benzoin enantiomers on a BSA-CSP column, used 
protein gradient method 1 (section 3.1.4.1). Results of this screen (Figure 21) 
indicate that Benzoin bound very weakly, therefore subsequent isocratic screening 
used a small concentration of 2-PrOH (3%). 
*Mobile  phase = protein gradient method 1, flow rate = 1.0 mLmin, viewed at 254 nm 
Figure 21 Screening of R and S-Benzoin on BSA-CSP 
Isocratic screening results (Figure 22) confirmed that the elution order was S-
Benzoin eluted before the more strongly retained R-enantiomer, which had already 









*Mobile  phase = Ammonium acetate buffer (pH 7.4)/2-PrOH (97:3), flow 
rate = 1.0 mLm in', viewed at 254 nm 
Figure 22 Screening of R and S-Benzoin on BSA-C'SP (rescreen with isocratic elution) 
Similar to the gradient screening on BSA-CSP, both HSA-CSP and AGP-CSP 
indicated a weak interaction between both proteins and the analyte enantiomers, 
and therefore both were analysed with isocratic runs with ammonium acetate buffer 
(pH 7.4) as the sole content of the mobile phase. 
*Mobile  phase = Ammonium acetate buffer (pH 7.4), flow rate = 0.5 mLmin', viewed at 
254 nm 
Figure 23 Screening of R and S-Benzoin on HSA-CSP 
HSA-CSP screening results (Figure 23) showed that S-Benzoin eluted before 
R-Benzoin, whereas in the AGP-CSP screen (Figure 24) this order was reversed; 




*Mobil e  phase = Ammonium acetate buffer (pH 7.4), flow rate = 1.0 mLmin t , viewed at 
254 nm 





Figure 25 S- and R- Warfarin 
Individual enantiomers of R and S-Warfarin are commercially available. However, 
the cost of these enantiomers was greater than £50 mg' and therefore a semi-
preparative chiral separation method was utilised. Racemic Warfarin, was 
separated using ChiralCel-OD, a commercially available chiral column 
manufactured by Daicel (150 mm length by 4.6 mm i.d). Chiral separation was 
achieved with sequential injections of (RS)-Warfarin (-10 mg per injection) with a 
mobile phase composition of heptane/2-PrOH/acetic acid (80:20:1) and flow rate of 
1.0 mLmin', with samples collected using an HPLC integrated automated collector 
based on detection at 254 nm. The dried single enantiomers of (R)-Warfarin 
(>99.9% ee, determined by HPLC integration) and (S)-Warfarin (>99.9% ee) were 




Gradient screenings of Warfarin indicated that organic modifier (2-PrOH) 
concentrations of approximately 10% should be suitable for the subsequent 
isocratic screenings for all three protein CSPs. However gradient screening of 
Warfarin on both HSA-CSP and AGP-CSP gave better results in comparison to the 
previous isocratic screening runs, which gave much larger peak tailing. 
For BSA-CSP isocratic screenings (Figure 26) showed a clear difference in 
retention of sample with S-Warfarin eluted before the more strongly retained 
R-Warfarin. 
*Mobile phase = Ammonium acetate buffer (pH 7.4)/2-PrOH (90:10), flow 
rate = 1.5 mLmin 1 , viewed at 280 nm 
Figure 26 Screening of R and S- Warfarin on BSA-CSP. 





* Mobile phase = protein gradient method 2, flow rate = 1.0 mLmin', viewed at 280 nm 
Figure 27 Screening of R and S- Warfarin on HSA-CSP. 
AGP-CSP gave the same order of enaritiomer elution as BSA-CSP (S before R) 
(Figure 28). 
* Mobile phase = protein gradient method 2, flow rate = 1.0 mLmin 1 , viewed at 280 nm 










Figure 29 R- and S-Ibuprofen 
Unlike Warfarin, single enantiomers of Ibuprofen were commercially available and 
reasonably priced with good optical purity (>99% ee). 
Results from preliminary gradient screenings of Ibuprofen indicated that relatively 
high concentrations of 2-PrOH modifier were necessary for elution. The screening 
of Ibuprofen on BSA (Figure 30) required the mobile phase to contain some 40% 
2-PrOH. 
N 
* Mobile phase = Ammonium acetate buffer (pH 7.4)/2-PrOH (60:40), flow 
rate = 1.0 mLmin', viewed at 230 nm 
Figure 30 Screening of R and S-Ibuprofen on BSA -('SF 
The screening of Ibuprofen on HSA-CSP (Figure 31) was better using the protein 
gradient method 2 (section 3.1.4.1). The elution order observed for R and 
S-enantiomers on both BSA and HSA-CSP was the same, with S-Ibuprofen eluting 
before R-Ibuprofen. No separation was observed when screened on AGP-CSP. 
This may be due to a much lower binding interaction between the acidic Ibuprofen 
and the acidic protein AGP. However, screenings of Ibuprofen on AGP-CSP in the 






* Mobile phase = protein gradient method 2, flow rate = 1.0 mLmin', viewed at 230 nm 









Figure 32S- and D- Tryptophan 
The final analyte for screening on the protein CSP was Tryptophan. Tryptophan is 
a common a-amino acid and is therefore readily available in both enantiomeric 
forms. Although it was not originally included as a possible screening analyte, its 
ease of availability gave a good opportunity to expand the screening data set. No 
organic modifier was necessary for any of the screenings. On BSA-CSP (Figure 
33), Tryptophan was weakly retained, by the column. However, analysis was 




* Mobile phase = Ammonium acetate buffer (pH 7.4), flow rate = 1.0 mLmin 1 , viewed at 
280 nm 
Figure 33 Screening of R(D) and S(L)-Tryptophan on BSA-CSP 
BSA-CSP (Figure 34), gave similar to results to HSA-CSP, and again gave low 
overall retention of Tryptophan on the column, but in this case R(D)-Tryptophan 
was better retained than the S(L)-Tryptophan enantiomer. 
On the final protein CSP column, AGP-CSP, Tryptophan was found to bind so 
weakly that both enantiomers were eluted within 2 mm, even with the flow rates as 
low as 0.2 mLmin'. 
* Mobile phase = Ammonium acetate buffer (pH 7.4), flow rate = 1.0 mLmin 1 , viewed at 
280 nm 




3.1.5 	Summary of protein CSP screening results 
Four analytes were screened on three separate protein CSP columns, using reverse 
phase HPLC. Chiral separation values for each separation have not been taken in 
this case. The nature of chiral separation means that there are numerous variable 
chromatographic factors resulting in an infinite number of specific conditions 
possible for each given separation and the screening results obtained. Thus 
Ibuprofen on HSA-CSP and Benzoin on BSA-CSP can not be compared directly by 
separation factor, because neither separation is fully optimised, nor are they 
optimised to the same degree. As well as the number of controllable 
chromatographic conditions possible, there are a number of uncontrollable factors 
such as the amount and condition of protein immobilised. 
One resultant factor that should not change, within the same HPLC mode, is the 
order of elution for enantiomers of the analyte. The order of elution gives definitive 
information as to which enantiomer binds more strongly to the immobilised protein 
in the CSP column. The relative binding strength is opposite to that of the 
measured elution order and the overall results of the protein CSP screenings are 






Screening elution order 











Ibuprofen No data 
Tryptophan No data 







3.2 	Surface plasmon resonance biosensor 
3.2.1 	Introduction 
SPR biosensors enable label-free detection of analytes binding to immobilised 
biomolecules and provide real-time quantitative information on binding 
interactions. 
The sensor chip contains a gold layer, which creates the physical conditions 
required for surface plasmon resonance. Essentially, SPR detects mass changes in 
the aqueous layer close to the sensor chip surface by measuring changes in 
refractive index. Binding molecules increase the mass and the dissociation of 
bound molecules decrease mass, which allows continuous, real-time measurements 
via a sensorgram. 
SPR biosensors can provide information on a number of factors: specificity, of the 
binding between two sets of molecules; concentration, of a particular active 
molecule; kinetics, the rates of association and dissociation of the binding partners; 
affinity, how strong the binding is between analyte and the immobilised partner 
molecule. 
The screening of the same enantiomer analytes, as used for the previous HPLC 
protein CSP screening, on the SPR biosensor will show if there are useful 
relationships between the two different analytical technologies. A link in the results 
obtained from the SPR biosensor and chiral HPLC gives the possibility of utilising 
a modified SPR biosensor device as a high-throughput determinator of suitable 
CSP media for larger scale separation. The high-throughput possibility arises as 
some modem SPR biosensors can be used to screen large numbers of immobilised 
molecules simultaneously with the same analyte {Biacore, Accessed on 10/12/07 
#219}. 
The screening in this section was carried out using a BlAcore S5 1 0 SPR biosensor. 
This particular device can accommodate two different immobilised samples as well 
a blank sample for reference. The screening makes use of the SPR biosensor' s 
ability to measure the affinity of binding interaction and screening was carried out 
using both individual single enantiomer analytes as well as the racemate analyte of 




As the sensitivity of the equipment will be challenged, it possible that systematic 
and human error may affect these screening results. To reduce the amount of 
screening data affected by this, a nested design (Figure 35) was developed so that 
all the controllable factors are duplicated. 
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Figure 35 Nested design of SPR biosensor enantioner screening structure. 
The Biacore®  S51 SPR biosensor uses a 96 well plate for analyte samples. The 
screening ran every compound (e.g. Warfarin) as both of its single enantiomers and 
as the racemate. Each analyte (e.g. R-Warfarin) was run over a large concentration 
range (from 0.195 M to 100 riM) as well as two zero concentration runs for each 
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* 72 of the 96 wells are shown. The other (2 x12) wells were unused. 
Figure 36 Typical layout of BIA core SPR biosensor sample well plate. 
3.2.2 	SPR Biosensor chip preparation 
Before screening of the enantiomers and racemates on the SPR biosensor, the 
protein binding partners of the analytes had to be immobilised onto the sensor chip 
(Series S - CM5). 
Chapter 3 	 95 
The sensor chip consists of a glass surface coated with a thin layer of gold covered 
with carboxymethylated dextran. Surface carboxy group are available for 
derivatisation, allowing the immobilisation of biomolecules. 
The immobilisation of the proteins onto the sensor chip were achieved in-situ, with 
all reagents flowing over the sensor's surface, in the same way as screenings take 
place. The sensor chip has three separately addressable spots. The first spot will 
contain one immobilised protein (e.g. BSA sample 1), the second spot will also 
contain another immobilised protein (e.g. BSA sample 2 or HSA sample 1), and the 
third spot is left blank and is used as a reference spot for vital run calibration. 
3.2.2.1 Amine coupling immobilisation of BSA and HSA 
Both BSA and HSA were immobilised onto the sensor surface by forming covalent 
amide bonds with the carboxy derivatised surface. This was achieved using 
standard amine-coupling procedure in accordance with BlAcore® procedural 
handbook. 
Initially a new sensor chip (S series CM5) was flushed with a steady flow of the 
running buffer (PBS (pH 7.4)/DMSO (99:1). The first step in immobilisation was 
activation of the sensor chip with EDC and NHS, to form active succinimide esters. 
Injected protein ligand (BSA or HSA) then flows over the sensor surface and the 
succinimide esters react with the amino groups or other nucleophilic groups on the 
protein to covalently link the protein ligand to the dextran. The BlAcore S51 
biosensor automatically immobilises the sensor surface to approximately the 
requested concentration of protein, which is measured by the biosensor device in 
response units (RU, 1RU 1 pgmm 2 for most proteins, normal immobilisation 
range 4-10 kRU). This is achieved by an initial small injection of protein, which 
corresponds to a measured level of immobilisation. From this, the approximate 
amount of protein required is calculated and injected into the system for complete 
immobilisation. Once the protein (BSA or HSA) has been immobilised onto the 
sensor chip surface, any remaining active succinimide ester groups are reacted with 
ethanolamine, followed by 'cleaning' of the sensor chip using BlAdesorb solutions 
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* Grey block represents the Dextran layer sitting on gold. 
"Immobilisation uses a flow of reagent over the sensor surface. 
(a) (i) Running buffer; PBS (pH 7.4)/DMSO (99:1), 
N-Hydroxysuccinimide (NHS) (400 mM), 
N -ethyl -N '-dimethylaminopropyl-carbodiimide (EDC) (400 mM), 
(b) BSA (50 .tgmL') in NaOAc (pH 5.5, 10 mM)(c)(i) Ethanolamine-HO (pH 8.5, 1.0 
M), (ii) BlAdesorb 1; sodium dodecyl sulphate (0.5% w/v), 
BlAdesorb 2; Glycine (pH 9.5, 50 mM), 
Running buffer; PBS (pH 7.4)/DMSO (99:1) 
Scheme 21 Loading of a BIA core S series CM5 chip with BSA onto the surface. 
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* 30-150s = Injection of protein ligand solution (test concentration), 350-950s = NHS/EDC 
injected, 1100-1 700s = sequential injection of protein ligand solution with subsequent 
immobilisation to sensor surface. 
** Blocking of unreacted succinimide ester with Ethanolamine after immobilisation is not 
shown in sensorgram. 




3.2.2.2 Surface thiol coupling immobilisation ofAGP 
The amine coupling immobilisation method used for BSA and HSA proteins could 
not be used for the immobilisation of AGP. Both BSA and HSA have a relatively 
high isoelectric point (p1 = 4.7) and available amine groups, so amine coupling is 
the first choice for these ligands. AGP (p1 = 2.7) is much more acidic therefore is 
not suitable for amine coupling, with the lack of free amine groups and electrostatic 
repulsion from the negatively charged dextran matrix on the sensor chip means 
than an alternative method was necessary. 
The thiol coupling chemistry is an alternative to the amine chemistry which can 
give fast and efficient immbolisation. For thiol coupling the protein ligand (AGP) 
has to be substituted with PDEA (2-(2-pyridinyldithio)ethaneamine), which raises 
the isoelectric point of the protein and improves the electrostatic interaction with 
the surface dextran matrix prior to coupling. - - 
Initially the new sensor chip (S series CM5) was flushed with a steady flow of the 
running buffer (PBS (pH 7.4)IDMSO (99:1). The first step involves formation of 
the active succinimide ester on the surface with the addition of EDC and NHS. The 
surface is then derivatised by the addition of cystamine, leaving free thiol groups 
on sensor chip. This step may leave some unreactive disulphide groups on excess 
cystamine reacting with the surface thiol groups. To resolve this, a solution of DTE 
(Dithioerythritol) is flown across the sensor to reduce the disulphide groups back 
into their reduced thiol forms. 
The PDEA-modified-AGP solution was prepared by dissolving human a-acid 
glycoprotein (AGP) and PDEA in MES buffer (pH 5.0, 0.1 M), followed by the 
addition of EDC (400 mM) and was then left to incubate for ten minutes at room 
temperature before changing the buffer to citrate buffer (pH 3.6, 10 mm) by size 
exclusion chromatography using an equilibrated NAP-10 column (prepacked 
sephadex G-25 column). The PDEA-modified-AGP was then further diluted with 
citrate buffer to 100 mlvi. 
As before, this solution is then flowed across the thiol sensor chip surface and the 
reactive disulfide groups on the protein ligand react spontaneously with the 
immobilised thiols to covalently attach the protein to the surface. The 




flowing solutions of PDEA and ethanolamine sequentially, followed by washing 
with BlAdesorb solutions. 
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* Grey block represents the Dextran layer sitting on gold. 
**Immobilisation procedure uses flow of reagent sequentially over the sensor surface. 
(a) (i) Running buffer; PBS (pH 7.4)/DMSO (99:1), 
(ii) N-Hydroxysuccinimide (NHS) (400 mM), 
N-ethyl-N'-dimethylaminopropyl-carbodiimide (EDC) (400 mM), (b) Cystamine (40 mM) 
in borate buffer (pH 8.0, 0.1 M), 
(c) Dithioerythritol (DTE) (0.1 M) in borate buffer (pH 8.0, 0.1 M), 
(d) PDEA-modified-AGP (-100 p.gmL') in citrate buffer (pH 3.6, 10 mM), 
(e) (I) PDEA (20 mM), (ii) Ethanolamine-HCI (pH 8.5, 1.0 M), 
(ii) BlAdesorb 1; sodium dodecyl sulphate (0.5% w/v), 
(iii) BlAdesorb 2; glycine (pH 9.5, 50 mM), 
(iv) Running buffer; PBS (pH 7.4)/DMSO (99:1) 





3.2.3 	Screening on SPR Biosensor 
3.2.3.1 Introduction 
Once the protein has been immobilised onto the sensor surface, the SPR biosensor 
was ready for the screening of analytes. All analyte samples were taken from 
identical batches used in previous HPLC protein screening (section 3.1.3). Samples 
were firstly weighed using a calibrated high precision balance (±0.00000005 g or 
±0.00005 mg). Samples were then dissolved in DMSO (ca.> 1000 L) (±0.25 tL), 
followed by vortexing and sonication if necessary to give a fully dissolved 10 mM 
sample in DMSO. An aliquot (10 p.L) of this solution was then taken up into PBS 
buffer (990 j.tL, pH 7.4) to give a 100 j.tM sample in PBS (pH 7.4)/DMSO (99:1). 
The 100 jiM sample was used as the highest concentration sample of the SPR 
biosensor well plate. Serial dilutions of the 100 jiM sample, with the running buffer - 
of PBS (pH 7.4)IDMSO (99:1), across the subsequent nine wells, gave samples 
with concentrations of: 50 jiM, 25 jiM, 12.5 jiM, 6.25 jiM, 3.125 jiM, 1.5625 jiM, 
0.78 125 jiM, 0.39063 jiM and 0.19531 jiM. Each of the samples are in a solution 
equal to the running buffer (PBS (pH 7.4)/DMSO (99:1)), with the final two wells 
as blanks, filled only with the running buffer. 
For one 96 well plate used for screening on the SPR biosensor, each sample 
(e.g. R-Warfarin) had one row of wells (ten sample solutions at different 
concentration and two blanks). Six rows of wells on the plate were used per run; 
corresponding to six different samples. The BlAcore S51 screened each row 
sequentially. Firstly the two blank runs were screened, followed by the 0.19531 jiM 
sample and then in order of increasing sample concentration, after which the next 
row of samples were screened. 
3.2.3.2 Warfarin 
The screening, data collection and data reprocessing was carried out in the same 
manner for all analytes. SPR biosensors measure the 'crude' sensorgram's response 
(RU) versus time after injection. Following this, the sensorgram data was then 
corrected by the BlAcore S51, for possible small errors between the composition of 
the running buffer (PBS (pH 7.4)/DMSO (99:1)) and the solution of the samples 




solution flowing over the sensor spot, will result in a large difference in refractive 
index and therefore response measures. This is achieved by running further blank 
samples with slightly altered composition to cover the possible error in solution 
make-up. The response measured from the reference spot, with no immobilised 
protein, is compared to the simultaneous response measured from a protein 
immobilised spot (Figure 38). 
RU 
-1000 	4100 	-000 	- 	-200 	0 	200 	400 	600 	800 	1000 
80R9RnRR (lI) 	 RU 
* Red lines represents the range of the data measured on the reference spot (no protein 
immobilised) 
Figure 38 Typical solvent correction on BIA core S51 
The software plots the average response of each sample (RU) versus sample 
concentration (p.M) (e.g. Figure 39). At this point, all erroneous data points are 
removed. These are a fairly common occurrence in the BlAcore screening, which 
arise due to several factors which may affect the screening data. One likely cause is 
small solids in the running buffer (even after two filtration steps; in preparation and 
in the BlAcore device). These can cause partial blockages in the small channels 
that lead the flow over a sensor spot. It is therefore common that numerous 
consecutive sample runs or even a whole batch of run have erroneous results. A 
partial blockage can sometimes be unblocked spontaneously by the flow of running 
buffer, thus returning the system to normal. Erroneous results are generally far 
from the expected binding curve formed. 
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Figure 39 BIA core screening of R-Warfarin on HSA 
To compare the screenings of enantiomers, which were run separately to each 
other, the binding response values are extracted and comparative runs of 
enantiomers zeroed (so that all response data curves start at 0 RU) and then plotted 
on the same graph for comparison. 
I 	 I 
Response vs concentration! jiM 	 Response vs concentration/ pM 
Blue = R-Warfarin, Hiik = RS-Warfarin, 	= S-Warfarin 
Graph 12 Normalised results of BJA core screening of Warfarin (screening order R, RS, S) 
on HSA (left) and BSA (right). 
A comparison between the SPR biosensor binding strength results of the R and S 
enantiomers is shown in Graph 12. The results are compared for each given 




immobilised protein. Data is also shown with other factors which may contribute 
towards systematic and human error, enantiomer run order (R or S screened first), 
sample preparation number and the age of the chip (after immobilisation of the 
protein). 
Strongest 	Run 	 Strongest 	Run 
Sample 	binding Order Sample 	
Chip 
Age 	
Sample 	binding Order 
conc./i.JM enantiomer (R or S 	Prep. conc./pM enantiomer (R or S 





0.19531 S R 1 4 6.25 5 
0.39063 S R 1 4 12.5 5 
0.78125 S R 1 4 25 5 
1.5625 5 R 1 4 50 5 
3.25 5 R 1 4 100 5 
6.25 S R 1 4 0.19531 S 
12.5 S R 1 4 0.39063 5 
25 S R 1 4 0.78125 5 
50 R R 1 4 1.5625 5 
100 R R 1 4 3.25 5 
0.19531 S S 2 1 6.25 5 
0.39063 5 5 2 1 12.5 5 
0.78125 S 5 2 1 25 R 
1.5625 S 5 2 1 50 R 
3.25 S S 2 1 100 R 
Table 10 Results from BIA core SPR screening of Warfarin on HSA 
5 	2 1 
5 2 1 
5 	2 1 
5 2 1 
5 	2 1 
R 2 1 
R 	2 1 
R 2 1 
R 	2 1 
R 2 1 
R 	2 1 
R 2 
R 	2 1 
R 2 1 
R 	2 1 
For the Warfarin analyte there were a total of six successful runs, three on HSA 
and three on BSA. This gave a total of thirty pairs of R and S data points for 
Warfarin on HSA and twenty eight pairs for Warfarin on BSA. 
Strongest 	Run 	 Strongest 	Run 
Sample 	binding Order 	Sample 	
Chip 
Sample 	binding Order Sample 	
Chip 
conc./iiM enantiomer (R or S 	Prep. 






0.19531 5 R 1 4 12.5 R 
0.78125 5 R 1 4 25 R 
1.5625 5 R 1 4 50 R 
3.25 5 R 1 4 100 R 
6.25 R R 1 4 0.19531 R 
12.5 R R 1 4 0.39063 R 
25 R R 1 4 0.78125 R 
50 R R 1 4 1.5625 R 
100 R R 1 4 3.25 R 
0.19531 R S 2 1 6.25 R 
0.39063 S S 2 1 12.5 S 
0.78125 5 S 2 1 25 R 
1.5625 R 5 2 1 50 R 
6.25 R 5 2 1 100 R 
Table 11 Results from BIA core SPR screening of Warfarin on BSA 
5 	2 1 
S 2 1 
5 	2 1 
5 2 1 
R 	2 1 
R 2 1 
R 	2 1 
R 2 1 
R 	2 1 
R 2 1 
R 	2 1 
R 2 1 
R 	2 1 
R 2 1 
SPR biosensor screenings of Warfarin on AGP gave no usable data. The overall 


















































































values of Warfarin on HSA and BSA. This caused an increase of the noise to signal 
ratio and resulted in a larger number of erroneous results. The binding of Warfarin 
and AGP proved to be too weak, for the particular concentrations of immobilised 
AGP and Warfarin used, for reliable data. 
All the data obtained from the screening of Warfarin on SPR biosensor was then 
collated with the data obtained from other SPR biosensor analyte screenings. 
3.2.3.3 Ibuprofen 
Screening and data analysis of Ibuprofen on the SPR biosensor was carried out 
using procedures analogous to those described for Warfarin. Larger numbers of 
Ibuprofen sample preparations and the overall number of times the analyte was 
screened was higher in comparison to the Warfarin screens, to increase the overall 
quantity of the data set for SPR screenings. 
For the Ibuprofen analyte there were a total of fourteen successful runs, seven on 
HSA and seven on BSA. This gave a total of sixty six pairs of R and S data points 
for Ibuprofen on HSA and sixty-five pairs for Ibuprofen on BSA. 
	
Sample Chip 	
Strongest 	Run 	 Chip 
Sample 	binding Order Sample 
Prep 	
Age conc/pM enantiomer (R or S 	Prep. 	
Age 
(days) 	 (days) 
(SPR) 	first)  
1 	1 6.25 R 5 4 0 
1 1 12.5 R 5 4 0 
1 	1 25 R 5 4 0 
1 1 50 R 5 4 0 
1 	1 100 5 5 4 0 
1 1 0.19531 R R 4 0 
1 	1 0.39063 R R 4 0 
1 1 0.78125 R R 4 0 
1 	1 1.5625 R R 4 0 
2 3 3.25 R R 4 0 
2 	3 6.25 R R 4 0 
2 3 12.5 R R 4 0 
2 	3 25 R R 4 0 
2 3 50 R R 4 0 
2 	3 100 R R 4 0 
2 3 0.39063 R R 5 2 
2 	3 0.78125 R R 5 2 
2 3 1.5625 R R 5 2 
3 	3 3.25 R R 5 2 
3 3 6.25 R R 5 2 
3 	3 12.5 R R 5 2 
3 3 25 R R 5 2 




6.25 R R 3 3 100 R R 5 2 
12.5 R R 3 3 0.39063 S S 5 2 
25 R R 3 3 0.78125 R S 5 2 
50 R R 3 3 1.5625 R S 5 2 
100 R R 3 3 3.25 S S 5 2 
0.19531 R S 4 0 6.25 S S 5 2 
0.39063 R S 4 0 12.5 S S 5 2 
0.78125 R S 4 0 25 S S 5 2 
1.5625 R 5 4 0 50 R S 5 2 
3.25 R S 4 0 100 S 5 5 2 
Table 12 Results from BL4 core SPR screening of Ibuprofen on HSA 
Strongest Run 
Chip Strongest Run Chi 
Sample  binding Order Sample A Sample binding Order Sample Age  
con  M p 
enantiomer (R or S Prep. 
(days)  conc/pM enantiomer (R or S Prep. 'd (SPR) first) (SPR) first) ' 
0.19531 S R 1 1 50 R S 4 0 
0.39063 R R 1 1 100 R 5 4 0 
0.78125 R R 1 1 0.19531 R R 4 0 
1.5625 . R R 1 1 0.39063 . 	R R 4 0. 
6.25 R R 1 1 0.78125 R R 4 0 
12.5 R R 1 1 1.5625 R R 4 0 
25 R R 1 1 3.25 R R 4 0 
50 R R 1 1 6.25 R R 4 0 
100 R R 1 1 12.5 R R 4 0 
0.19531 R R 2 3 25 R R 4 0 
039063 S R 2 3 50 R R 4 0 
0.78125 R R 2 3 100 R R 4 0 
1.5625 R R 2 3 0.19531 R R 5 2 
3.25 R R 2 3 0.39063 R R 5 2 
100 S R 2 3 0.78125 R R 5 2 
0.19531 R R 3 3 1.5625 R R 5 2 
0.39063 R R 3 3 3.25 R R 5 2 
0.78125 R R 3 3 6.25 R R 5 2 
1.5625 R R 3 3 12.5 R R 5 2 
3.25 R R 3 3 25 R R 5 2 
6.25 R R 3 3 50 R R 5 2 
12.5 R R 3 3 100 R R 5 2 
25 R R 3 3 0.19531 S S 5 2 
50 R R 3 3 0.39063 5 S 5 2 
100 R R 3 3 0.78125 R 5 5 2 
0.19531 R 5 4 0 1.5625 R 5 5 2 
0.39063 R 5 4 0 3.25 R S 5 2 
0.78125 R 5 4 0 6.25 S S 5 2 
1.5625 R 5 4 0 12.5 R S 5 2 
3.25 R S 4 0 25 R 5 5 2 
6.25 R S 4 0 50 R 5 5 2 
12.5 R S 4 0 100 R 5 5 2 
25 R 5 4 0 
Table 13 Results from BIA core SPR screening oflbuprofen on BSA 
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However, as with Warfarin, the interaction of Ibuprofen with immobilised AGP 
failed to give any meaningful results. Again, the overall magnitude of binding 
response was too low between this pair both of which are acidic. 
3.2.3.4 Benzoin 
SPR biosensor screenings of Benzoin gave a lower magnitude of response in 
comparison to Warfarin and Ibuprofen. This indicates that both enantiomers of 
Benzoin have lower affinity to bind to the immobilised proteins than Warfarin and 
Ibuprofen analytes (this was also indicated by the short rentention times in the 
HPLC screenings of Benzoin). Therefore the noise to signal ratio was larger, 
reducing the reliability of accurate screened patterns between enantiomer binding 
differences. 
The binding responses measured were approximately zero for all samples of 
concentration of 12.5 tM and below, leaving only three useful pairs of results per 
sample. For the Benzoin analyte there were a total of six completed runs, three on 
HSA and three on BSA. This gave only nine pairs of R and S data points for 
Benzoin on HSA and nine pairs for Benzoin on BSA. The results show that R-
Benzoin binds more strong to BSA immobilised protein and conversely S-Benzoin 
more strongly to HSA, however there are limited data available to support 
definitive conclusions for this (these data will be collated with Warfarin and 
Ibuprofen SPR screening results for further analysis later in this chapter). All 
screening attempts involving Benzoin on AGP failed to give any useful data. 
3.2.3.5 Tryptophan 
These result displayed a similar binding response magnitude as seen in the SPR 
screening of Benzoin with very low binding levels making analysis with all but the 
highest concentration samples useless. 
Tryptophan was run twice on HSA and twice on BSA; six sets of data obtained for 
each protein. Results indicated that S (or L)-Tryptophan enantiomer had stronger 
binding to both immobilised proteins, compared to R (or D)-Tryptophan. 
However, as with the Benzoin SPR screening the low number of data points 




As with the data from the Benzoin screen, AGP screening with Tryptophan failed 
to give any usable results. 
3.2.4 	Summary of SPR biosensor screening results 
Warfarin, Ibuprofen, Benzoin and Tryptophan enantiomer analytes were screened 
over a large sample concentration range on a BlAcore S5 1 SPR biosensor. The 
analytes were screened for their binding affinity to immobilised proteins (HSA, 
BSA and AGP). The comparative binding affinities of each analyte enantiomer 
were used to ascertain which enantiomer had the strongest binding affinity with 
each immobilised protein, at each sample concentration. 
Warfarin and Ibuprofen were found to have a relatively strong binding affinity to 
HSA and BSA, which meant large quantities of data were obtained, not only on the 
relative binding strengths of the enantiomer, but also towards the robustness of the 
screening system [variables include sample preparation (up to five different 
preparations for Ibuprofen), the order of screening enantiomers (R or S first), and 
the age of the immobilised protein]. 
The SPR screenings of Warfarin and Ibuprofen were useful for comparison with 
HPLC screens of the same analytes. Information is garnered on the robustness and 
reliability of the system towards potentially determination of appropriate HPLC 
chiral stationary phase media. 
The data obtained for Benzoin and Tryptophan analytes was much less extensive, 
but still give some insight into the HPLC-SPR biosensor relationship and how it 
changes when analytes with lower binding affinities are used. 
All the SPR screenings with immobilised AGP gave very poor results, mainly due 
to very low overall binding affinity observed with all analytes. This was party due 
to a smaller quantity of protein successfully immobilised onto the sensor chip. The 
reasons for poor immobilisation of AGP onto the sensor are unknown and although 
the immobilisation process was repeated until what was thought to be a high 
enough immobilisation level was obtained, the binding affinity levels were still too 




3.3 	Comparing SPR biosensor screening results with protein CSP 
screening data 
3.3.1 	Screening data correlation 
Chiral HPLC screening of four analytes were carried out to obtain the relative order 
of elution for each pair of analyte enantiomers. The order of elution of an analyte 
was effectively a measure of the binding strength between individual enantiomer 
and the protein immobilised onto the packing materials in the HPLC column. The 
stronger binding enantiomer was retained longer in the column and thus will be 
eluted more slowly, in comparison to the weaker binding and faster eluting 
enatiomers. 
SPR biosensor screenings measure continuous real-time binding interactions 
between analyte enantiomer samples and the protein immobilised onto the sensor 
chip. From these data the magnitude of each binding affinity was obtained and was 
compared with values for the corresponding opposite enantiomers. This gave SPR 
biosensor results showing which enantiomer bound more strongly. 
The following section compares the results of HPLC and SPR to show that the 
screens give comparable data. Chiral HPLC is a very robust screening technique, 
with very little variation in sample retention times. Therefore the elution order of 
enantiomers on HPLC is always the same (under identical chromatographic 
conditions). SPR biosensor binding affinity measurements are less reliable, with a 
certain degree of variation between identical sample runs. HPLC results come from 
the sum of many thousands of interactions as the sample flows through the column, 
therefore creating a natural average. In comparison, SPR measures instantaneous 
real-time interactions between sample and immobilised protein, with these 
interactions averaged over the sample injection time (90 s). 
However, the SPR biosensor does benefit from being faster, more automated and 
has the ability to supply more information simultaneously than HPLC. The use of 
multiple spots gives the possibility of samples being run on numerous immobilised 
materials. The direct comparison between HPLC and SPR biosensor screenings, 
showing all twelve combinations of immobilised protein and analyte are shown 
(Table 14). This summary of SPR biosensor data shows the most predominant 
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results from all of the pairs of data for a particular combination of analyte and 
immobilised protein. 
Protein 	
HPLC Screening elution 	
SPR Screening 
Analyte 	order (e.g. C 	= 	
Predominant binding 
CSP before Y) 
strength (e.g. X-Y = Y 
stronger binding affinity) 
Benzoin S-R 	 s-Ra 
Warfarin S-R 	 SRb 
BSA 
Ibuprofen S-R 
Tryptophan R-S 	 R-S' 
Benzoin S-R SRe 
Warfarin R-S R-S 
Ibuprofen S-R S-R5 
Tryptophan S-R R-S' 
Benzoin S-R No data 
Warfarin S-R No data 
Ibuprofen No data 
Tryptophan No data 
a Predominant relative binding strength from 9 pairs of data (8 = R strongest binder and 
1 = S strongest binder), b  28 pairs of data (21 = S and 7 = R strongest), 
65 pairs of data (6 = Rand 59 = S strongest), d  6 pairs of data (6 = S strongest), 
9 pairs of data (6 = Rand 3 = S strongest), "30 pairs of data (25 = Rand 5 = S strongest), 
g  66 pairs of data (52 = Rand 14 = S strongest), 
h 6 pairs of data (4 = S and 2 = R strongest). 







Apart from AGP, which had no SPR biosensor data, all of the HPLC data 
correlated with the equivalent results from the SPR biosensor on first inspection. 
The exception to the trend was for Tryptophan on HSA, but this had a limited data 
set. 
Statistical analysis 
The correlated data from both the HPLC and SPR biosensor screens of Warfarin 
and Ibuprofen on HSA and BSA immobilised proteins are shown (Figure 40). Each 
mark represents a single SPR biosensor enantiomer screening, which is placed at 
the top or bottom depending on its relative binding strength (SPR). This point is 
correlated with the expected HPLC relative retention of enantiomer on the left or 
right scale. In short, areas at the top-right and bottom left quadrants are collections 
of points where the chiral HPLC and SPR biosensor data correlated well. 
Conversely, marks in the top-left and bottom-right quadrants are miss-matches 
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Ui .' 
: • 
I-1PLC rententian (2=Strongest, 1= Weakest) 
* Warfarin marks represented with circles, Ibuprofen represented with squares 
** Red marks are enantiomer ran first on SPR screenings, blue are enantiomer that 
followed. 
Figure 40 Correlation of all data point between HPLC and SPR biosensor screenings of 




The graph contains 378 marks (from 189 pairs of data). The total number of miss-
matches is 64 marks (or 32 pairs of data). The cumulative binomial probability 
(CBP) of up to 32 failures out of 189 trials is 2.63 x 1021,  using: 
CBP =X!(n-x)!P  (1 - 
p ) fl_X 
Where z = 32 (the number of failed trials), n = 189 (the number of trials) and 
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* Graduated colour of points, higher white saturation indicates lower sample concentration. 
** Triangle marks represent screenings on immobilised BSA, circles on HSA. 
Figure 41 Correlation of all data point between HPLC and SPR biosensor screenings of 
Warfarin and Ibuprofen analytes on HSA and BSA in7mobilised proteins. 
SPR screening order of the enantiomers had no great affect on the results. Figure 
40 shows red marks for the first screened enantiomer of the pair and blue for the 
latter screened enantiomer in the pair. Of the miss-matched pairs, 19 occur when 
what should be the weaker binding enantiomer (from HPLC) was screened first and 
13 occur when the weaker binding enantiomer (from HPLC) was screened second. 
This slight bias can be explained by the presence of a slightly lower quantity of 
immobilised protein being present in the later run. The amount of protein 




but it may be slightly less, which in turn could contribute towards the reduced 
binding affinity recorded for the second enantiomer. 
Concentration of sample used in the SPR biosensor screening is marked with a 
graduated colour scheme; Red (high concentration, 100 .tM) to Clear/White 
(lowest concentration, 0.19531 MM). The miss-match points are a mixture of 
different concentrations; with slightly more being lower concentration samples. 
Therefore the sample concentration range used in SPR biosensor screening is 
suitable for these strong binding analytes (Warfarin and Ibuprofen). 
3.4 	Summary 
Chiral HPLC and SPR biosensor screens were carried out on the enantiomers of 
four analytes; Warfarin, Ibuprofen, Benzoin and Tryptophan. These analytes were 
screened on three proteins; HSA, BSA and AGP, which were all immobilised onto 
either column packing materials or onto the surface of a sensor spot, for HPLC and 
SPR biosensor analysis respectively. 
HPLC screens were carried out on commercially available protein chiral columns. 
Sample retention data were gathered for single enantiomers of each of the analytes. 
The analyte enantiomers were then compared for their relative retention times, 
which was effectively information on the relative binding strength of the 
enantiomers with the immobilised protein of the packing materials. 
SPR biosensor screening focussed on the relative binding strength of the two 
enantiomers constituting an analyte. This was done by obtaining the binding 
affinity value, averaged over the sample injection, for a range of sample 
concentrations. 
Results for the two screening methods were then compared. This was done by 
investigating the relative binding affinity of the enantiomers. If the SPR biosensor 
could correctly predict the relative binding strength of enantiomers in an analyte to 
match the corresponding data from chiral HPLC, then it could lead to the 
possibility of developing high-throughput SPR screenings which would then be 
scaled up for chiral HPLC. 
Compared results were found to match very well, with the majority of SPR 




and Ibuprofen, which were strong binders to HSA and BSA proteins were very 
good. 157 out of 189 pairs of screening data for these analytes gave a matching 
order of elution between chiral HPLC and the SPR biosensor. Weaker binding 
analytes; Benzoin and Tryptophan gave less reliable results. Their lower over 
binding increased the noise to signal ratio therefore the comparative enantiomer 
binding affinities were more likely to switch over compared to the expected result. 
For these analytes results for the higher concentration samples which gave larger 
binding affinities were therefore used, reducing the error and giving more reliable 
results. 
Drawbacks of the SPR biosensor system are the longer overall time required for 
accurate sample preparation, immobilisation of the protein, screening of multiple 
identical samples of different concentrations and the extensive data collection, 
correction and correlation required. As well as this the BlAcore S51 system suffers 
from numerous partial blockages in the flow lines due to their small size. This 
resulted in the loss of information for runs and sometimes whole plates of runs. 
As this research represents only initial findings in this area, it is differcult to draw 
any definitive conclusions. However, with further development and the future 
improvements of SPR technology could make SPR biosensors a valuable tool for 
high-throughput determination of chiral stationary phase media and chiral 
chromatographic conditions for scaled up chiral HPLC. 
Although the BlAcore S51 SPR biosensor has the ability to simultaneously analyse 
samples over two immobilised materials, other SPR biosensors have the ability to 
exceed this number and further future improvement will only increase the number 
of simultaneous analyses possible. Sensor chips with a large range of pre-
immobilised protein can all be analysed simultaneously with the same sample to 
give information as to which protein can best differentiate between enantiomer 
binding strength. A larger array of immobilised materials would also improve the 
accuracy of analysis, by being able to immobilise the materials as duplicates or 
triplicates. 
Further improvement of the SPR biosensing technology will also lead to 
enhancement in measured sensitivity. This gives the possibility of measuring 




molecules. Therefore the SPR biosensor will be able to screen more potential chiral 




4 	Reciprocal based CSPs 
4.1 	Introduction 
This work was based on the premise that, if an immobilised enantiomer (+)-A as a 
CSP could separate a given racemate (+)-B and (-)-B, the counter argument should 
hold that an immobilised enantiomer of (+)-B as a CSP will be able to separate 
racemate (+)-A and (-)-A 210212 . 
Following on from the work carried out in chapter 2, peptidic based materials were 
used to separate a range of racemate analytes, analogues based on the structure of 
anthryl ethanol (34). This chapter investigated the chiral stationary phases based 
upon the use of one enantiomer of anthryl ethanol tethered to a silica support. 
Following a successful synthesis, the CSP was screened against a small array of 
peptidic racemates and epimers, so as to reciprocate the results obtained in Chapter 
2. 
4.2 	Synthesis of reciprocal CSPs 
4.2.1 	Retro-synthesis plan 
Covalent attachment of an enantiomer of anthryl ethanol to the silica required 
modification of the anthryl ethanol structure. Aminopropyl silica was the support 
of choice, so the most appropriate solution was to incorporate a carboxylic acid 
moiety onto the anthryl ethanol. At the same time careful consideration had to be 
paid towards preserving as much of the anthryl ethanol structure as possible, so that 
the interactions between CSP and analyte were not drastically affected. 
As the CSP had to be synthesised en masse, for packing into a HPLC column, the 
amount of optically pure small molecule required was in the region of 1.0 mmol. 
The most obvious point of attachment was the opposite side of the anthracene ring 
to the ethanol moiety, via a 9,10-disubstituted anthracene. Initial plans using this 
approach, started with 9,1 0-dibromoanthracene, however asymmetric 
monoderivatisation of 9,1 0-dibromoanthracene was only possible in very low yield. 
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An alternative point of attachement was via derivatisation of the ethanol moiety. 
This seemed to be a more appropriate choice as it could be achieved starting from, 
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Scheme 23 Planned retrosynthesis of Reciprocal CSP. 
4.2.2 	Forward synthesis of reciprocal CSP 
9-Anthraldehyde 	underwent 	a 	Wittig 	reaction 250, 	251 	with 
methyltriphenylphosphonium bromide, using n-BuLi used as the base to form the 
reactive phosphorus ylide, to give 9-vinylanthracene (60). 
Next the molecule's optical character had to be incorporated. This was achieved 
using a Sharpless asymmetric dihydroxylation method 252 253 using AD-mix a 
reagent to form the desired single enantiomer diol, (S)-1-(9-anthracenyl) ethane-
1 ,2-diol (61), in good yield and excellent optical purity. 
The next part of the synthesis involved both protection of the secondary alcohol 
and leaving the primary alcohol as a free hydroxyl group. This was achieved by 
selective protection of the primary hydroxyl group with TBDMS-Cl, using a bulky 
silyl protecting group (TBDMS), which was achieved in good yield and did not 
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lead to protection of the more sterically hindered secondary hydroxy1254' 255,  which 
gave (S)-1 -(9-anthracenyl)-2-(tert-butyldimethylsilyloxy) ethanol (62). 
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(a) Ph3PCH3Br, BuLj, THF (b) AD-mix a, Water/ tBuOH (1:1), 
(c) TBDMS-C1, Imidazole, DMF, (d) MEM-Ci, DIPEA, DCM, (e) Bu 4NF, MeCN. 
Scheme 24 Start of the synthesis of reciprocal CSP 
The first choice of protecting group for the secondary alcohol was as a 'butyl ether. 
This was due to the extensive use of 'butyl protection in solid phase chemistry, and 
the belief that 'butyl groups could be removed once attached to the solid phase. 
However, two common methods for introducing the 'butyl ether functionality were 
unsuccessful. The use of liquid Isobutylene at -78 °C with sulfuric acid catalyst 256 
or Amberlyst H- 15 resin 257  and with 'butyl alcohol and sulfuric acid 258  all gave no 
desired product. 
Other hydroxyl protecting groups were then considered instead. The desired 
protecting group had to fulfil a number of considerations for successful use, 
including; orthogonality to the TBDMS protecting group, deprotection not 
requiring strong base (to maintain silica integrity), protecting group incorporation 
should not use strong acid (due to potential deprotection of TBDMS) and 
deprotection should be possible under solid-phase synthesis conditions. As 
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alkoxyalkyl ethers fulfil all these requirements, the MEM protecting group was 
used. Protection of (S)- 1 -(9-anthracenyl)-2-(tert-butyldimethylsilyloxy) ethanol 
(62) was achieved by addition of MEM-Ci and DIPEA in DCM259' 260  and 
purification gave the desired orthogonally protected diol (63). This was followed 
by deprotection of the TBDMS group, using TBAF259' 260  to give the primary 
alcohol (64) in good yield. 
The next step required oxidation of the primary alcohol to give the carboxylic acid. 
A litrature procedure 254  that was successful for a similar compound was explored, 
which involved the use of combined oxidants NaOC12, NaOC1 and TEMPO under 
pH controlled phosphate buffer conditions, however, this gave no desired product. 
Many more oxidative procedures were tried, including Jones reagent261' 262  using 
different conditions; from which the only product was thought to be the unwanted 
ring oxidised anthraquinone 263 . Oxidation of the primary alcohol (64) to the 
required carboxylic acid was not possible under the conditions tried. Therefore, the 
structure of the planned reciprocal CSP was altered. 
4.2.2.1 MEM protecting group removal on solid phase methodology 
The final step of the synthesis involved the removal of the MEM protecting group 
to give the final CSP with a free hydroxyl group. However, because the reaction 
was using a synthetic method which is not well established on solid-phase, this 
reaction was first trialed by using a structurally similar, surrogate CSP. 
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Firstly, (R)-(+)-methyl mandalate was protected with the MEM group using a 
procedure identical to that used for the synthesis of (63), to give (65). 
Saponification with LiOH gave the chiral carboxylic acid (66), which was then 
coupled to aminopropyl silica using DIC and HOBt peptide coupling reagents. This 
gave the MEM protected silica (67), which was subsequently deprotected by 
agitation as a slurry in DCM with ZnBr 2 for four days264266, to give the final CSP 
(68). (67) and (68) were compared by elemental analysis to confirm MEM 
deprotection. 
4.2.2.2 Continuing synthesis of reciprocal CSP 
Synthesis of the reciprocal CSP was continued from primary alcohol (64), by 
derivatising it with 4-(bromomethyl)methylbenzoate, to give the methyl ester (69), 
which was subsequently saponified to give the carboxylic acid derivative (70). 
Subsequently (70) was coupled to APS and MEM deprotection was achieved by 
utilising the same methodologies performed successfully in the synthesis of CSP 
(68). Compound (70) was then coupled to APS using DIC and HOBt to give (71), 
and finally the MEM preotecting group was then removed using ZnBr2 yielding the 
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(a) (i) NaH, THF, (ii) 4-(bromomethyl) methylbenzoate, THF (b) NaOH, MeOH, 
(c) Aminopropyl silica (12 gm), DIC, HOBt, DCM/DMF (4:1), (d) ZnBr 2, DCM. 
Scheme 26 Synthesis of reciprocal CSP (72). 
4.3 	Synthesis of small peptide screening library 
To screen the reciprocal designed CSP (72), a small array of peptides was 
synthesised, to be used as chiral I-IPLC analytes. Two of these analytes were 
dipeptides and were therefore a mixture of four stereoisomers. The synthesis of 
these (Scheme 27) was achieved using standard peptide chemistries. Starting with 
4-hydroxymethylbenzoyl-aminomethyl polystyrene resin allowed cleavage of the 
peptide from the resin to leave an ester functionality. The resin was loaded with a 
racemic mixture of Fmoc-protected amino acids (Fmoc-D/L-Phe-OH or Fmoc-
D/L-Tyr(OtBu)-OH), followed by Fmoc deprotection to give resins (73) and (74) 
respectively. A second racemic Fmoc amino acid was then coupled (Fmoc-D/L-
Phe-OH), again followed by Fmoc deprotection to give the resins (75) and (76). 
Both of these resins were then derivatised with 3,5-dinitrobenzoic acid, to give 
capped dipeptidic resins (77) and (78). Cleavage from the resin was achieved using 
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(73), (75), (77) and (79), X = H, Y= 4-hydroxymethylbenzoyl-aminomethyl; 
(a)(i) Fmoc-D/L-Phe-OH, DIC, HOBt, DMAP, DMF, (ii) piperidine/DMF (20:80); 
(74), (76), (78) and (80), X = OtBu, Y= 4-hydroxymethylbenzoyl-aminomethyl 
(a)(i) Fmoc-D/L- Tyr(tBu)-OH, DIC, HOBt, DMAP, DMF, (ii) piperidine/DMF (20:80); 
(b)(i) Fmoc-D/L-Phe-OH, DIC, HOBt, DMF, (ii) piperidine/DMF (20:80), 
(c) 3,5-dinitrobenzoic acid, DIC, HOBt, DMF, DCM, (d) DIPEA/DMF/MeOH (1:5:5). 
Scheme 27 Synthesis of two dipeptidic analytes. Each is a mixture offour stereoisomers. 
Four capped amino acids were also synthesised, through the use of rink amide 
resin, the derivatives, containing methyl amide end fuctionalities instead of the 
methyl esters of (79) and (80). The 3,5-dinitrobenzoyl amides of D and L-
Phenylalanine and the 3,5-dinitrobenzoyl amides of D and L-Analine were 
synthesized using a rink linker2268 
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4.4 	Screening of the reciprocal CSPs 
CSP (72) was screened with the various different analytes, the first of which were 
the peptides (79-84). 
Dipeptides (79) and (80) both showed separation using moderate concentrations of 
organic modifier (--20%), concentrations lower than this did not elute the analyte 
fast enough. However, separation of both analytes was always into two peaks, 
rather than showing all four stereoisomers present in the analytes. Figure 43 shows 
the separation of (80) on CSP (72), with the top HPLC trace showing two clear 
peaks when using 20% 2-PrOH in the mobile phase. It is presumed that each peak 
is two enantiomers and that the separation is only of diastereomer pairs. The 
bottom HPLC trace (Figure 43) again shows two peaks, but this time the most 
retained peak is close to showing 'internal' separation. Attempts to resolve the 
peaks to reveal more stereoisorners proved fruitless with the quality of 
chromatography on this CSP low, with poor peak shapes and a high degree of peak 
tailing, even with low analyte injection levels. 
a 
Figure 43 Separation of (80) on C'SP (72); (Top) Heptane/2-PrOH (90:20), 
0.3 mLmin; (Bottom,) Heptane/2-PrOH (90:10), 0.3 mLmin'. 
Capped amino acids (81)-(84) were then screened using similar chromatographic 
conditions. 3,5-Dinitrobenzoyl capped phenylalanine (81) and (82) were 
moderately separated by CSP (72) (Figure 44). 3,5-Dinitrobenzoyl capped alanine 
was also separated, but with a very small selectivity factor. The library of 
racemates (29)-(31) and (35)-(39) previously synthesised (section 2.2.2), was also 







Figure 44 Screening of enantiomers (81) and (82) on CSP (72). 
The final library of racemate analytes was a selection of other commercially 
available pharmaceutical small molecules and amino acids: Bendroflumethiazide, 
Flavanone, Proglumide, Ibuprofen, Warfarin, Ephedrine, Flumequine, Indapamide, 
Chiorpheniramine, Benzoin, Phenylethanol, Benzyl-2-oxazol idinone. Tryptophan 
and Phenylalanine. 
Due to the vast variety of different properties that the analytes posed, the screening 
was carried out using a gradient spanning a large polarity range (0-90% 2-PrOH). 
Three of the fourteen members of the racemate library were separated to some 
extent on CSP (72), these were Ibuprofen, Proglumide and Chiorpheniramine. 
The summary of results for analytes successfully separated on CSP (72) is shown 
in Table 15. CSP (68) was also screened using the same racemate analytes, but no 
separation was observed. This was expected as CSP (68) was not specifically 
designed for chiral separation, but to test synthetic methodologies used in the 
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* Separation is probably diastereomeric rather than enantiomeric 
a Mobile phase is heptane/2-propanol (90:10), flow rate of 0.3 mL/min. 
a Mobile phase is heptane/2-propanol (70:30), flow rate of 0.3 mL/min. 
Gradient mobile phase heptane(A)12-propanol(B) t = 0; 0% (B), t = 15; 10% (B), t = 25; 
90% (B), t = 30; 90% (B), flow rate of 0.5 mL/min. 





Previously synthesised CSPs were capped dipeptidic structures attached to silica 
beads and were very successful in separating anthryl ethanol and other similar 
racemates. A reciprocal CSP (72) was synthesised based on an anthryl ethanol 
enantiomer attached to the silica bead. This was achieved starting from 9-
anthraldehyde, the optical character of this CSP was inserted into the molecule 
using Sharpless asymmetric dihydroxylation. Some reciprocal racemates were 
synthesised as screening analytes, using solid-phase peptide chemistry. 
The screening of reciprocal CSP (72) was carried out with a range of racemates, 
including a series commercially available small molecules and a previously 
synthesized library of carbinol racemates. Results obtained show some separation 
of the reciprocal peptide based analytes, although not as much as was hoped. Also 





5 	3,5-Dinitrophenylalanine, non-proteinogenic amino acid 
based CSPs 
5.1 	Introduction 
3,5-Dinitrobenzoyl was found to be the best CSP end group from a screened library 
of CSPs (section 2). Trying to augment chiral separation by using two 
3,5-dinitrobenzoyl end groups, was found to give no improvement over the CSP 
with one end group. 
The 3,5-dinitrobenzoyl group is a it-acceptor and as such interacts strongly with 
it-donating functionalities, such as most aryl groups. Other groups in common to 
CSPs, including all from section 2, are amino acids. They benefit from being 
synthetically useful through well known solid-phase amide bond formation and 
also posses natural chirality required for CSP's. Although the 3,5-dinitrobenzoyl 
groups has been used not only as an end group, it has not been used as an 'amino 
acid' in a CSP. Therefore we investigated using an amino acid equivalent of 3,5-
dinitrobenzoyl, in a small number of simple peptidic CSPs. 
5.2 	Synthesis of Fmoc-3,5-dinitrophenylalanine 
3,5-Dinitrophenylalanine was chosen as the amino acid equivalent of 
3,5-dinitrobenzoyl group. Inducing the chirality into the amino acid was achieved 
by resolution by deacetylation, which is a common method used in the synthesis of 
amino acids. 
Synthesis was achieved starting with the commercially available 
3,5 -dinitrophenyl methanol. Chlorination using PC1 5269 gave 1 -(chioromethyi)-3 ,5 - 
dinitrobenzene (85) in excellent yield. The next step incorporated the acid and 
amine functionalities. Diethyl acetamidomalonate was firstly deprotonated with 
NaOEt23 ' which was then added to (85) and displaced the chloride to give diethyl 
2-acetamido-2-(3,5-dinitrobenzyl) malonate (86) in good yield. Base hydrolysis of 





Resolution of (87) was carried out after consideration of literature precedent 
270-272 
Deacetylation was achieved using Acylase I (from Aspergillus melleus, 
1.06 Umg') with a catalytic amount of Colbalt (II) chloride hexahydrate in water, 
whilst carefully controlling the pH (7.0-7.2). This gave the deacetylated 
S-enantiomer L-3,5-dinitrophenylalaine (88) as well as the remaining optically 
resolved acylated D-enantiomer starting material, 
N-acetyl-D-3 ,5 -dinitrophenylalanine (89). L-3 ,5 -Dinitrophenylalanine (88) was 
Fmoc protected using Fmoc-N-hydroxysuccinimide ester (Fmoc-OSu) 273 to give 
the desired final amino acid Fmoc-L-3 ,5-dinitrophenylalanine (90). 
The enantiomer (90) was also synthesised from the resolved product of N-acetyl-
D-3,5-dinitrophenylalanine (89), firstly by acid hydrolysis to give 
D-3,5-dinitrophenylalanine (91) and then by Fmoc protection, again using 

























45%, 98%;/42%,  
98% 






e 62% 	 CO2H 














(a) PC1 5, CHC13, 50 °C, (b) Diethyl acetoamidomalonate, NaOEt, 50 °C, 
(c) NaOH, EtOH, water, 
(d) Acylase I (Aspergillus melleus, 1 .06Ug 1 ), CoC12 .6H20, water, 37-40 °C, 
(e) Fmoc-OSu, Na2CO3, water, dioxane, (f) HC1 (0.2 M), 60 °C, 
(g) Fmoc-OSu, Na2CO3, water, dioxane. 
Scheme 28 Synthesis of 3,5-dinitrophenylalanine. 
5.3 	Synthesis of CSPs containing 3,5-dinitrophenylalanine 
Three CSPs containing the amino acid 3,5-L-dinitrophenylalanine were synthesised 
using standard solid-phase peptide chemistry, where each coupling step was 




aminopropyl silica to give (93). This in turn was capped with 3,5-dinitrobenzoic 
acid to give CSP (94), which contains one 3,5-L-dinitrophenylalanine amino acid 
unit and one 3,5-dinitrobenzoyl end group. Another unit of 
3,5-L-dinitrophenylalanine was coupled to (93), to give silica support dipeptide 
(95), which was subsequently capped with 3,5-dinitrobenzoic acid to give CSP 
(96). This CSP contains two 3,5-L-dinitrophenylalanine units and one 















NO2 	 02 N 	 02 N 
/ 
02N 	 02 N 
95 S-02 0 	
5tNO2 96 	
Silica 
H2 N 	 N 
Silica 








 0 2N 
92 
0 	










30 	 0 	
NO2 
NO2 	 02N 	 02N 
(a)(i) Aminopropyl silica (12 pm), DIC, HOBt, DMF/DCM (1:4), 
(ii) piperidine/DMF (5:95), (b) 3,5-dinitrobenzoic acid, DIC, HOBt, DMF/DCM (1:4), 
(c)(i) (90), DIC, HOBt, DMF/DCM (1:4), (ii) piperidinefDMF (5:95), 
(d) 3,5-dinitrobenzoic acid, DIC, HOBt, DMF/DCM (1:4), 
(e)(i) Aminopropyl silica (12 pm), DIC, HOBt, DMF/DCM (1:4), 
(ii) piperidine/DMF (5:95), (f) benzoic acid, DIC, HOBt, DMF/DCM (1:4). 
Scheme 29 Synthesis of three CSPs containing 3,5-dinitrophenylalanine. 
The other 3,5-dinitrophenylalanine enantiomer was used for synthesis of a final 




subsequently capped with benzoic acid giving CSP (98), which is analogous to 
CSP (94), but with the absence of nitro moieties in the end group. 
5.4 	Screening of 3,5-dinitrophenylalanine based CSPs 
CSPs (94), (96) and (98) were packed into empty HPLC columns and screened 
with a previously synthesised array of racemic analytes (section 2.2.2). The 
screenings were then compared to results for CSP (5). Of particular interest was 
CSP (96), which is analogous to CSP (5), being dipeptidic with a 3,5-
dinitrobenzoyl end group. The amino acids; Phe and Tyr(O tBu) of CSP (5), have 
been replaced with stronger n-acceptor groups, using the amino acid 3,5-
dinitrophenylalanine. 
Screening results were very suprising, as CSPs (94) and (96) both showed zero 
chiral separation of any members of the the racemic analytes. Chromatographic - - 
conditions used were varied over the range found to be successful for similar csP 
of section 2.2.3. Sample rentention values were similar to that of CSP (5), but no 
separation was observed. 
CSP (98) was almost as unsuccessful, but separated one member of the analytes. 
Racemate (31) was separated, but with only a small separation factor (k 1 = 4.23, 
a = 1.11; mobile phase = 2-PrOH/Heptane (3:97), flow rate = 0.3 mLmin 1 ). 
Figure 45 Racemate (31) 
The negative results for CSPs (94) and (96) in particular indicate that the multiple 
3,5-dinitrobenzoyl groups in the CSP structure actually negate the chiral separation 
properties rather than augment it. This could be because multiple similar groups 
will interact with the analyte with similar magnitude, meaning the analyte can 
interact with a variety of different areas of the CSP structure, rather than having a 




importance of the CSP structure containing complimentary it-accepting and it-
donating moieties, rather than exclusively using multiple groups of one character. 
5.5 	Summary 
The non-proteinogenic a-amino acid, 3,5-dinitrophenylalanine was successfully 
synthesised. Chirality was introduced into the molecule by resolution using 
Acylase I (Aspergillus melleus) to deacetylate the L-enantiomer, whilst leaving the 
D-enantiomer acetylated. Both enantiomers were followed through to give the 
Fmoc protected amino acid optical isomers. These were used in the solid-phase 
synthesis of three novel CSPs and screened with a range of racemic analytes. 
The results showed no chiral separation of any analytes for two CSPs and one low 
selectivity separation for the other CSP. This indicates that rather than augmenting 
chiral separation of peptidic and amino-acid based CSP by using the 
3,5-dinitrophenylalanine amino acid, it actually made the CSP ineffectual. 
This is possibly due the other it-accepting 3,5-dinitrophenylalanine groups 
interacting with analyte molecules in a similar way to that of the 3,5-dinitrobenzoyl 






The aims of this thesis were towards the improvement of chiral separation 
technology. For this several areas of chiral separation were explored by a number 
of experiments to establish a greater understanding for the resolution of a given 
enantiomer; by measuring changes in chiral separation through altering of chiral 
stationary phase structure, synthesis of peptide based libraries of chiral stationary 
phases towards fast and efficient development of novel chiral stationary phases, 
utilising high-throughput screening technology for faster determination of 
appropriate chiral stationary phase media, synthesis of specifically designed chiral 
stationary phases. 
Chapter 2 involved the synthesis of a series of small libraries of Pirkie type chiral 
stationary phases. As Pirkie type chiral stationary phases rely heavily on 71-71 
interactions for chiral resolution, the first library investigated the use of numerous 
head-groups for the CSP structure. The 3,5-dinitrobenzoyl end group which is 
utilised in many commercially available CSPs was found to be more successful in 
separating a range of racemates. The importance comes from its ability to interact 
strongly, mainly through 7t-7t forces, with analyte enantiomers. This strong 
interaction enhances the scale of transient diastereomeric energies, thus improving 
the chances for chiral separation. Although alternative CSPs could not improve 
upon the separation ability of 3,5-dinitrobenzoyl, they did highlight important 
features of the end group. Such as, the removal or movement around the ring, of 
nitro moieties caused a large detrimental effect to the resolution observed. Other 
chiral stationary phase libraries helped determine that the second amino acid from 
the silica bead was found to have more influence over the overall chiral separation 
ability of the CSP, the incorporation two 3,5-dinitrobenzoyl groups into the CSP 
structure could also not improve the CSP's ability over that containing one 3,5-
dinitrobenzoyl group. Also achiral spacers in CSP structure cause a detrimental 
effect on the chiral resolution, most notibily when placed next to the end group 
moiety. 
Chapter 3 focused on probing the relationship between protein based chiral 
stationary phase separations of pharmaceutical compounds with the developing 




biosensor screens were carried out on the enantiomers of four analytes; Warfarin, 
Ibuprofen, Benzoin and Tryptophan. These analytes were screened on three 
proteins; HSA, BSA and AGP, which were all immobilised onto either column 
packing materials or onto the surface of a sensor spot, for HPLC and SPR 
biosensor analysis respectively. Using the resulting relative binding strength for 
enantiomers of each analyte in both HPLC and SPR gave a way of comparing these 
technologies. Results were found to match very well, with the majority of SPR 
screening results agreeing with HPLC precedent. The results obtained for Warfarin 
and Ibuprofen, which were strong binders to HSA and BSA proteins were very 
good. 157 out of 189 pairs of screening data for these analytes gave a matching 
order of elution between chiral HPLC and the SPR biosensor. Weaker binding 
analytes; Benzoin and Tryptophan gave less reliable results. Their lower over 
binding increased the noise to signal ratio therefore the comparative enantiomer 
binding affinities were more likely to switch compared to the expected result. 
Although there were some drawbacks with the SPR system, the advantages of the 
system and future potential improvements make it a valuable tool for high-
throughput determination of chiral stationary phase media and chiral 
chromatographic conditions for scaled-up chiral HPLC. 
Chapters 3 and 4 involved the synthesis of more structurally focused Pirkle type 
CSPs. In chapter 3 a chiral stationary phase based on an enantiomer of anthryl 
ethanol was developed in a 'reciprocal CSP' manner. However, the final CSP 
failed to convincingly show true CSP reciprocal ability in attempting to separate 
some peptide racemates; this may be due to the excessive structural changes 
necessary for the attachment of the chiral selector to silica stationary phase. 
Chapter 4 focused on developing CSP containing a non-proteinogenic amino acid 
3,5-dinitrophenylalanine. This particular amino acid was chosen due to its 
structural similarity of the 3,5-dinitrobenzoyl group which is successfully 
employed as an end-group. However the resulting CSP gave very poor separation 
of a range of racemates, possibly due to too much structural similarity between the 
peptide chain and end-groups, therefore resulting in both groups competing for the 





7.1 	General Information 
NMR spectra were recorded on a Bruker ARX250, AV300, DPX360 and DPX 400 
spectrometers operating at 250 MHz, 300 MHz, 360 MHz and 400 MHz for 'H and 
62.5 MHz, 75 MHz, 90 MHz and 100 MHz for 13 C spectra respectively. Chemical 
shifts (ö), referenced to the residual protonated solvent as an internal standard, are 
quoted in ppm, coupling constants (J) are reported in Hz. ESI mass spectra were 
recorded on a Fisons VG platform quadropole or a Waters ZMD single quadropole, 
equipped with an electronspray ionisation source, measuring monoisotopic masses. 
Electron ionization (El) and Chemical ionization (Cl) mass spectra were run on a 
ThermoQuest TraceMS gas chromatography mass spectrometer. Major peaks are 
reported with percentage intensities of the base peak. HRMS were run on a Bruker 
APEX3. 
The Smith Synthesiser from Personal Chemsitry was used to perform microwave 
irradiations. Infra-red spectra were recorded on a BIORAD FTS 135 with a Golden 
Gate ATR access. All samples were run neat. Melting points were determined 
using a Gallenkamp melting point apparatus and are uncorrected. UV-Vis spectra 
were recorded using an 8452 A diode array detector. Elemental analyses were 
performed by Medac Ltd or the service within the School of Chemistry at St. 
Andrews University. HPLC and chiral HPLC were carried out on HP Agilent 
systems. 
Dry solvents were obtained by passing through an alumina column. Reagents were 
used as purchased from commercial sources unless otherwise specified. TLC 
analysis was carried out using foil-backed sheets coated with silica gel (0.25 mm) 
and containing the fluorescent indicator UV2 54. Flash column chromatography was 
performed, on Sorbsil C60, 40-60 mesh silica. 




7.2 	General solid-phase chemistry procedures 
7.2.1 	Colorimetric tests 
7.2.1.1 Quantitative Ninhydrin test 
A known mass of resin (Ca. 5 mg) in a small test tube was treated with 3 drops of 
reagent A and 1 drop of reagent B and heated at 100 °C for 10 mm. The test tube 
was cooled and 60 % aq EtOH (2 mL) added. The resin was removed by filtration 
through cotton wool and the deep blue filtrate collected in a 25 mL volumetric 
flask. The resin was washed with a solution of Et 4NC1 (0.5 M in CH202, 2 x 0.5 
mL) and the sample made up to 25 mL with 60 % aq EtOH. The absorbance at 570 
nni was measured against a reagent blank. The level of amine present was 
calculated using the equation: 
Amount of amine present (mmol/g) = [(A 570 x V)/(E 570 x m)] x 103 
where A570 is the recorded absorbance at 570 rim, V is the final volume (mL), 8570 
is an extinction coefficient suitable for most peptides (1.5 x iO4 M' cm') and in is 
the mass of the resin sample (mg). 
Reagent A 
. Solution 1: Phenol (40.0 g) was dissolved in EtOH (10 mL) with warming 
and then stirred over Amberlite mixed-bed resin MB-3 (4.0 g) for 45 mm. 
The mixture was filtered. 
Solution 2: Potassium cyanide (65 mg) was dissolved in H 20 (100 mL). A 2 
mL aliquot of this solution was diluted with pyridine (freshly distilled from 
ninhydrin) and stirred over Amberlite mixed-bed resin MB-3 (4.0 g). The 
solution was filtered and mixed with 'Solution 1' to give reagent A. 
Reagent B 
Ninhydrin (2.5 g) was dissolved in absolute EtOH (50 mL). 
7.2.1.2 Quantitative Fmoc test 
A known mass of resin (ca. 5 mg) was weighed into a 1 mL SPE syringe and 




mL volumetric flask. The filtrate was made up to volume with 20 % piperidine in 
DMF. The absorbance at 302 nm was measured against 20 % piperidine in DMF. 
The loading was calculated using the equation: 
Loading (mmol/g) = [(A 3 02 x V)/(E302 x m)] x 10 3 
where A302 is the recorded absorbance at 302 nm, V is the final volume (mL), C302 
is the extinction coefficient of the piperidyl-fulvene adduct (7.8 x 10 3 M' cm') and 
in is the mass of the resin sample (mg). 
7.2.1.3 Qualitative chioranil test 
To a small amount of resin (ca. 1-3 mg), one drop of 2 % acetaldehyde in DMF 
was added followed by one drop of 2 % p-chloranil in DMF and was allowed to 
stand for 5 mm. Blue stained beads indicated the presence of secondary amines. 
7.2.1.4 Qualitative TNBS test (2,4, 6-trinitrobenzenesulfonic acid) 
A few beads were suspended in 2 drops of a solution of 10% DIPEA in DMF and 2 
drops of a solution 1% TNBS in DMF (commercially available). After a few 
minutes, the beads were washed with DMF to remove the red solution. A positive 
test was indicated by red beads and confirmed the presence of primary amines. 
7.2.2 	Silica purification procedures 
7.2.2.1 Filtration procedure to separate silica beads from reaction solution. 
Silica/reaction mixture slurries were poured into microfiltration tubes (Wh atman® , 
12 mL, 5 jim pore size), attached to a vacuum pump or a vacuum manifold. Mother 
liquor, drained and the silica was washed normally washed with DMF (2 x 20 mL), 
DCM (2 x 20 mL) and Et 20 (2 x 20 mL). The silica was then normally dried in 
vacuo. 
7.2.2.2 Centrifugation to separate silica beads from reaction solution. 
Silica/reaction mixture slurries were transferred from the reaction vessel to a 
centrifuge tube (50 mL), the solution was made up to 40 mL with DMF. The tube 




was repeated with further washings of DMF (2 x 40 mL) and Et20 (2 x 40 mL). 




7.3 	Experimental for Chapter 2 
7.3.1 	Synthesis of compounds 







To a suspension of beaded aminopropyl silica (3, 10, 12 jtm from ThermoHypersil 
and 4 tm from Capital HPLC, 0.45mrnolg 1 , 1.0g. 0.45 mmol) in a solution of 
DCMIDMF (8:2, 10 mL), was added a mixture of Fmoc-Tyr( tBu)-OH (10 eq., 4.5 
mmol, 0.60 g) and HOBt (10 eq., 4.5 mmol, 0.6 g) in DCMIDMF (8:2, 10 mL). 
After gentle shaking of the resulting mixture for 10 mm, DIC (10 eq., 4.5 mmol, 
0.58 g, 0.7 mL) was added. The reaction mixture was then heated at reflux (50°C) 
for 3h. After cooling, the beads were filtered (Whatman microfiltration device, 12 
mL volume, 5 m pore size) or centrifugated and washed with DMF (50 mL), 
DCM (50 mL) and Et20 (50 mL). A negative TNBS test indicated complete 
coupling. Fmoc deprotection was achieved by shaking the fuctionalised silica in 
DMF (5% piperidine) for 15 mill. The silica was filtered and washed with DMF (50 
mL). Then shaking in DMF (5% piperidine) was repeated for 15 mm, followed by 
filtration and washing with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). The 
silica beads were then suspended in DCM/DMF (8:2, 10 mL) and Fmoc-Phe-OH 
coupled using the same procedure as described above. The beads were again 
filtered, washed and Fmoc deprotected, followed by filtration, washing and drying 




3.5-DNB-Phe-Tyr(tBu)-aminopropyl silica (33)jJ) and (3) 
02N
IC 0 JeH  0 
H  
	
NO2 	 aoj< 
To a suspension of H-Phe-Tyr( tBu)-aminopropyl silica (2) (1.0 g, 0.45 mmol) in 
DCM/DMF (8:2, 10 mL), was added a mixture of the 3,5-dinitrobenzoic acid (10 
eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 mmol, 0.6 g) in DCM/DMF (8:2, 
lOmL). After gentle shaking of the resulting mixture for 10 mm, DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 mL) was added. The reaction mixture was then heated to 
reflux (50°C) for 3h. After cooling the beads were filtered or centrifuged and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL), followed by drying 
under high vacuum. A negative TNBS indicated complete coupling. 
3.2.1. H-Phe-Tyr( tBu)-aminopropyl silica (4) 
'0 0 
H2N f N H N 
aoj< 
Procedure 	identical 	to 	H-Phe-Tyr(tBu)-aminopropyl 	silica 	(2). 
H-Phe-Tyr(tBu)-aminopropyl silica (4) involved only the use of 10 tm 





To a suspension of the H-Phe-Tyr( tBu)-aminopropyl silica (4) (1.0g, 0.45rnmol) in 
a solution of DCMIDMF (8:2, 10 mL), was added a mixture of the carboxylic acid 
(X) (10 eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 mmol, 0.6 g) in DCMIDMF 
(8:2, 10 mL). After gentle shaking of the resulting mixture for 10 mm, DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 mL) was added. The reaction mixture was then heated to 
reflux (50'C) for 3h. After cooling the beads were filtered and washed with DMF 
(50 mL), DCM (50 mL) and Et20 (50 mL), followed by drying under high vacuum. 
A negative TNBS indicated complete coupling. 
3.5-DNB-Phe-Tyr( tBu)-aminopropyl silica (5) 
0 J( H 0 
02N H  
NO2 	aolll< 
3,4-DNB-Phe-Tyr( tBu)-aminopropyl silica (6) 
O 















N -ez -~H N--~~  
aloj< 
Benzoyl-Phe-Tyr( tBu)-aminopropyl silica (9) 
0O 
aloj< 
3,5-dimethoxybenzoyl-Phe-Tyr( tJ3u)-aniinopropyl silica (10) 
I 	0 
0 
 IC ~ "e 
0 
o 
3,5-dihydroxybenzoyl-Phe-Tyr( tBu)-aminopropyl silica (11) e 




3,5-diaminobenzoyl-Phe-Tyr( tBu)-amjnopropyl silica (12) 
1 0 
H2N N JHN 
NH 2 	 aoj< 
2-Naphthoyl-Phe-Tyr( tJ3u)-amjnopropyl silica (13) 
0 
N -e- 
2-Pyridoyl -Phe-Tyr( tBu)-aminopropyl silica (14) 
1 UN_I- N N 
aloj< 










4-Heptylbenzooyl-Phe-Tyr( tBu)-aminopropyl silica (17) 
0 	-10, 0 
LNJHN 




35-Bis(trifluromethyl) -Phe-Tyr(tBu) -aminopropyl silica (19) 
F3C NJ HN '  
CF3 	~oj< 
143 Chapter 7 
3.5-disulfobenzoyl-Phe-Tyr( tBu)-aminopropyl silica (20) 
HO3S 	
N N" Q 
SO3 H 
3,5-Bis(methoxcarbonyl)-Phe-Tyr( tBu)-aminopropyl silica (21) 
5,-" 
1 
o 	1, 0 
MeO2C}..N 0 
CO2Me 
3,5-Bis(acetamido)benzoyl-Phe-Tyr( tBu)-aminopropyl silica (22) 










Benzene-1,3.5-tricarboxylic acid trimethyl ester (24)274 
Me02C.0O2 Me 
CO2Me 
Following a procedure by Erickson et a1 274. 1 ,3,5-Benzenetricarboxylic acid (1.00 
g, 1.0 eq.) was dissolved in DCM (20 mL), MeOH (20 mL) and conc. H2SO4 (200 
tL). The reaction mixture was refluxed for 12h, cooled to room temperature and 
solvents removed in vacuo. The solid was dissolved in EtOAc (50 mL) and washed 
with sat. NaHCO3 (100 mL) The organic layer was concentrated in vacuo to give a 
white solid, 1.15g (96%): m.p. 140°C (EtOH), literature 141-143°C 274; 'H NMR 
(d6 -DMSO, 300MHz): 8.62 (s, 3H, 3 x ArH), 3.96 (s, 9H, 3 x ArC(0)OC). 13C 
NMR (d6 -DMSO, 75MHz): 164.5 (C), 133.3 (CH), 130.9 (C), 52.7 (CH3); m/z 




Benzene-1,3.5-tricarboxylic acid dimethyl ester, (25)274 
HO2CCO2Me 
CO2 Me 
Following a procedure by Erickson et a1 274. Benzene-1,3,5-tricarboxylic acid 
trimethyl ester (24) (1.0 g, 1.0 eq.) was dissolved in MeOH (10 mL). NaOH (159 
mg/i .0 eq.) was added to the reaction and stirred for 4 days. The reaction mixture 
was poured onto water (100 mL) and the solution washed with Et20 (3 x 50 mL). 
The aqueous layer was acidified to pH 1 with HC1 and extracted with Et20 (3 x 100 
mL), the combined organic layers were concentrated in vacuo, to give a cream 
solid 790mg (84%): m.p. 145°C (H20), literature 145-147°C (H20)275 ; 'H NMR (d6 
-DMSO, 300MHz): 8.61 (s, 2H, 2 x ArH), 8.56 (s, 1H, 1 x ArH), 3.90 (s, 6H, 2 x 
ArC(0)OC). ' 3 C NMR (d6 -DMSO, 75MHz): 165.5 (C), 164.6 (C), 133.6 (CH), 
133.0 (CH), 132.1 (C), 130.7 (C), 52.7 (CH3); m/z (ES-) 236.9 EM-Hr (100%), 




35-Bis(acetylamino)benzoic acid (26) 276 
HO2C7NO 
HNO 
Following a procedure by Komatsu et a1 277 . 3,5-Diaminobenzoic acid (1.0 g, 1 eq.) 
was slurried in Et20 (100 mL) and treated with a solution of acetyl chloride (2.0 
mL) in Et20 (10 mL). To the reaction mixture was added a solution of pyridine (2.0 
mL) in Et20 (10 mL) over lh, followed by stirring for 72h. EtOH (100 mL) was 
poured into the reaction and the solvents were removed in vacuo to give a dark oil. 
Water (100 mL) was added to oil to give a grey precipitate, which was collected by 
filtration, washed with water (100 mL) and 0.5 M HC1 (50 mL). A wet grey 
precipitate was collected and dried in vacuo to give a grey solid, 1.30 g (84%): m.p. 
300-305°C (1120), literature 299-300°C (H20) 276 ; 1 H NMR (d6 -DMSO, 300MHz): 
10.11 (s, 2H, 2 x ArNHC(0)CH3) 8.12 (s, 1H, ArH), 7.88 (s, 2H, 2 x ArH), 2.15 (s, 
6H, 2 x ArNHC(0)C). 13C NMR (d6 -DMSO, 75MHz): 168.5 (C), 167.1 (C), 
139.7 (C), 131.4 (C), 114.6 (CH), 113.4 (C), 23.9 (CH3); m/z (ES-) 236.9 [M-H] 




Benzene-1,3,5-tricarboxylic acid bis((1R,2S,5S)-menthol) ester (27) 
FF, 
1,3,5-Benzenetricarbonyl chloride (1.00 g, 1 eq.) was dissolved in dry THF 
(20 mL), to this was added Et3N (1.64 mL, 3.2 eq.) and the reaction mixture was 
cooled to 0°C in an ice bath. To the reaction was added a solution of (1R, 2S, 5R)-
(-)-Menthol (3.2 eq.) in THF (20 mL), dropwise over 2h. The reaction was left to 
stir for a further 20h under a nitrogen atmosphere whilst being allowed to warm to 
room temperature. Water (50 mL) was added slowly to the reaction, which was left 
to stir for 2h. The reaction was extracted with Et 20 (4 x 50 mL) and the combined 
organic layers washed with water (50 mL), brine (50 mL), then dried with 
magnesium sulfate, filtered and concentrated in vacuo. The residue was crystalised 
from warm water to give a grey solid 960 mg (53%): m.p. 78-82°C (H 20); 'H 
NMR (d6 -DMSO, 250MHz): 8.86 (d, 2H, J= 2Hz, 2 x ArH), 8.78 (t, 1H, J = 2Hz, 
1 x ArH), 5.10 (td, 211, J = 10Hz, J = 4Hz), 2.70 (quintet, 2H, J = 2Hz), 2.20 (m, 
2H), 2.05 (m, 2H), 1.88-1.73 (m, 8H), 1.40-1.36 (m, 4H), 1.08 (dd, 12H, J = 711z, J 
= 411z), 0.95 (m, 6H, J = 311z). ' 3C NMR (d6 -DMSO, 62.5MHz): 166.5 (C), 164.4 
(C), 146.9 (C), 140.0 (CH), 131.22 (C), 75.4 (CH), 46.9 (CH), 40.7 (CH2), 34.0 
(CH2), 31.2 (CH), 26.6 (CH), 23.6 (CH), 22.2 (CH3), 20.8 (CH3), 16.8 (CH 3); m/z 
(ES-): 485 [M-H] - (100%); HR-m/z (FAB): [M-H] (C 29H4206) calculated: 
485.2903, found: 485.2905 [M-H]. 
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149-Anthracenyl)-propan-1-ol (29) 278, 279 
OH 
Magnesium turnings (118mg, 10 eq.) and a magnetic stirrer bar were oven dried, a 
subaseal fixed in place and cooled to room temperature under a nitrogen 
atmosphere. THF (2 mL) was added and the reaction stirred for 5 mm. Ethyl 
bromide (180 iL, 2.5 eq.) was added slowly to the reaction. The reaction was 
catalysed by the addition of a small amount of iodine (colourless to light brown). 
The reaction was stirred for 15 mm (the flask became warm, light brown to 
colourless/grey/yellow), and further ethyl bromide (180 jtL/2.5 eq.) was added 
slowly to the reaction (15 mm) and the reaction stirred for a further 30 mm. A 10 
p.L aliquot was taken from the reaction mixture and dissolved in water (1 mL). The 
basic solution was titrated against HC1 (0.01 M), using phenolphthalene as an 
indicator, to give the concentration of the Grignard reagent in-situ. 
9-Anthraldehyde (100 mg/1.0 equiv.) under a nitrogen atmosphere was dissolved in 
freshly distilled THF (10 mL) and the reaction mixture cooled to 0°C in an ice bath. 
The prepared Grignard reagent (1.2 eq.) was added to 9-Anthraldehyde solution 
slowly over 15 mm. The reaction was stirred at 0°C for a further 3h, then overnight. 
NH4C1 10% (w/v, 10 mL) was added slowly to the reaction and extracted with Et 20 
(3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried 
with MgSO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (Silica; Hexane: DCM 2:1 to 0:1), to give a yellow solid 92 mg 
(40%)278,279 : M.P. 110-112°C; 1 H NMR (CDC13, 400MHz): 8.40-8.50 (bs, 2H, 2 x 
ArH), 8.17 (s, 1H, ArH), 7.76-7.79 (m, 2H, 2 x ArH), 7.19-7.32 (m, 4H, 4 x ArH), 
5.98 (dd, 1H, J = 8.5Hz, 6.5Hz, ArCH(OH)CH2), 2.17-2.31 (m, 1H, 
ArCH(OH)CHH), 1.95-2.07 (m, 114, ArCH(OH)CHH), 0.87 (t, 3H, J = 7Hz, 








Following a procedure by Kanemasa et a1 281 . 9-Anthraldehyde (500 mg, 1.0 eq.) is 
dissolved in dry THF (15 mL) and the reaction mixture is cooled to 0°C in an ice 
bath. BuLi (1 . 165 mL, 2.5 M, 1.2 eq.) was added slowly over 20 mm. The reaction 
was stirred for a further 3h at 0°C. To the reaction was added crushed ice and 
diluted with Et20 (50 mL). The organic layer was extracted with Et 20 (3 x 30 mL), 
the combined organic layers were washed with brine (50 mL), then concentrated in 
vacuo. The crude yellow oil was purified by flash chromatography (silica; 
HexaneIDCM) to give a yellow solid, 535 mg (83%)280:_  m.p. 79-80°C, 1 H NMR 
(CDC13 , 400MHz): 8.42-8.76 (bs, 2H, 2 x ArH), 8.30 (s, 1H, ArH), 7.91 (d, 2H, J 
9Hz, 2 x ArH), 7.33-7.42 (m, 4H, 4 x ArH), 6.18 (dd, 1H, J = MHz, 6.5Hz, 
ArCH(OH)CH2), 2.32-2.43 (m, 11-1, ArCH(OH)CHH), 2.01-2.11 (m, 11-1, 
ArCH(OH)CHH), 1.49-1.63 (m, 2H, CH2CCH2), 1.25-1.35 (septet, 211, J= 7Hz, 
CH2CllCH3), 0.80 (t, 3H, J= 7Hz, CH2C); m/z (El) 264 [Mt] (21%), 246 [Mt-




9-Anthracenyl(phenyl)methanoL (31) 282 
Following a procedure by Chem et a1 283 . THF (l0mL) was added to 9-
Anthraldehyde (1.0 g/1.0 eq.) and this solution was cooled to 0°C using an ice bath. 
Phenylmagnesium bromide (5.33 mLI 1.0 M, 1.2 eq.) was added slowly over 10 
minutes. The reaction was stirred for a further 3h at 0°C. The reaction mixture was 
poured onto water (100mL) and extracted with Et20 (3 x 100 mL). The combined 
organic layers were washed with brine, then concentrated in vacuo. The crude 
yellow oil was purified by flash chromatography (silica; Hexane/DCM) to give a 
yellow foam which is recrystalised from DCM/Hexane, to give cream crystals, 1.05 
g (76%): m.p. 110-11°C (DCMIHexane), literature 110-112 C212;   'H NMR (CDC13, 
300MHz): 8.52 (s, 1H, ArH), 8.37-8.42 (m, 2H, 2 x ArH), 8.04-8.08 (m, 211, 2 x 
ArH), 7.39-7.50 (m, 7H, 7 x ArH), 7.21-7.34 (m, 3H, 2 x ArH, 1 x ArCH(OH)Ph), 
2.72 (d, lH, OH). ' 3 C NMR (CDC13 , 75MHz): 143.8 (C), 134.0 (C), 131.8 (C), 
129.9 (C), 129.3 (CH), 128.7 (CH), 128.3 (CH), 126.8 (CH), 126.1 (CH), 125.7 




141-Pyrenyf)-ethanol (33) 2 
OH 
Following a procedure by Flowers et a1 284 . 1 -Pyrenecarboxaldehyde (500 mg/i .0 
eq.) was dissolved in dry THF (15 mL), then cooled to 0°C in a ice bath. Methyl 
lithium (1.86 mL/1.4 M/1.2 eq.) was added to the reaction slowly over 10 mm. The 
reaction was stirred at 0°C for 2h, then warmed to room temperature and stirred for 
a further 12h. The reaction was diluted with water (50 mL). The organic layer was 
extracted with Et20 (3 x 50 mL). The combined organic layers were washed with 
brine and concentrated in vacuo. Purification was achieved by Flash 
Chromatography (DCMIHexane, 1:1) to give a yellow oil/precipitate, which was 
recrystalised from benzene to give yellow crystals, 866 mg (81%): m.p. 112-
113.5°C (Benzene), literature 113°C (Benzene) 284; 'H NMR (CDC13, 300MHz): 
8.31-8.35 (d, 1H, J= MHz, ArH), 8.17-8.25 (m, 411, 4 x ArH), 8.08-8.12 (d, 1H, J 
= 9.511z, ArH), 7.99-8.06 (m, 3H, 3 x ArH), 5.94-6.03 (q, 1H, J = 8.5Hz, 
ArCH(OH)CH3), 2.22 (s, 111, ArCH(OH)CH3), 1.76-1.80 (d, 3H, J = 8.511z, 
ArCH(OH)C). ' 3C NMR (CDC13, 75MHz): 139.1 (C), 131.4 (C), 130.6 (C), 
130.6 (C), 127.6 (CH), 127.6 (C), 127.5 (CH), 127.4 (C), 127.2 (C), 127.2 (CH), 
125.9 (CH), 125.2 (CH), 125.1 (CH), 125.0 (CH), 124.8 (C), 122.5 (CH), 122.4 





Following a procedure by Sanyal et a1 285 , THF (10 mL) was added to 1-(9-
anthracenyl)-ethan-i-ol (500 mg/i .0 eq) and the reaction mixture cooled to 0°C in 
an ice bath. Dried NaH (64 mg/i .2 eq.) was suspended in a small quantity of dry 
THF (1 mL), which was added slowly, over 20 minutes, to the reaction mixture. 
After 1.5h stirring, methyl iodide (386 mg/1.2 eq.) was slowly added to the 
reaction, and stirred at room temperature for 5h. Crushed ice (approx. 500 mg) was 
added to the reaction mixture and diluted with Et 20 (50 mL). The organic layer 
was extracted with Et20 (3 x 50 mL), combined, washed with brine (50 mL) and 
concentrated in vacuo. The crude yellow oil was purified by flash chromatography 
(silica; Hexane/DCM) then recrystallised from DCM/Hexane to give yellow 
crystals, 420 mg (79%): m.p. 93.5-94°C (DCMIHexane), literature 94-95°C 
(DCM!Pentane) 285 ; 'H NMR (CDC13 , 400MHz): 8.52-8.66 (bs, 2H, 2 x ArH), 8.3 
(s, 111, ArH), 7.89-7.94 (m, 2H, 2 x ArH), 7.34-7.42 (m, 4H, 4 x ArH), 5.84 (q, 1H, 
J = 7Hz, ArCH(OCH 3)CH3), 3.12 (s, 3H, OCth),  1.77 (d, 3H, J = 711z, 
ArCH(OCH3)C3). 13C NMR (CDC13 , 100MHz): 133.9 (C), 132.0 (C), 130.0 
(C), 129.8 (CH), 129.7 (CH), 128.2 (CH), 126.0 (CH), 125.1 (CH), 77.0 (CH), 57.0 
(CH3), 23.0 (CH3); m/z (El) 236 [M] (90%),221 [M-15(CH3)] (100%). 
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9-(1-Benzyloxy-ethyl)-anthracene (36)285 
o-> 
- 	 - - 
Following a procedure by Sanyal et a! 285 . THF (10 mL) was added to 1-(9-
Anthracenyi)-ethan-1 -ol (500 mg/i .0 eq) and the reaction mixture cooled to 0°C on 
an ice bath. Dried NaH (64 mg/i .2 eq.) was suspended in a small quantity of dry 
THF (1 mL), which was added slowly, over 20 minutes, to the reaction mixture. 
After 1 .5h stirring, benzyl bromide (460 mg/i .2 eq.) was slowly added to the 
reaction, and stirred at room temperature for 5h. Crushed ice (approx. 500 mg) was 
added to the reaction mixture and diluted with Et 20 (50 mL). The organic layer 
was extracted with Et20 (3 x 50 mL), combined, washed with brine (50 mL) and 
concentrated in vacuo. The crude yellow oil was purified by flash chromatography 
(Hexane/DCM) to give a yellow oil, 502 mg (73%)285:  'H NMR (CDC13, 
300MHz): 8.61-8.91 (bs, 2H, 2 x ArH), 8.45 (s, 1H, ArH), 8.1 (m, 2H, 2 x ArH), 
7.45-7.55 (m, 4H, 4 x ArH), 7.25-7.35 (m,514, 5 x ArH), 6.14 (q, iH, J = 714z, 
ArCH(OBn)CH3), 4.40 (d, 1H, J = 12Hz, ArCH(CH 3)OCH(H)Ar'), 4.33 (d, iH, J 
= 12Hz, ArCH(CH3)OCH(H)Ar'), 1.90-1.96 (d, 3H, J = 7Hz, ArCH(OBn)C). 
13C NMR (CDC13 , 75MHz): 138.6 (C), 133.5 (C), 131.7 (C), 129.3 (C), 129.0 
(CH), 128.8 (CH), 128.3 (CH), 128.0 (CH), 128.0 (CH), 127.5 (CH), 125.6 (CH), 





14anthracen-9-yl)ethyl acetate, 	285 
Following a procedure by Sanyal et a1 285 . 1-(9-Anthracenyl)-ethan-1-ol (500 
mgI1.0 eq.) and DMAP (27 mgI0.1 eq.) were dissolved in NEt3 (5 mL). The 
solution was cooled to 0°C. Ac20 (276 jtL/1 .2 eq.) added dropwise over 15 mm. 
The reaction was stirred at 0°C whilst warming to room temperature overnight 
(15h). The reaction was diluted with Et20 (2 mL), washed with 1M HC1 (50 mL). 
The organic phase was washed with saturated Na2CO3 (50mL) and brine (50 mL), 
then concentrated in vacuo to give a yellow oil. Purification was achieved by Flash 
Chromatography (silica; Hexane/DCM, 2:1) to give yellow oil, which was 
crystalised with EtOH to give cream crystals 422mg (71%): m.p. 99.5-100.5°C 
(EtOH), literature 99-100°C (EtOH) 285 ; 'H NMR (CDC1 3, 300MHz): 8.62-8.68 (d, 
2H, J= 9.51-1z, 2 x ArH), 8.45 (s, 1H, ArH), 8.01-8.06 (m, 211, 2 x ArH), 7.44-7.60 
(m, 5H, 4 x ArH, 1 x ArCH(OAc)CH 3), 2.12 (s, 3H, ArCH(CH 3)OC(0)C), 1.96-
2.00 (d, 3H, J = 7Hz, ArCH(OAc)CH3). ' 3C NMR (CDC13 , 75MHz): 170.4 (C), 
132.2 (C), 131.7 (C), 129.4 (CH), 129.1 (C), 128.5 (CH), 125.9 (CH), 124.8 (CH), 
124.7 (CH), 68.9 (CH), 21.6 (CH3), 21.2 (CH3); mlz (El) 264 [M] (69%), 205 
(100%). 
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H-Dap(H)-aminopropyl silica, (40) 
H2N 	H N 
NH2 
To a suspension of beaded aminopropyl silica (10 j.tm from ThermoHypersil, 0.45 
mmolg', 1.0 g, 0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a 
mixture of Boc-Dap(Boc)-OH (10 eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 
mmol, 0.6 g) in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting 
mixture for 10 mm, DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was added. The 
reaction mixture was then heated at reflux (50°C) for 3h. After cooling, the beads 
were filtered (Whatman microfiltration device, 12 mL volume, 5 lim pore size) and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS 
test indicated complete coupling. Boc amide and tButyl  ether deprotection was 
achieved by shaking the fuctionalised silica in a solution of DCM/TFA/ Water 
(50:50:1, 10 inL) for 10 mm. Silica is filtered and washed with DCM (50 mL). 
Then skaking with DCMITFA/Water (50:50:1, 10 mL) was repeated for 10 mm. 




H-Lys(H)-aminopropyl silica, (41) 
H2 NJHN 
NH2 
To a suspension of beaded aminopropyl silica (10 tm from ThermoHypersil, 0.45 
mmolg', 1.0 g, 0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a 
mixture of Fmoc-Lys( tBu)-OH (10 eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 
mmol, 0.6 g) in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting 
mixture for 10 mm, DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was added. The 
reaction mixture was then heated at reflux (50°C) for 3h. After cooling, the beads 
were filtered (Whatman microfiltration device, 12 ml, volume, 5 tm pore size) and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS 
test indicated complete coupling. Fmoc deprotection was achieved by shaking the 
fuctionalised silica in DMF/piperidine (95:5, 10 mL) for 15 mm. The silica was 
filtered and washed with DMF (50 mL). Then shaking in DMF/piperidine (95:5, 10 
mL) was repeated for 15 mm, followed by filtration and washing with DMF (50 




H-Ser(H)-aminopropyl silica, (42) 
H 2  N 
OH 
To a suspension of beaded aminopropyl silica (10 .tm from ThermoHypersil, 0.45 
mmolg 1 , 1.0 g, 0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a 
mixture of Fmoc-Ser( tBu)-OH (10 eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 
mmol, 0.6 g) in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting 
mixture for 10 mm, DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was added. The 
reaction mixture was then heated at reflux (50°C) for 3h. After cooling, the beads 
were filtered (Whatman microfiltration device, 12 ml, volume, 5 pm pore size) and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS 
test indicated complete coupling. Fmoc deprotection was achieved by shaking the 
fuctionalised silica in DMF/piperidine (95:5, 10 mL) for 15 mm. The silica was 
filtered and washed with DMF (50 mL). Then shaking in DMF/piperidine (95:5, 10 
mL) was repeated for 15 mm, followed by filtration and washing with DMF (50 
mL), DCM (50 mL) and Et20 (50 mL). 'Butyl ether deprotection was achieved by 
shaking the fuctionalised silica in a solution of DCMITFAIWater (50:50:1, 10 mL) 
for 10 mm. Silica is filtered an washed with DCM (50 mL). Then shaking with 
DCM/TFA!Water (50:50:1, 10 mL) was repeated for 10 mm. The silica was 











To a suspension of H-Dap(H)-aminopropyl silica (40) (1.0 g, 0.45 mmol) in 
DCMIDMF (8:2, 10 mL), was added a mixture of the 3,5-dinitrobenzoic acid (10 
eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 mmol, 0.6 g) in DCMIDMF (8:2, 
lOmL). After gentle shaking of the resulting mixture for 10 min,DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 rnL) was added. The reaction mixture was then heated to 
reflux (50°C) for 3h. After cooling the beads were filtered or centrifuged and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL), followed by drying 



















To a suspension of H-Lys(H)-aminopropyl silica (41) (1.0 g, 0.45 mmol) in 
DCMIDMF (8:2, 10 mL), was added a mixture of the 3,5-dinitrobenzoic acid (10 
eq., 4.5 mmol, 0.60 g) and HOBt (10 eq., 4.5 mmol, 0.6 g) in DCMIDMF (8:2, 
lOmL). After gentle shaking of the resulting mixture for 10 min,DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 mL) was added. The reaction mixture was then heated to 
reflux (50°C) for 3h. After cooling the beads were filtered or centrifuged and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL), followed by drying 
















To a suspension of H-Ser(H)-aminopropyl silica (42) (1.0 g, 0.45 mmol) in 
DCM!DMF (8:2, 10 mL), was added a mixture of the 3,5-dinitrobenzoic acid (10 
eq., 4.5 mmol, 0.60 g), HOBt (10 eq., 4.5 mmol, 0.6 g), DMAP (0.05 eq., 
0.0225 mmol, 2.5 mg) in DCM!DMF (8:2, lOmL). After gentle shaking of the 
resulting mixture for 10 mm, DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was added. 
The reaction mixture was then heated to reflux (50°C) for 3h. After cooling the 
beads were filtered or centrifuged and washed with DMF (50 mL), DCM (50 mL) 
and Et20 (50 mL), followed by drying under high vacuum. A negative TNBS 




3,5-DNB-Phe-Tyr( tBu)-Gly-aminopropyl silica (46) 
NO2 
02NX Y NYL NHJ 
	
0 
To a suspension of beaded aminopropyl silica (10, p.m from ThermoHypersil, 0.45 
mmolg, 1.0 g, 0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a 
mixture of Fmoc-Gly-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 
0.3 g) in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 
10 mm, DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture 
was then heated at reflux (5 0'Q for 3h. After cooling, the beads were filtered 
(Whatman microfiltration device, 12 mL volume, 5 p.m pore size) or centrifuged 
and washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative 
TNBS test indicated complete coupling. Fmoc deprotection was achieved by 
shaking the fuctionalised silica in DMF (5% piperidine) for 15 mm. The silica was 
filtered and washed with DMF (50 mL). Then shaking in DMF (5% piperidine) 
was repeated for 15 mm, followed by filtration and washing with DMF (50 mL), 
DCM (50 mL) and Et20 (50 mL). The functionalised silica was then coupled with 
two further amino acids sequentially. These were Fmoc-Tyr( tBu)-OH, Fmoc-Phe-
OH and used the same coupling condition described above for Fmoc-Gly-OH. 
Each coupling was also followed by Fmoc deprotection. To a suspension of H-Phe-
Tyr(tBu)-Gly-aminopropyl silica (1.0 g, 0.45 mmol) in DCMIDMF (8:2, 10 mL), 
was added a mixture of the 3,5-dinitrobenzoic acid (5 eq., 2.25 mmol, 0.30 g) and 
HOBt (5 eq., 2.25 mmol, 0.3 g) in DCM!DMF (8:2, lOmL). After gentle shaking of 
the resulting mixture for 10 min,DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was 
added. The reaction mixture was then heated to reflux (50'Q for 3h. After cooling 
the beads were filtered or centrifuged and washed with DMF (50 mL), DCM 
(50 mL) and Et20 (50 mL), followed by drying under high vacuum. A negative 




3,5-DNB-Phe-Tyr( tBu)-Abu-aminopropyl silica (47) 
NO2 
02N 	 "'H'  
(L 
O o O 
To a suspension of beaded aminopropyl silica (10, pm from ThermoHypersil, 0.45 
mmolg', 1.0 g, 0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a 
mixture of Fmoc-Abu-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 
0.3 g) in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 
10 min,DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture 
was then heated at reflux (50'Q for 3h. After cooling, the beads were filtered 
(Whatman microfiltration device, 12 mL volume, 5 jtm pore size) or centrifuged 
and washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative 
TNBS test indicated complete coupling. Fmoc deprotection was achieved by 
shaking the fuctionalised silica in DMF (5% piperidine) for 15 mm. The silica was 
filtered and washed with DMF (50 mL). Then shaking in DMF (5% piperidine) 
was repeated for 15 mm, followed by filtration and washing with DMF (50 mL), 
DCM (50 mL) and Et20 (50 mL). The functionalised silica was then coupled with 
two further amino acids sequentially. These were Fmoc-Tyr( tBu)-OH, Fmoc-Phe-
OH and used the same coupling condition described above for Fmoc-Gly-OH. 
Each coupling was also followed by Fmoc deprotection. To a suspension of H-Phe-
Tyr(Bu)-Abu-aminopropyl silica (1.0 g, 0.45 mmol) in DCM/DMF (8:2, 10 mL), 
was added a mixture of the 3,5-dinitrobenzoic acid (5 eq., 2.25 mmol, 0.30 g) and 
HOBt (5 eq., 2.25 mmol, 0.3 g) in DCM!DMF (8:2, lOmL). After gentle shaking of 
the resulting mixture for 10 min,DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was 
added. The reaction mixture was then heated to reflux (50'Q for 3h. After cooling 
the beads were filtered or centrifuged and washed with DMF (50 mL), DCM 
(50 mL) and Et20 (50 mL), followed by drying under high vacuum. A negative 




35-DNB-Phe-Tyr( tBu)-Ahx-aminopropyl silica (48) 
NO2 





To a suspension of beaded aminopropyl silica (10, pm from ThermoHypersil, 0.45 
mmolg', 1.0 g, 0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a 
mixture of Fmoc-Ahx-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 
0.3 g) in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 
10 mm, DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture 
was then heated at reflux (50°C) for 3h. After cooling, the beads were filtered 
(Whatman microfiltration device, 12 ml, volume, 5 jim pore size) or centrifuged 
and washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative 
TNBS test indicated complete coupling. Fmoc deprotection was achieved by 
shaking the fuctionalised silica in DMF (5% piperidine) for 15 mm. The silica was 
filtered and washed with DMF (50 mL). Then shaking in DMF (5% piperidine) 
was repeated for 15 mm, followed by filtration and washing with DMF (50 mL), 
DCM (50 mL) and Et20 (50 mL). The functionalised silica was then coupled with 
two further amino acids sequentially. These were Fmoc-Tyr( tBu)-OH, Fmoc-Phe-
OH and used the same coupling condition described above for Fmoc-Gly-OH. 
Each coupling was also followed by Fmoc deprotection. To a suspension of H-Phe-
Tyr(tBu)-Ahx-aminopropyl silica (1.0 g, 0.45 mmol) in DCMIDMF (8:2, 10 mL), 
was added a mixture of the 3,5-dinitrobenzoic acid (5 eq., 2.25 mmol, 0.30 g) and 
HOBt (5 eq., 2.25 mmol, 0.3 g) in DCMIDMF (8:2, lOmL). After gentle shaking of 
the resulting mixture for 10 min,DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 mL) was 
added. The reaction mixture was then heated to reflux (50°C) for 3h. After cooling 
the beads were filtered or centrifuged and washed with DMF (50 mL), DCM (50 
mL) and Et20 (50 mL), followed by drying under high vacuum. A negative TNBS 









N f  
°i;c < 
To a suspension of beaded H-Phe-Tyr(tBu)-aininopropyl silica (4) (10 tm, 1.0 g, 
0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a mixture of 
Fmoc-Gly-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) in 
DCM/DMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 10 mm, 
DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture was then 
heated at reflux (50°C) for 3h. After cooling, the beads were filtered and washed 
with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS test 
indicated complete coupling. Fmoc deprotection was achieved by shaking the 
fuctionalised silica in DMF (5% piperidine) for 15 mm. The silica was filtered and 
washed with DMF (50 mL). Then shaking in DMF (5% piperidine) was repeated 
for 15 mm, followed by filtration and washing with DMF (50 mL), DCM (50 mL) 
and Et20 (50 mL). The functionalised silica was suspended with 3,5-dinitrobenzoic 
acid (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) in DCM/DMF 
(8:2, lOmL). After gentle shaking of the resulting mixture for 10 mm, DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 mL) was added. The reaction mixture was then heated to 
reflux (50°C) for 3h. After cooling the beads were filtered and washed with DMF 
(50 mL), DCM (50 mL) and Et 20 (50 mL), followed by drying under high vacuum. 








N 02N L 
To a suspension of beaded H-Phe-Tyr(tBu)-aminopropyl silica (4) (10 tm, 1.0 g, 
0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a mixture of 
Fmoc-Abu-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) in 
DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 10 mm, 
DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture was then 
heated at reflux (5 0'C) for 3h. After cooling, the beads were filtered and washed 
with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS test 
indicated complete coupling. Fmoc deprotection was achieved by shaking the 
fuctionalised silica in DMF (5% piperidine) for 15 mm. The silica was filtered and 
washed with DMF (50 mL). Then shaking in DMF (5% piperidine) was repeated 
for 15 mm, followed by filtration and washing with DMF (50 mL), DCM (50 mL) 
and Et20 (50 mL). The functionalised silica was suspended with 3,5-dinitrobenzoic 
acid (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) in DCMIDMF 
(8:2, lOmL). After gentle shaking of the resulting mixture for 10 mm, DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 mL) was added. The reaction mixture was then heated to 
reflux (5 0'C) for 3h. After cooling the beads were filtered and washed with DMF 
(50 mL), DCM (50 mL) and Et20 (50 mL), followed by drying under high vacuum. 








To a suspension of beaded H-Phe-Tyr(tBu)-aminopropyl silica (4) (10 m, 1.0 g, 
0.45 mmol) in a solution of DCM/DMF (8:2, 10 mL), was added a mixture of 
Fmoc-Ahx-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) in 
DCM/DMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 10 mm, 
DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture was then 
heated at reflux (50°C) for 3h. After cooling, the beads were filtered and washed 
with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS test 
indicated complete coupling. Fmoc deprotection was achieved by shaking the 
fuctionalised silica in DMF (5% piperidine) for 15 mm. The silica was filtered and 
washed with DMF (50 mL). Then shaking in DMF (5% piperidine) was repeated 
for -15 mm, followed by filtration and washing with DMF (50 mL), DCM (50 mL) 
and Et20 (50 mL). The functionalised silica was suspended with 3,5-dinitrobenzoic 
acid (5 eq., 2.25 rnmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) in DCM/DMF 
(8:2, lOmL). After gentle shaking of the resulting mixture for 10 mill, DIC (10 eq., 
4.5 mmol, 0.58 g, 0.7 mL) was added. The reaction mixture was then heated to 
reflux (50°C) for 3h. After cooling the beads were filtered and washed with DMF 
(50 mL), DCM (50 mL) and Et20 (50 mL), followed by drying under high vacuum. 




3,5-DNB-D-Phe-Tyr( tBu)-aminopropyl silica (52) 
0 "10 Hj 
O2N qANThr N 
NO2 
Synthesis identical to that of 3,5-DNB-Phe-Tyr( tBu)-aminopropyl silica (5), except 
Fmoc-D-Phe is used instead of Fmoc-Phe-OH. 




Synthesis identical to that of 3,5-DNB-Phe-Tyr( tBu)-aminopropyl silica (5), except 
Fmoc-D-Tyr(tBu)-OH is used instead of Fmoc-Tyr( tBu)-OH. 
35-DNB-D-Phe-D-Tyr( tBu)-aminopropyl silica (54) 
0 '10 
O2N 2A 
H 0  qH 
NO2 	 Oj< 
Synthesis identical to that of 3,5-DNB-Phe-Tyr( tBu)-aminopropyl silica (5), except 










02N L0 	IIIII OH 
NO2 
To a suspension of beaded H-Phe-Tyr(tBu)-aminopropyl silica (4) (10 jim, 1.0 g, 
0.45 mmol) in a solution of DCMIDMF (8:2, 10 mL), was added a mixture of 
Fmoc-Ser(tBu)-OH (5 eq., 2.25 mmol, 0.30 g) and HOBt (5 eq., 2.25 mmol, 0.3 g) 
in DCM!DMF (8:2, 10 mL). After gentle shaking of the resulting mixture for 
10 mm, DIC (5 eq., 2.25 mmol, 0.29 g, 0.35 mL) was added. The reaction mixture 
was then heated at reflux (50'C) for 3h. After cooling, the beads were filtered and 
washed with DMF (50 mL), DCM (50 mL) and Et20 (50 mL). A negative TNBS 
test indicated complete coupling. Fmoc deprotection was achieved by shaking the 
functionalised silica in DMF (5% piperidine) for 15 mm. The silica was filtered 
and washed with DMF (50 mL). Then shaking in DMF (5% piperidine) was 
repeated for 15 mm, followed by filtration and washing with DMF (50 mL), DCM 
(50 mL) and Et20 (50 mL). tButyl ether deprotection was achieved by shaking the 
silica in a solution of DCMITFAJWater (50:50:1, 10 mL) for 10 mm. Silica was 
filtered and washed with DCM (50 mL). Then shaking with DCMITFAIWater 
(50:50:1, 10 mL) was repeated for 10 mm. The silica was filtered, washed with 
DCM (50 mL) and dried. The functionalised silica was suspended with 3,5-
dinitrobenzoic acid (5 eq., 2.25 mmol, 0.30 g), HOBt (5 eq., 2.25 mmol, 0.3 g) and 
DMAP (0.05 eq., 0.0225 mmol, 2.5 mg) in DCM/DMF (8:2, lOmL). After gentle 
shaking of the resulting mixture for 10 min,DIC (10 eq., 4.5 mmol, 0.58 g, 0.7 
mL) was added. The reaction mixture was then heated to reflux (50°C) for 3h. 
After cooling the beads were filtered and washed with DMF (50 mL), DCM (50 
mL) and Et20 (50 mL), followed by drying under high vacuum. A negative TNBS 




7.3.2 	Solid-phase loading from Elemental analysis 
Using: 
Loading (nmi019 1 ) x ma (gmol') x atoms in compound 	 Elemental 
x 100 = composition 
WHO 11 	 (%) 
CSP Formula C/%  H I % N/%  C H* N* Average* 
 Silica- 14.22 1.34 2.66 0.37 0.37 0.38 0.37 
C32H36N508  
 Silica- 14.64 1.22 2.53 0.38 0.34 0.36 0.36 
C32H36N505  
 Silica- 13.58 1.44 2.42 0.35 0.40 0.35 0.37 
C32H36N508 
 Silica- 14.5 1.24 1.92 0.38 0.34 0.34 0.35 
C32H37N406  
 Silica- 12.89 1.11 1.51 0.34 0.29 0.36 0.33 
C32 H38 N304  
 Silica- 14.02 1.17 1.43 0.34 0.28 0.34 0.32 
CH42N306  
 Silica- 12.65 1.07 1.61 0.33 0.28 0.38 0.33 
C32 H 38 N306 
 Silica- 13.34 1.24 2.34 0.35 0.31 0.33 0.33 
C32H40N504  
 Silica- 13.89 1.27 1.33 0.32 0.32 0.32 0.32 
C36H40N 304  
 Silica- 12.34 1.19 1.98 0.33 0.32 0.35 0.34 
C31 H 37N0 
 Silica- 10.03 1.23 1.33 0.28 0.34 0.32 0.31 
C30H 36N 304S 
 Silica- 12.89 1.33 1.68 0.28 0.30 0.40 0.33 
C39HN304  
 Silica- 13.43 1.55 1.45 0.29 0.30 0.35 0.31 
C39H52N304 
 Silica- 12.94 1.45 1.52 0.34 0.40 0.36 0.37 
C32H36F2N304  
 Silica- 
12.88 1.33 1.32 0.32 0.37 0.31 0.33 
CH36F6N304  
 Silica- 
11.99 1.33 1.63 0.31 0.35 0.39 0.35 
C32H35N301052  
 Silica- 
13.75 1.34 1.29 0.32 0.32 0.31 0.31 
C36 H42N308  
 Silica- 
14.54 1.55 2.09 0.34 0.35 0.30 0.33 
C36HN506 





(53) Silica- 14.54 1.55 2.09 0.34 0.35 0.30 0.33 
C36HN5O6 
* = loading / nimolg' 




7.4 	Experimental for Chapter 3 
7.4.1 	Synthesis of compounds 
succinimidylcarbonate-aminopropyl silica (57) 
VN _0 ~" N 
Using a procedure by Haginaka et a1 128 . Aminopropyl silica (1.0 g, 0.45 mmolg', 
10 p.m) was slurried in acetonitrile (20 mL) and reacted with NN-disuccinimidyl 
carbonate (1.0 g) at 30 °C for 24 h. The silica was filtered and washed with 
acetonitrile (3 x 20 mL), water (2 x 20 mL) and methanol (2 x 20 mL) and then 
dried in vacuo. 
BSA-urea-aminopropyl silica (58) 
0 
Using a procedure by Haginaka et al 128 . Succinimidylcarbonate-aminopropyl silica 
(57) (1.0 g, 0.45 nmiolg', 10 irn) was slurried in phosphate buffer (10 mL, 20 
mM, pH 6.8). Bovine Serum Albumin (300 mg, Sigma-Aldrich, lyophilized 
powder, ?95%) in phosphate buffer (5 mL, 20 mM, pH 6.8) was slowly added to 
the mixture at room temperature over 1 h. The reaction pH was monitored during 
the protein addition and corrected as necessary to keep it steady at 6.8. The reaction 
was stirred for a further 24 h at 30 °C. After cooling the reaction mixture was 
washed with water and reacted with; aminoethanol/water (1:50) adjusted to pH 6.8 
with HC1, at room temperature for 1 h. The silica was filtered and washed with 




HSA-urea-aminopropyl silica (59) 
[HSA 1N 
Procedure identical to BSA-urea-aminoproply silica (58), except the use of Human 
Serum Albumin instead of Bovine Serum Albumin. 
7.5 	Experimental for Chapter 4 
7.5.1 	Synthesis of compounds 
9-vinylanthracene (60)286,287 
Using a procedure by Schurch et a1 253, methyltriphenylphosphonium 
bromide (19.05 g, 53.34 mmol, 1.1 eq.) was added to THF (100 mL). The 
suspension was stirred at 0 °C and n-BuLi (1.0 M in THF, 50.91 mL, 50.91 mmol, 
1.05 eq.) was added slowly. The mixture was warmed to room temperature and 
stirred for 30 mm. 9-Anthraldehyde (10 g, 48.49 mmol, 1 eq.) in THF (100 mL) 
was added slowly to the reaction, which was stirred for a further 15 h, then MeOH 
(1 mL) added to the reaction. The slurry was diluted with petroleum ether (100 mL) 
and the supernatant solution was decanted and filtered through celite. The solids 
remaining in the mask were washed with petroleum ether (3 x 100 mL) and the 
supernatant solutions filtered through celite. The filtrate was concentrated in vacuo. 
Purification achieved by flash chromatography (silica; hexane/EtOAc) to give 
9-vinylanthracene as a yellow solid, 9.32 g (80%): m.p. 58-59°C (DCM), literature: 
60-63°C 286;  'H NMR (CDC1 3 , 250MHz): 8.58 (s, 1H, 1 x ArH), 8.56-8.48 (m, 2H, 
2 x ArH), 8.16-8.24 (m, 5H, 4 x ArH), 6.21 (dd, 2H, J= 12Hz, J= 4Hz), 5.83 (dd, 
2H, J = 12Hz, J = 4Hz). ' 3C NMR (CDC13, 62.5MHz): 134.0 (C), 133.9 (CH), 
131.8 (C), 129.6 (C), 129.0 (CH), 126.7 (CH), 126.4 (CH), 125.7 (CH), 125.5 
(CH), 123.3 (CH2); m/z (El): 204 [M] (93%), 203 [M-H] (100%). HR-m/z (El): 





Using a procedure by Schurch et a1 253 , AD-mix a (50.0 g, 31.96 mmol, 1.1 eq.) in 
Water/tBuOH (1:1, 500 mL) was cooled to 0 °C. 9-Vinylanthracene (60) (5.75 g, 
28.14 mmol, 1.0 eq.) was added to the reaction which was stirred at 0 °C for 24 h. 
The mixture was quenched with Na2S03 (38 g), warmed to room temperature, and 
stirred for 1 h. Organic layers was extracted with EtOAc (3 x 200 mL) and 
combined and washed with water (2 x 100 mL), dried with MgSO4, filtered and 
concentrated in vacuo. Purification achieved by flash chromatography (silica; 
hexane/EtOAc), which gave (S)- 1 -(9-anthracenyl)ethane- 1 ,2-diol as yellow 
crystals, 4.45 g (78%, 98%ee from Chiral-HPLC (Chiralcel-OD; Heptane/2-PrOH 
(90:10) screened versus opposite enantiorner)). m.p. 129-130 °C (DCM/Hexane); 
'H NMR (CDC13, 250MHz): 8.47 (d, H, J = 9 Hz, 2 x ArH), 8.24 (s, 1H, 1 x Aril), 
7.87-7.78 (m, 2H, 2 x ArH), 7.37-7.24 (m, 4H, 4 x ArH), 6.19 (dd, 1H, J= 10Hz, J 
4Hz), 4.28 (dd, 1H, J = 12Hz, J = 10Hz), 3.73 (dd, 1H, J = 12Hz, J = 4Hz). 13 C 
NMR (CDC13 , 62.5MHz): 132.3 (C), 130.4 (C), 130.1 (C), 129.2 (CH), 129.0 
(CH), 126.1 (CH), 125.2 (CH), 125.0 (CH), 74.6 (CH), 69.5 (CH2); m/z (ES+): 261 




(S)-1-(9-anthracenyl)-2-(tert-butvldimethvlsilvloxv) ethanol (62) 
lj< 
Using 	a 	procedure 	by 	Nieuwenhuis 	et 	a1255 . 
(S)-1-(9-anthracenyl)ethane-1,2-diol (61) (10.0 g, 42.00 mmol, 1.0 eq.) was 
dissolved in DMF (100 mL). Imidazole (2.86 g, 84.00 mmol, 2.0 eq.) and tert-
butyldimethylsilyl chloride (6.33 g, 42.00 mmol, 1.0 eq.) were added at room 
temperature. After stirring for 24 h at room temperature, the solution was poured 
into water (50 mL) and extracted with Et20 (3 x 50 mL). The combined organic 
layers were washed, with brine (50 mL), dried with MgSO4, filtered and 
concentrated in vacuo. Purification was achieved by flash chromatography (silica; 
hexane/EtOAc) to give (S)- 1 -(9-anthracenyl)-2-(tert-butyldimethylsilyloxy) 
ethanol as a clear/yellow oil, 11.09 g (75%); 'H NMR (CDC13, 250MHz): 8.60 (d, 
21I, J= 8 Hz, 2 x ArH), 8.32 (s, 111, 1 x ArH), 7.92-7.87 (m, 2H, 2 x Ar), 7.44-
7.32 (m, 4H, 4 x An-I), 6.24 (dd, 1H, J = 10 Hz, J = 4 Hz), 4.28 (dd, 1H, J = 1211z, 
J= 10Hz), 3.82 (dd, 1H, J = 12Hz, J = 411z), 3.16 (s, 1H), 0.88 (s, 9H), 0.04 (s, 
3H), 0.00 (s, 3H); ' 3C NMR (CDC13, 62.5MHz): 132.0 (C), 130.6 (C), 130.4 (C), 
129.7 (CH), 129.0 (CH), 126.1 (CH), 125.3 (CH), 125.1 (CH), 72.6 (CH), 67.1 
(CH2), 26.4 (CH 3), 18.8 (C), -4.8 (CH3); m/z (ES+): 335 [M-OH] (100%), 375 
[M+Na] (20%), 407 [M+Na+MeOH] (15%). 
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(S)-1-(9-anthracenyl)-1-((2-methoxyethoxy)methoxy)-2-
(tert-buty1dimethylsilyloxy) ethane (63) 
* O,, 10,.SL 0 f 
11 
Using a procedure by Williams et a1 266. (S)- 1 -(9-anthracenyl)-2-(tert-
butyldimethylsilyloxy) ethanol (62) (2.0 g, 5.672 mmol, 1.0 eq.) was dissolved in 
DCM (20 mL). DIPEA (1.48 mL, 8.308 mmol, 1.5 eq.) was added to the stirred 
reaction. Methoxyethoxymethyl chloride (1.06 mL, 8.308 mmol, 1.5 eq.) was 
added slowly to the reaction, which was stirred for a further 6 h. Then the solution 
was poured into water (20 mL) and extracted with Et20 (3 x 50 mL). The 
combined organic layers were washed with brine (50 mL), dried with MgSO 4 , 
filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (silica; hexane/EtOAc) to give (S)- 1 -(9-anthracenyl)- 1-
(methoxyethoxymethoxy)-2-(tert-butyldimethylsilyloxy) ethane as a clear oil, 1.83 
g (73%). 'H NMR (CDC13, 250MHz): 9.09 (s, 1H, 1 x ArH), 8.54 (s, 2H, 2 x ArFI), 
8.13-8.10 (m, 2H, 2 x ArH), 7.65-7.54 (m, 411, 4 x ArH), 6.42 (dd, 11-1, J= 8 Hz, J 
= 4 Hz), 5.02 (d, 1H, J= 7 Hz), 4.82 (d, 1H, J= 7 Hz), 4.64 (dd, 1H, J = 11 Hz, J= 
8 Hz), 4.11 (dd, 1H, J= 11 Hz, J = 4 Hz), 3.62-3.48 (m, 2H), 3.42-3.35 (m, 4H), 
0.93 (s, 914), 0.06 (s, 3H), 0.01 (s, 311); ' 3CNMR (CDC13, 62.5MHz): 132.2 (C), 
131.6 (C), 130.5 (C), 129.5 (CH), 128.7 (CH), 127.3 (CH), 126.6 (CH), 125.2 
(CH), 94.6 (CH2), 67.1 (CH 2), 76.5 (CH), 72.0 (CH2), 67.0 (2 x CH2), 59.2 (CH3), 
26.2 (CH3), 18.7 (C), -5.0 (CH3); m/z (ES+): 463 [M+Na] (100%). Elem. 








Using 	a 	procedure 	by 	Boger 	et 	a1238 . 
(S)- 1 -(9-anthracenyl)- 1 -(methoxyethoxymethoxy)-2-(tert-butyldimethylsilyloxy) 
ethane (63) (1.50 g, 3.404 mmol, 1.0 eq.) was dissolved in MeCN (15 mL). Bu4NF 
(1 M in THF, 6.81 mL, 6.808 mmol, 2.0 eq.) was slowly added to the stirred 
reaction. The reaction was stirred for a further 1 h, then the solution was poured 
into water (20 mL) and extracted with Et20 (3 x 50 mL). The combined organic 
layers were washed with brine (50 mL), dried with MgSO4, filtered and 
concentrated in vacuo. Purification was achieved by flash chromatography (silica; 
hexane/EtOAc) to give (S)-2-(9-anthracenyl)-2-((2-methoxyethoxy)methoxy) 
ethanol as a clear oil, 1.06 g (95%). 'H NMR (CDC1 3 , 250MHz): 8.72 (bs, 2H, 2 x 
An-I), 8.22 (s, 1H, 1 x ArH), 7.82-7.75 (m, 2H, 2 x ArH), 7.32-7.20 (m, 4H, 4 x 
ArH), 6.10 (dd, 1H, J = 8 Hz, J = 4 Hz), 4.61 (d, 1H, J = 7 Hz), 4.48 (d, 1H, 
J= 7 Hz), 4.32 (dd, 1H, J = 12 Hz, J= 8 Hz), 3.78-3.60 (m, 2H), 3.43-3.18 (m, 
3H), 3.15 (s, 3H); 13C NMR (CDC13 , 62.5MHz): 132.2 (C), 130.7 (C), 129.6 (CH), 
129.3 (C), 129.1 (CH), 127.3 (CH), 126.6 (CH), 125.3 (CH), 95.0 (CH2), 78.5 
(CH), 72.2 (CH2), 67.9 (CH2), 66.2 (CH2), 59.4 (CH); m/z (ES-): 325 [M-H] 




(R)-methyl 2-((2-methoxvethoxy)methoxv)-2-phenylacetate (65) 
0 
Using a procedure by Williams et a1 266. (S)-(+)-Methyl mandelate (1.0 g, 6.018 
mmol, 1.0 eq.) was dissolved in DCM (20 mL). DIPEA (1.572 mL, 9.027 mmol, 
1.5 eq.) was added to the stirred reaction. Methoxyethoxymethyl chloride (1.031 
mL, 9.027 mmol, 1.5 eq.) added slowly to the reaction, which was stirred for a 
further 6 h. Then the solution was poured into water (10 mL) and extracted with 
Et20 (3 x 25 mL). The combined organic layers were washed with brine (25 mL), 
dried with MgSO4, filtered and concentrated in vacuo. Purification was achieved by 
flash chromatography (silica; hexane/EtOAc) to give (R)-methyl 2-((2-
methoxyethoxy)methoxy)-2-phenylacetate as a clear oil, 1.22 g (80%). 1 H NMR 
(CDC13, 250MHz): 7.30-7.25 (m, 2H, 2 x ArH), 7.23-7.14 (m, 3H, 3 x ArH), 5.06 
(s, 11-1), 4.68 (d, 1H, J= 7 Hz), 4.60 (d, 11-1, J= 7 Hz), 3.67-3.58 (m, in), 3.54 (s, 
3H), 3.52-3.44 (m, 111), 3.35-3.30 (m, 2H), 3.18 (s, 3H); 13CNMR (CDC13 , 
62.5MHz): 171.6 (C), 136.5 (C), 129.1 (CH), 129.0 (CH), 127.8 (CH), 94.4 (CH2), 





(R)-2-((2-methoxyethoxv)methoxv)-2-phenylacetic acid (66)288 
U 
(R)-methyl 2-((2-methoxyethoxy)methoxy)-2-phenylacetate (65) (500 mg, 1.966 
mmol, 1.0 eq.) was dissolved in MeOH (5 mL). To the stirred reaction was added a 
solution of LiOH (239 mL, 10.0 mmol) in water (5 mL) and the reaction was 
stirred for a further 6 h. Then the reaction mixture was extracted with Et20 (3 x 25 
mL). The combined organic layers were washed with brine (25 mL), dried with 
MgSO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography 	(silica; 	hexane/EtOAc) 	to 	give 
methoxyethoxy)methoxy)-2-phenylacetic acid as a clear oil, 270 mg (57%). 'H 
NMR (CDC13 , 250MHz): 8.70-8.20 (bs, 114), 7.30-7.22 (m, 2H, 2 x ArH), 7.20-
7.13 (m, 3H, 3 x ArH), 5.06 (s, 1H), 4.65 (d, 1H, J= 7 Hz), 4.56 (d, 1H, J= 7 Hz), 
3.67-3.58 (m, 1H), 3.52-3.44 (m, 11-1), 3.35-3.30 (m, 2H), 3.17 (s, 3H); ' 3C NMR 
(CDC13 , 62.5MHz): 175.1 (C), 135.9 (C), 129.3 (CH), 129.1 (CH), 127.9 (CH), 





(R)-2-((2-methoxyethoxy)methoxy)-2-phenylacetoyl aminopropyl silica (67) 
o1 
0 ox °N 
To a suspension of aminopropy! silica (10 p.m, 0.45 mmolg', 1.0 g, 0.45 mmol, 1.0 
eq.) in DCM/DMF (8:2, 5 mL), was added a mixture of the ((S)-2-((2-
methoxyethoxy)methoxy)-2-phenylacetic acid (203 mg, 0.9 mmol, 2.0 eq.) and 
HOBt (120 mg, 0.9 mmo!, 2.0 eq.) in DCMIDMF (8:2, 5mL). After gentle shaking 
of the resulting mixture for 10 min,DIC (140 L, 0.9 mmol, 2.0 eq.) was added. 
The reaction mixture was then heated to reflux (50°C) for 3h. After cooling the 
beads were filtered and washed with DMF (2 x 20 mL), DCM (2 x 20 mL) and 
Et20 (2 x 20 mL), followed by drying under high vacuum. A negative TNBS 
indicated complete coupling. 
(R)-2-hydroxy-2-phenylacetoyl aminopropyl silica (68) 
HONA 
Using a procedure by Moreau et a1 264 . (R)-2-((2-methoxyethoxy)methoxy)-2-
phenylacetoyl aminopropyl silica (67) (700 mg, 0.3150 mmol, 1 eq.) was 
suspended in DCM (10 mL). ZnBr2 (709 mg, 3.150 mmol, 10 eq.) was added to the 
reaction which was stirred at room temperature for 96 h. EtOH (made up to 40 mL) 
was added to the reaction and this was centrifuged (8000 rpm, 5 mm), the 
supernatant was removed and the centrifuge procedure was repeated (3 x 40 mL). 
The silica was then dried in vacuo. The compound was then compared to (67) by 







Using a procedure by Yamaguchi et a1 289, to a stirred suspension of NaH (60% in 
mineral oil, 147 mg, 3.679 mmol, 1.5 eq.) in TI-IF (10 mL) was added dropwise a 
solution of (S)-2-(9-anthracenyl)-2-((2-methoxyethoxy)methoxy) ethanol (64) (800 
mg, 2.453 mmol, 1.0 eq.) in THF (20 mL) over,1 h. The reaction was stirred for a 
further 1 h. Then methyl 4-(bromomethyl)benzoate (618 mg, 2.698 mmol, 1.1 
eq.)was added and the reaction was stirred for a further 1 h, then water was added 
and the solvents removed in vacuo. The remaining suspension was diluted with 
water and EtOAc and acidified with HC1. Organic layers were extracted with 
EtOAc (3 x 50 mL), washed with brine (50 mL), dried with MgSO 4, filtered and 
concentrated in vacuo. Purification was achieved by flash chromatography 
(silica; hexane/EtOAc) to give (S)-2-(9-antbracenyl)-2-
((2-methoxyethoxy)methoxy)ethoxymethyl(4-methylbenzoate) as a yellow oil, 800 
mg (69%). 'H NMR (CDCI3, 250MHz): 9.23 (bs, 1H, 1 x ArH), 8.67 (s, 214, 2 x 
ArH), 8.27-8.18 (m, 4H, 4 x ArH), 7.80-7.68 (m, 4H, 4 x ArH), 7.60 (d, 2H, J 8 
Hz, 2 x ArH), 6.75 (dd, 1H, J = 9 Hz, J = 4 Hz), 5.12 (d, 1H, J = 7 Hz), 5.02-4.85 
(m, 3H), 4.83-4.73 (m, 1H), 4.17 (s, 314), 4.05-3.97 (m, 2H), 3.78-3.63 (m, 311), 
3.53 (s, 314); 13 C NMR (CDC13 , 62.5MHz): 167.4 (C), 144.0 (C), 130.8 (CH), 130.0 
(CH), 129.8 (C), 129.7 (2 x C), 129.6 (CH), 129.0 (CH), 127.3 (CH), 126.7 (CH), 
125.3 (CH), 125.1 (CH), 94.3 (CH2), 78.3 (CH), 74.2 (CH 2), 73.0 (CH2), 












methylbenzoate (69) (750 mg, 1.582 mmol, 1.0 eq.) was dissolved in MeOH 
(20 mL). To the stirred reaction was added a solution of NaOH (632 mg, 10.0 
mmol) in MeOH (20 mL), the reaction was heated to 50 °C and stirred for a further 
96 h. After cooling the solvents were removed in vacuo. The residue was 
redissolved in EtOAc (25 mL) and water (25 mL). The aqueous layer was acidified 
with HC1 and the organic layer was extracted with EtOAc (3 x 25 mL). The 
combined organic layers were washed with brine (25 mL), dried with MgSO4, 
filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (silica; hexane/EtOAc) to give (S)-2-(9-anthracenyl)-2-((2-
methoxyethoxy)methoxy)ethoxymethyl-4-benzoic acid as an orange waxy oil/solid, 
560 mg (77%). 1 H NMR (CDC13 , 250MHz (Na salt)): 8.84 (bs, 1H, 1 x ArH), 8.33 
(s, 2H, 2 x ArH), 7.96-7.87 (m, 4H, 4 x ArH), 7.45-7.32 (m, 4H, 4 x ArH), 7.27 (d, 
214, J= 8 Hz, 2 x ArH), 6.42 (dd, 1H, J = 9 Hz, J = 4 Hz), 4.80 (d, 1H, J = 7 Hz), 
4.56-4.45 (m, 311), 4.44-4.38 (m, 11-1), 3.85-3.74 (m, 2H), 3.45-3.30 (m, 311), 
3.2 (s, 3H); 13 C NMR (CDC13, 62.5MHz): 171.8 (C), 144.9 (C), 131.8 (C), 131.6 
(C), 130.7 (CH), 129.8 (C), 129.7 (C), 129.6 (CH), 129.0 (CH), 127.4 (CH), 
127.1 (CH), 125.8 (CH), 125.3 (CH), 94.3 (CH2), 74.3 (CH), 74.2 (CH 2), 73.0 










(265 mg, 0.576 mmol, 1.28 eq.) and HOBt (78 mg, 0.576 mmol, 1.28 eq.) were 
dissolved in DCM/DMF (8:2, 10 mL). After gentle shaking of the resulting mixture 
for 10 mm, DIC (89 jtL, 0.576 mmol, 1.28 eq.) was added. After a further 10 mm 
shaking, the reaction was charged with aminopropyl silica (12 gin, 0.45 mmolg', 
1.0 g, 0.45 mmol, 1.0 eq.). The reaction mixture was stirred at room temperature 
for 24 h, then heated to reflux (50°C) for 3h. After cooling the beads were filtered 
and washed with DMF (2 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 20 mL), 
followed by drying under high vacuum. A negative TNBS indicated complete 
coupling. 
(S)-2-(9-anthracenyl)-2-hydroxy-ethoxymethyl-4-benzOvl aminopropyl silica 
L2 
HO,, 	
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Using a procedure by Moreau et a1264,  (S)-2-(9-anthracenyl)-2-((2-
methoxyethoxy)methoxy)ethoxymethyl-4-benzoyl aminopropyl silica (67) (1199 
mg, 0.45 mmol, 1 eq.) was suspended in DCM (20 mL). ZnBr (1013 mg, 4.5 mmol, 
10 eq.) was added to the reaction which was stirred at room temperature for 96 h. 
EtOH (made up to 40 mL) was added to the reaction and this was centrifuged 
(8000 rpm, 5 mm), the supernatant was removed and the centrifuge procedure was 













Based on a procedure by Novabiochem® 290, Fmoc-D/L-Phe-OH (496 mg, 1.28 
mmol, 5 eq.) dissolved in DCM/DMF (1:1, 10 mL and HOBt (173 mg, 1.28 mmol, 
5 eq.). After gentle shaking for 10 mm, DIC (200 pL, 1.28 mmol, 5 eq.) was added 
to the mixture. This mixture was shaken for 15 mm, then added to HMBA-AM 
polystyrene resin (0.8 mmolg 1 , 0.32 g, 0.256 mmol, 1 eq.) preswelled in DMF (20 
mL). Excess DMF was removed after swelling. DMAP (3 mg, 0.0256 mmol, 0:1 
eq.) was added to the reaction which was shaken at room temperature for 3 h. The 
resin was filtered and washed with DMF (3 x 20 mL), DCM (2 x 20 mL) and Et20 
(2 x 20 mL). The resin was then swelled in DMF and shaken in a solution of 
DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was then filtered and washed 
with DMF (2 x 20 mL), followed by shaking again in DMF/piperidine (80:20, 15 
mL) for 15 mm. The resin was filtered, washed with DMF (4 x 20 mL), DCM (2 x 




N-D/L-Tyr(O tBu)-HMBA-aminomethyl polystyrene (74) 
0 
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Based on a procedure by Novabiochem® 290, Fmoc-D/L-Tyr-OH (587 mg, 1.28 
mmol, 5 eq.) was dissolved in DCMIDMF (1:1, 10 mL) and HOBt (173 mg, 1.28 
mmol, 5 eq.). After gentle shaking for 10 mm, DIC (200 tL, 1.28 mmol, 5 eq.) was 
added to the mixture. This mixture was shaken for 15 mm, then added to HMBA-
AM polystyrene resin (0.8 mmolg', 0.32 g, 0.256 mmol, 1 eq.) preswelled in DMF 
(20 mL). Excess DMF was removed after swelling. DMAP (3 mg, 0.0256 mmol, 
0.1 eq.) was added to the reaction which was shaken at room temperature for 3 h. 
The resin was filtered and washed with DMF (3 x 20 mL), DCM (2 x 20 mL) and 
Et20 (2 x 20 mL). The resin was then swelled in DMF and shaken in a solution of 
DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was then filtered and washed 
with DMF (2 x 20 mL), followed by shaking again in DMF/piperidine (80:20, 15 
mL) for 15 mm. The resin was filtered, washed with DMF (4 x 20 mL), DCM (2 x 




ijN-D/L-Phe-D/L-Phe-HMBA-aminomethv1 polystyrene (75) 
1 
0 -~Y 0 
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Fmoc-D/L-Phe-OH (496 mg, 1.28 mmol, 5 eq.) was dissolved in DCM/DMF (1:1, 
10 mL), to this was added HOBt (173 mg, 1.28 mmol, 5 eq.). After gentle shaking 
for 10 mm, DIC (200 !.tL, 1.28 mmol, 5 eq.) was added to the mixture. This mixture 
was shaken for 15 mm, then added to H 2N-D/L-Phe-HMBA-aminomethyl 
polystyrene (73) (0.8 mmolg', 0.32 g, 0.256 mmol, 1 eq.) preswelled in DMF (20 
mL). Excess DMF was removed after swelling. The reaction was shaken at room 
temperature for 3 h. The resin was filtered and washed with DMF (3 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL). The resin is then swelled in DMF and 
shaken in a solution of DMF/piperidine (80:20, 15 mL) for 15 mm. The resin is 
then filtered and washed with DMF (2 x 20 mL), followed by shaking again in 
DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was filtered, washed with 












Fmoc-D/L-Phe-OH (496 mg, 1.28 mmol, 5 eq.) was dissolved in DCM/DMF (1:1, 
10 mL), to this was added HOBt (173 mg, 1.28 mmol, 5 eq.). After gentle shaking 
for 10 mm, DIC (200 iL, 1.28 mmol, 5 eq.) was added to the mixture. This mixture 
was shaken for 15 mm, then added to H 2N-D/L-Tyr(O tBu)-HMBA-aminomethyl 
polystyrene (74) (0.8 mmolg 1 , 0.32 g, 0.256 mmol, 1 eq.) preswelled in DMF (20 
mL). Excess DMF was removed after swelling. The reaction was shaken at room 
temperature for 3 h. The resin was filtered and washed with DMF (3 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL). The resin was then swelled in DMF and 
shaken in a solution of DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was 
then filtered and washed with DMF (2 x 20 mL), followed by shaking again in 
DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was filtered, washed with 





35-DNB-D/L-Phe-D/L-Phe-HMBA-aminomethyl polystyrene (77) 
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3,5-Dinitrobenzoic acid (272 mg, 1.28 mmol, 5 eq.) was dissolved in DCMIDMF 
(1:1, 10 mL), to this was added HOBt (173 mg, 1.28 mmol, 5 eq.). After gentle 
shaking for 10 mm, DIC (200 j.iL, 1.28 mmol, 5 eq.) was added to the mixture. This 
mixture was shaken for 15 mm, then added to H 2N-D/L-Phe-D/L-Phe-HMBA-
aminomethyl polystyrene (75) (0.8 mmolg', 0.32 g, 0.256 mmol, 1 eq.) preswelled 
in DMF (20 mL). Excess DMF was removed after swelling. The reaction was 
shaken at room temperature for 3 h. The resin was filtered and washed with DMF 




3,5-DNB-D/L-Phe-D/L-Tvr(O tBu)-HMBA-aminomethvl polystyrene (78) 
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3,5-Dinitrobenzoic acid (272 mg, 1.28 mmol, 5 eq.) was dissolved in DCM/DMF 
(1:1, 10 mL), to this was added HOBt (173 mg, 1.28 mmol, 5 eq.). After gentle 
shaking for 10 mm, DIC (200 pL, 1.28 mmol, 5 eq.) was added to the mixture. This 
mixture was shaken for 15 mm, then added to H 2N-D/L-Phe-D/L-Tyr(O tBu)-
HMBA-aminomethyl polystyrene (76) (0.8 mmolg', 0.32 g, 0.256 mmol, 1 eq.) 
preswelled in DMF (20 mL). Excess DMF was removed after swelling. The 
reaction was shaken at room temperature for 3 h. The resin was filtered and washed 
with DMF (3 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 20 mL), followed by 
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Based on a procedure by Novabiochem®291 , 3,5-DNB-D/L-Phe-D/L-Phe-HMBA-
arninomethyl polystyrene (77) (0.32 g, 0.256 mmol, 1 eq.) in a solution of 
DMF/MeOI-TIDIPEA (5:5:1, 50 mL) was heated to 50 °C. This was stirred for 62 h 
and then cooled to room temperature. The resin was filtered and washed with 
DMFIMeOH (1:1, 3 x 20 mL). The collected solution was evaporated in vacuo and 
the residue precipitated in petroleum ether (20 mL). The collected solid was dried 
under high vacuo, 81 mg (61%). 'H NMR (CDC13, 250MHz): 8.90-8.85 (m, 1H, 1 
x ArH), 8.70-8.65 (m, 2H, 2 x ArH), 8.00-7.90 (m, 1H), 7.10-6.52 (m, 11H, 10  
ArH), 4.78-4.69 (m, 211), 3.53 (s, 3H), 2.92-2.80 (m, 411); m/z (ES+): 543 [M+Na] +  




35-DNB-D/L-Phe-D/L-Tyr(O tBu)-OMe (80) 





Based on a procedure by Novabiochem® 291 , 3,5 -DNB-D/L-Phe-D/L-Tyr(O tBu)-
HMBA-aminomethyl polystyrene (78) (0.32 g, 0.256 mmol, 1 eq.) in a solution of 
DMF/MeOHIDIPEA (5:5:1, 50 mL) was heated to 50 °C. This was stirred for 62 h 
and then cooled to room temperature. The resin was filtered and washed with 
DMF/MeOH (1:1, 3 x 20 mL). The collected solution was evaporated in vacuo and 
the residue precipitated in petroleum ether (20 mL). The collected solid was dried 
under high vacuo, 79 mg (52%). 1 H NMR (CDC13 , 250MHz): 9.30-9.26 (m, 1H, 1 
x ArH), 9.12-9.08 (m, 214, 2 x ArH), 8.74-8.64 (m, 1H), 7.45-6.87 (m, 1OH, 9 x 
ArH), 5.25-5.12 (m, 111), 5.10-5.00 (m, 1H), 3.82 (s, 3H), 3.40-3.17 (m, 4H), 1.40 
(s, 911); m/z (ES+): 615 [M+Na]+ (100%); (ES-): 591 EM-H] (100%), 705 [M-
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Based on a procedure by Novabiochem®267' 268  Fmoc-D-Phe-OH (136 mg, 0.35 
mmol, 5 eq.) and HOBt (47 mg, 0.35 mg, 5 eq.) were dissolved in DMF (5 mL). To 
this was added DIC (55 mg, 0.35 mmol, 5 eq.) and the mixture left to stand for 10 
mm. The mixture was then added to pre-swollen Rink amide resin (100 mg, 
0.070 mmol, 0.7 mmolg') and shaken for 3 h. The resin is collected by filtration 
and washed with DMF. ). The resin was then swelled in DMF and shaken in a 
solution of DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was then filtered 
and washed with DMF (2 x 20 mL), followed by shaking again in DMF/piperidine 
(80:20, 15 mL) for 15 mm. The resin was filtered, washed with DMF (4 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL), followed by drying in vacuo. 
3,5-Dinitrobenzoic acid (74 mg, 0.35 mmol, 5 eq.) was dissolved in DCM/DMF 
(1:1, 5 mL), to this is added DIC (55 j.tL, 0.35 mmol, 5 eq.) and HOBt (47 mg, 
0.35 mmol, 5 eq.). This mixture was shaken for 15 mm, then added to the 
preswelled resin. The reaction was shaken at room temperature for 3 h. The resin 
was filtered and washed with DMF (3 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 
20 mL), followed by drying in vacuo. 
The resin was then suspended in TFAIDCM (1:1, 5 mL) and left for 2 h. The resin 
was filtered and washed with DCM (3 x 20 mL). The combined filtrates were 
reduced in vacuo and dried to give the desired peptide 3,5-DNB-D-Phe-NHMe, 
20 mg (80%). 'H NMR(CD 3CN, 250MHz): 7.04 (t, 1H, J .= 2 Hz, 1 x ArH), 6.84 
(d, 2H, 2 x ArH), 5.38-5.22 (m, 5H, 5 x ArH), 2.82 (dd, 1H, J = 10 Hz, J = 5 Hz), 
1.32 (dd, lH, J = 14 Hz, J= 5 Hz), 1.06 (dd, 1H, J = 14 Hz, J— 10 Hz); m/z (ES+): 






O2N N NH2 
Based on a procedure by Novabiochem®267' 268 Fmoc-L-Phe-OH (136 mg, 0.35 
mmol, 5 eq.) and HOBt (47 mg, 0.35 mg, 5 eq.) were dissolved in DMF (5 mL). To 
this was added DIC (55 mg, 0.35 mmol, 5 eq.) and the mixture left to stand for 10 
mm. The mixture was then added to pre-swollen Rink amide resin (100 mg, 0.070 
mmol, 0.7 mmolg 1 ) and shaken for 3 h. The resin was collected by filtration and 
washed with DMF.). The resin was then swelled in DMF and shaken in a solution 
of DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was then filtered and 
washed with DMF (2 x 20 mL), followed by shaking again in DMF/piperidine 
(80:20, 15 mL) for 15 mm. The resin was filtered, washed with DMF (4 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL), followed by drying in vacuo. 
3,5-Dinitrobenzoic acid (74 mg, 0.35 mmol, 5 eq.) was dissolved in DCMIDMF 
(1:1, 5 mL), to this was added DIC (55 tL, 0.35 mmol, 5 eq.) and HOBt (47 mg, 
0.35 mmol, 5 eq.). This mixture was shaken for 15 mm, then added to the 
preswelled resin. The reaction was shaken at room temperature for 3 h. The resin 
was filtered and washed with DMF (3 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 
20 mL), followed by drying in vacuo. 
The resin was then suspended in TFAIDCM (1:1, 5 mL) and left for 2 h. The resin 
was filtered and washed with DCM (3 x 20 mL). The combined filtrates were 
reduced in vacuo and dried to give the desired peptide 3,5-DNB-L-Phe-NHMe, 
20 mg (80%). 'H NMR (CD 3CN, 250MHz): 7.04 (t, 1H, J = 2Hz, 1 x ArH), 6.84 
(d, 2H, 2 x ArH), 5.38-5.22 (m, 5H, 5 x ArH), 2.82 (dd, 1H, J = 10 Hz, J = 5 Hz), 
1.32 (dd, 11-I, J = 14 Hz, J— 5 Hz), 1.06 (dd, 1H, J = 14 Hz, J = 10 Hz); m/z (ES-): 








Based on a procedure by Novabiochem®267' 268  Fmoc-D-Ala-OH (109 mg, 0.35 
mmol, 5 eq.) and HOBt (47 mg, 0.35 mg, 5 eq.) were dissolved in DMF (5 mL). To 
this was added DIC (55 mg, 0.35 mmol, 5 eq.) and the mixture left to stand for 10 
mm. The mixture was then added to pre-swollen Rink amide resin (100 mg, 0.070 
mmol, 0.7 mmolg') and shaken for 3 h. The resin was collected by filtration and 
washed with DMF. ). The resin was then swelled in DMF and shaken in a solution 
of DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was then filtered and 
washed with DMF (2 x 20 mL), followed by shaking again in DMF/piperidinë 
(80:20, 15 mL) for 15 mm. The resin was filtered, washed with DMF (4 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL), followed by drying in vacuo. 
3,5-Dinitrobenzoic acid (74 mg, 0.35 mmol, 5 eq.) dissolved in DCMIDMF (1:1, 5 
mL), to this was added DIC (55 1iL, 0.35 mmol, 5 eq.) and HOBt (47 mg, 0.35 
mmol, 5 eq.). This mixture was shaken for 15 mm, then added to the preswelled 
resin. The reaction was shaken at room temperature for 3 h. The resin was filtered 
and washed with DMF (3 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 20 mL), 
followed by drying in vacuo. 
The resin was then suspended in TFA!DCM (1:1, 5 mL) and left for 2 h. The resin 
was filtered and washed with DCM (3 x 20 mL). The combined filtrates were 
reduced in vacuo and dried to give the desired peptide 3,5-DNB-D-Ala-NHMe, 12 
mg (61%). 'H NMR (CD 3 CN, 250MHz): 7.12 (t, 1H, J = 2 Hz, 1 x ArH), 6.90 (d, 










Based on a procedure by Novabiochem®267' 268  Fmoc-L-Ala-OH (109 mg, 0.35 
mmol, 5 eq.) and HOBt (47 mg, 0.35 mg, 5 eq.) were dissolved in DMF (5 mL). To 
this was added DIC (55 mg, 0.35 mmol, 5 eq.) and the mixture left to stand for 10 
mm. The mixture was then added to pre-swollen Rink amide resin (100 mg, 0.070 
mmol, 0.7 mmolg' 1 ) and shaken for 3 h. The resin was collected by filtration and 
washed with DMF.). The resin was then swelled in DMF and shaken in a solution 
of DMF/piperidine (80:20, 15 mL) for 15 mm. The resin was then filtered and 
washed with DMF (2 x 20 mL), followed by shaking again in DMF/piperidine 
(80:20, 15 mL) for 15 mm. The resin was filtered, washed with DMF (4 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL), followed by drying in vacuo. 
3,5-Dinitrobenzoic acid (74 mg, 0.35 mmol, 5 eq.) dissolved in DCMIDMF (1:1, 5 
mL), to this was added DIC (55 jiL, 0.35 mmol, 5 eq.) and HOBt (47 mg, 0.35 
mmol, 5 eq.). This mixture was shaken for 15 mm, then added to the preswelled 
resin. The reaction was shaken at room temperature for 3 h. The resin was filtered 
and washed with DMF (3 x 20 mL), DCM (2 x 20 mL) and Et 20 (2 x 20 mL), 
followed by drying in vacuo. 
The resin was then suspended in TFA/DCM (1:1, 5 mL) and left for 2 h. The resin 
was filtered and washed with DCM (3 x 20 mL). The combined filtrates were 
reduced in vacuo and dried to give the desired peptide 3,5-DNB-L-Ala-NHMe, 
12 mg (61%). 1 11 NMR (CD3CN, 250MHz): 7.12 (t, 1H, J= 2 Hz, 1 x AM), 6.90 





7.5.2 	Solid-phase loading from Elemental analysis 
CSP Formula C/%  H/% N/% C H* N* Average* 
Silica- 
 
C 15H21 N04 10.49 1.32 1.00 0.58 0.63 0.71 0.64 
Silica- 
 
C 1 1 H 13 NO2 9.88 1.18 0.97 0.75 0.91 0.69 0.78 
Silica- 
(72) 
C26H23 N04 11.86 1.24 1.07 0.38 0.54 0.76 0.56 
* = loading / mmolg' 




7.6 	Experimental for Chapter 5 
7.6.1 	Synthesis of compounds 
1-(chloromethyl)-3.5-dinitrobenzene (85) 292 
CI 
O2N 	NO2 
Based on a procedure by Lahiri et a1 269, 3,5-dinitrobenzyl alcohol (9.20 g, 
46.43 mmol, 1 eq.) was dissolved in chloroform (250 mL) and cooled to 0 °C. To 
the reaction Pd 5 (16.92 g, 81.260 mmol, 1.75 eq.) was added slowly over 10 mm, 
and the reaction was stirred for a further 1 h. The reaction was cooled to room 
temperature and poured onto ice water (100 mL). The organic layer was extracted 
with DCM (100 mL), which was washed with water (5 x 50 mL), dried with 
MgSO4, filtered and concentrated. The residue was redisolved in DCM (100 mL) 
and filtered through a silica bung, washed out with DCM, concentrated in vacuo, to 
give a yellow solid, 10.02 g (99%). m.p. 79-80°C (DCM), literature: 	79.2- 
79.7°C (Chloroform/petroleum ether) 292 ; ' H NMR (CDC13, 250MHz): 9.20 (t, 1H, 
J= 2 Hz, 1 x ArH), 8.81 (d, 2H, J— 2 Hz, 2 x ArH), 4.96 (s, 2H); ' 3 C NMR 
(CDC13, 62.5MHz): 149.1 (C), 142.0 (C), 129.0 (CH), 119.1 (CH), 43.9 (CH 2); m/z 




Diethyl 2-acetamido-2-(3.5-dinitrobenzyl)malonate (86)270 293,294 
EtO2C H  
' CO2 Et 
02N 	NO2 
Based on a procedure by Santagada et a! 231 , diethyl 2-acetamidomalonate (9.88 g, 
45.48, 1 eq.) dissolved in EtOH (50 mL) was added to a solution of NaOEt (3.42 g, 
1.05 eq.) in EtOH (100 mL). The reaction was stirred for 15 mm. 
1-(Chloromethyl)-3,5-dinitrobenzene (85) (9.85 g, 45.48 mmol, 1 eq.) was added 
slowly to the reaction at 0 °C. Further EtOH (100 mL) was added to the reaction, 
which was then warmed to 50 °C and stirred for 2 h. The reaction was cooled to 
room temperature and the solvents removed in vacuo. The residue was redissolved 
in EtOH and filtered. The collected solid was washed with DCM (2 x 50 mL). The 
combined collected organic washings were concentrated in vacuo to give a white 
solid, 15.40 g (85%). 'H NMR (CDC13 , 250MHz): 9.11 (t, 1H, J= 2 Hz, 1 x ArH), 
8.51 (d, 2H, J= 2 Hz, 2 x ArH), 6.77 (s, 1H), 4.48 (q, 4H, J= 8 Hz), 4.09 (s, 2H), 
2.27 (s, 3H), 1.50 (t, 611, J= 8 Hz); ' 3 C NMR (CDC13 , 62.5MHz): 170.3 (C0), 
167.1 (C=O), 148.7 (C), 140.4 (C), 130.5 (CH), 118.2 (CH), 67.2 (CH2), 63.9 
(CH), 37.7 (CH), 23.4 (CH 3), 14.4 (CH3); m/z (ES+): 420 [M+Na] (100%), 398 









Based on a procedure by Santagada et a1 231 , diethyl 2-acetamido-2-(3,5-
dinitrobenzyl)malonate (86) (5.70 g, 14.35 mmol, 1 eq.) was dissolved in EtOH (30 
mL). To the reaction was added a solution of NaOH (2.30 g, 57.40 mmol, 4 eq.) in 
Water (15 mL). The reaction was stirred for 2 h at room temperature. The reaction 
was acidified to pH 2 with HC1 (2 M). The solvents were removed in vacuo and the 
residue was redissolved in EtOH, filtered and concentrated in vacuo. The residue 
was purified by crystalisation from DCM to give yellow crystals, 2.93 g (70%). 'H 
NMR (d4- methanol, 250MHz): 8.89 (t, 1H, J= 2 Hz, 1 x ArH), 8.48 (d, 211, J= 2 
Hz, 2 x ArH), 4.79 (dd, 111, J= 9 Hz, J = 5 Hz ), 3.52 (dd, 1H, J = 14 Hz, 
J= 5 Hz,) 3.25 (dd, 1H, J= 14 Hz, J= 9 Hz), 1.94 (s, 3H); ' 3 C NMR (CDC13 ,. 
62.5MHz): 173.7 (C0), 173.3 (C=O), 149.9 (C), 143.6 (C), 131.0 (CH), 118.4 





(S)-2-Amino-3-(3.5-dinitrophenyl)propanoic acid (88)270 293, 294 
NH2 
O2 N - 	NO2 
Based on procedures by Sisido et a! 270, Whitesides et a1 272 and Pirrung et a! 271 , 
2-acetamido-3-(3,5-dinitrophenyl)propanoic acid (87) (1.00 g, 3.3 56 mmol, 1 eq.) 
was suspended in water (50 mL). Dii. NaOH was added to aid dissolving and then 
the pH readjusted (with dii. HC1) and maintained at 7.0-7.2. The solution was 
heated to 37 °C. Acylase I (from aspergillus genus) was dissolved in water (10 
mL), CoC12 .6H20 added to this solution which was then added to the reaction and 
stirred for 24 h. The reaction was adjusted to pH 5.0 with HC1 (1.0 M), warmed to 
40 °C with font, and filtered. The filtrate was acidified to pH 1.5 with HC1 (1.0 M) 
acid and extracted with ethyl acetate (3 x 25 mL). The aqueous was layer 
concentrated in vacuo, the residue was purified by crystallisation from MeOH to 
give (S)-2-Amino-3-(3,5-dinitrophenyi)propanoic acid (88) as a white powder, 386 
mg (45%, 98%ee from Chiral-HPLC (Chiralcel-OD; Heptane/2-PrOHIAcOH 
(90:20:0.1) screened versus opposite enantiomer (91)). 'H NMR (d4- methanol, 
250MHz): 8.95 (t, 1H, J = 2 Hz, 1 x ArH), 8.55 (d, 2H, J = 2 Hz, 2 x ArH), 4.85 
(dd, 1H, J= 9 Hz, J= 5 Hz), 3.52 (dd, 1H, J= 14 Hz, J= 5 Hz), 3.25 (dd, 1H, J 
14 Hz, J = 9 Hz); ' 3C NMR (CDC13, 62.5MHz): 174.8 (C0), 149.8 (C), 144.3 (C), 









Based on procedures by Sisido et a1 270, Whitesides et a1 272 and Pirrung et a1 271 , 
2-acetamido-3-(3,5-dinitrophenyl)propanoic acid (87) (1.00 g, 3.356 mmol, 1 eq.) 
was suspended in water (50 mL). Dii. NaOH was added to aid dissolving and then 
the pH readjusted (with di!. HC1) and maintained at 7.0-7.2. The solution was 
heated to 37 °C. Acylase I (from aspergillus genus) was dissolved in water (10 
mL), CoC12.61120 added to this solution which was then added to the reaction and 
stirred for 24 h. The reaction was adjusted to pH 5.0 with HC1 (1.0 M), warmed to 
40 °C with font, and filtered through celite. The filtrate was acidified to pH 1.5 
with HC1 (1.0 M) acid and extracted with ethyl acetate (3 x 25 mL). The combined 
organic layers were washed with HC1 (1.0 M), brine, dried with MgSO 4 , filtered 
and concentrated in vacuo. The residue was purified by crystallisation from 
water/methanol to give (R)-2-Acetamido-3 -(3,5 -dinitrophenyl)propanoic acid (89) 
as a white powder, 422 mg (42%, 98%ee from Chiral-HPLC of (92) (Chiraicel-
OD; Heptane/2-PrOH (90:10) screened versus opposite enantiomer (88)). 'H NMR 
(d4- methanol, 250MHz): 8.74 (t, 1H, J= 2 Hz, 1 x ArH),8.38 (d, 211, J= 2 Hz, 2 x 
ArH), 4.66 (dd, 1H, J= 9 Hz, J= 5 Hz), 3.35 (dd, 1H, J=14 Hz, J = 5 Hz), 3.07 
(dd, 1H, J = 14 Hz, J = 9 Hz), 1.80 (s, 3H); ' 3C NMR (CDC!,, 62.5MHz): 173.9 
(C=O), 173.6 (C=O), 150.1 (C), 143.8 (C), 131.1 (CH), 118.5 (CH), 54.6 (CH), 











Based on a procedure by Novellino et a1 273 , (S)-2-amino-3-(3,5-
dinitrophenyl)propanoic acid (88) (1.0 g, 2.095 mmol, 1 eq.) was suspended in 9% 
Na2CO3 (25 mL) and cooled to 0 °C. To this was added a solution of Fmoc-OSu 
(2.22 g, 6.285 mmol, 3 eq.) in dioxane (25 mL) and the reaction was stirred at room 
temperature for 6 h. Dioxane was removed in vacuo and the organic phase was 
extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried 
with MgSO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (silica; hexane/EtOAc) to give (S)-2-(((9H-Fluoren-
9-yl)methoxy)carbonylamino)-3 -(3,5 -dinitrophenyl)propanoic acid (90) as a white 
powder, 1.16 g (62%). 'H NMR (d4- methanol, 250MHz): 8.94 (t, 1H, J= 2 Hz, 1 x 
ArH), 8.65 (d, 2H, J— 2Hz, 2 x ArH), 7.86 (dd, 2H, J= 8Hz, J = 3 Hz, 2 x AM), 
7.65 (t, 2H, J = 8 Hz, 1 x ArH), 7.50-7.33 (m, 4H, 4 x ArH), 4.63 (dd, 1H, J= 9 
Hz, J= 5 H ), 4.50-4.32 (m, 3H) 3.60 (dd, 1H, J = 15 Hz, J— 4 Hz), 3.30 (dd, 1H, 








(R)-2-Acetamido-3-(3,5-dinitrophenyl)propanoic acid (89) (1.00 g, 3.356 mmol, 1 
eq.) was stirred with HC1 (0.2 M, 30 mL) for 3 h. To the reaction mixture ethyl 
acetate was added then extracted (3 x 25 mL). The aqueous layer was concentrated 
in vacuo, the residue was purified by crystallisation from MeOH to give (R)-2-
Amino-3-(3,5-dinitrophenyl)propanoic acid (91) as a white powder, 687 mg (80%). 
'H NMR (d4- methanol, 250MHz): 8.95 (t, 1H, J= 2 Hz, 1 x ArH), 8.55 (d, 2H, J 
2Hz, 2 x ArH), 4.85 (dd, 1H, J= 9Hz, J5Hz ), 3.52 (dd, 11-1, J = 14 Hz, 
J = 5 Hz), 3.25 (dd, 1H, J = 14 Hz, J = 9 Hz); 13C NMR (CDC13, 62.5MHz): 174.8 
(C0), 149.8 (C), 144.3 (C), 133.2 (CH), 118.9 (CH), 55.5 (CH), 3 8. 0 (CH 2), 22.4; 





dinitropheny0propanoic acid (92)270 293,294 
L L- OANH 
O2NNO: 
Based on a procedure by Novellino et a1 273, (R)-2-amino-3-(3,5-
dinitrophenyl)propanoic acid (89) (1.0 g, 2.095 mmol, 1 eq.) was suspended in 9% 
Na2CO3 (25 mL) and cooled to 0 °C. To this was added a solution of Fmoc-OSu 
(2.22 g, 6.285 mmol, 3 eq.) in dioxane (25 mL) and the reaction was stirred at room 
temperature for 6 h. Dioxane was removed in vacuo and the organic phase was 
extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried 
with MgSO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (silica; hexane/EtOAc) to give (R)-2-(((9H-Fluoren-
9-yl)methoxy)carbonylamino)-3 -(3,5 -dinitrophenyl)propanoic acid (91) as a white 
powder, 1.12 g (60%). 1 H NMR (d4- methanol, 250MHz): 8.94 (t, 1H, J= 2 Hz, 1 x 
ArH), 8.65 (d, 2H, J = 2 Hz, 2 x ArH), 7.86 (dd, 2H, J = 8 Hz, J = 3 Hz, 2 x ArH), 
7.65 (t, 21-1, J = 8 Hz, 1 x ArH), 7.50-7.33 (m, 4H, 4 x ArH), 4.63 (dd, 1H, J = 9 
Hz, J= 5 Hz), 4.50-4.32 (m, 3H) 3.60 (dd, 1H, J= 15 Hz, J= 4 Hz), 3.30 (dd, 1H, 








(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3 -(3,5 -dinitrophenyl)propanoic 
acid (90) (515 mg, 1.08 mmol, 1.5 eq.) and HOBt (146 mg, 1.08 mmol, 1.5 eq.) 
were dissolved in DCM/DMF (8:2, 20 mL). After gentle shaking of the resulting 
mixture for 10 mm, DIC (167 j.tL, 1.08 mmol, 1.5 eq.) was added. After a further 
10 min shaking, the reaction was charged with aminopropyl silica (12 gm, 
0.45 mmolg', 1.6 g, 0.72 nmiol, 1.0 eq.). The reaction was heated to reflux (50°C) 
for 6h. After cooling the beads were filtered and washed with DMF (2 x 20 mL), 
DCM (2 x 20 mL) and Et20 (2 x 20 mL), followed by drying under high vacuum. 
A negative TNBS test indicated complete coupling. Fmoc deprotection was 
achieved by shaking the fuctionalised silica in DMF/piperidine (95:5, 10 mL) for 
15 mm. The silica was filtered and washed with DMF (50 mL). Then shaking in 
DMF/piperidine (95:5, 10 mL) was repeated for 15 mm, followed by filtration and 
washing with DMF (50 mL), DCM (50 mL) and Et20 (50 rnL) to give (S)-2-











3,5-Dinitrobenzoic acid (0.24 g, 1.80 mmol, 5 eq.) and HOBt (0.24 g, 1.80 mmol, 
5 eq.) were dissolved in DCMIDMF (8:2, 10 mL). After gentle shaking of the 
resulting mixture for 10 mm, DIC (350 tL, 1.80 mmol, 5 eq.) was added. After a 
further 10 min shaking, the reaction was charged with (S)-2-Amino-3-(3,5-
dinitrophenyl)propanoylamidopropyl silcia (93) (0.8 g, 0.36 mmol, 1 eq.) and the 
reaction was heated to reflux (5 0'Q for 6h. After cooling the beads were filtered 
and washed with DMF (2 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 20 mL), 
followed by drying under high vacuum. A negative TNBS test indicated complete 
coupling giving (S)-2-(3 ,5 -Dinitrobenzoylarnido)-3 -(3,5 - 













(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3 -(3 ,5-dinitrophenyl)propanoic 
acid (90) (260 mg, 0.54 mmol, 1.5 eq.) and HOBt (73 mg, 0.54 mmol, 1.5 eq.) 
were dissolved in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting 
mixture for 10 mm, DIC (84 iL, 0.54 mmol, 1.5 eq.) was added. After a further 10 
min shaking, the reaction was charged with (S)-2-Arnino-3-(3,5-
dinitrophenyl)propanoylamidopropyl silica (93) (0.8 g, 0.36 mmol, 1 eq.) and the 
reaction was heated to reflux (5 0'Q for 6h. After cooling the beads were filtered 
and washed with DMF (2 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 20 mL), 
followed by drying under high vacuum. A negative TNBS test indicated complete 
coupling. Fmoc deprotection was achieved by shaking the fuctionalised silica in 
DMF/piperidine (95:5, 10 mL) for 15 mm. The silica was filtered and washed with 
DMF (50 mL). Then shaking in DMF/piperidine (95:5, 10 mL) was repeated for 15 
mm, followed by filtration and washing with DMF (50 mL), DCM (50 mL) and 
Et20 (50 mL) to give (S,S)-2-(2-amino-3-(3,5-dinitrophenyl)propoylamido)-













3,5-Dinitrobenzoic acid (0.24 g, 1.80 mmol, 5 eq.) and HOBt (0.24 g, 1.80 mmol, 
5 eq.) were dissolved in DCMIDMF (8:2, 10 mL). After gentle shaking of the 
resulting mixture for 10 mm, DIC (350 tL, 1.80 mmol, 5 eq.) was added. After a 
further 10 min shaking, the reaction was charged with (S,S)-2-(2-amino-3-(3,5-
dinitrophenyl)propoylamido)-3 -(3,5 -dinitrophenyl)propanoylamidopropyl silica 
(95) (0.8 g, 0.36 mmol, 1 eq.) and the reaction was heated to reflux (50°C) for 6h. 
After cooling the beads were filtered and washed with DMF (2 x 20 mL), DCM (2 
x 20 mL) and Et20 (2 x 20 mL), followed by drying under high vacuum. A 
negative TNBS test indicated complete coupling giving (S,S)-2-(2-(3,5-
Dinitrobenzoylamido)-3 -(3,5 -dinitrophenyl)propoylamido)- 




(S)-2-Amino-3-(3,5-dinitrophenyl)propanoylamidopropyl silcia (97) 
0 
H 2 N N 
/ \ NO 
02N 
(R)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3 -(3 ,5-dinitrophenyl)propanoic 
acid (92) (260 mg, 0.54 mmol, 1.5 eq.) and HOBt (73 mg, 0.54 mmol, 1.5 eq.) 
were dissolved in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting 
mixture for 10 mill, DIC (84 p.L, 0.54 mmol, 1.5 eq.) was added. After a further 10 
min shaking, the reaction was charged with aminopropyl silica (12 gm, 0.45 
mmolg', 0.8 g, 0.36 mmol, 1.0 eq.). The reaction was heated to reflux (50°C) for 
6h. After cooling the beads were filtered and washed with DMF (2 x 20 ML), DCM 
(2 x 20 mL) and Et20 (2 x 20 mL), followed by drying under high vacuum. A 
negative TNBS test indicated complete coupling. Fmoc deprotection was achieved 
by shaking the functionalised silica in DMF/piperidine (95:5, 10 mL) for 15 mm. 
The silica was filtered and washed with DMF (50 mL). Then shaking in 
DMF/piperidine (95:5, 10 mL) was repeated for 15 mm, followed by filtration and 
washing with DMF (50 mL), DCM (50 mL) and Et 20 (50 mL) to give (S)-2-




(S)-2-(Benzoylamido)-3-(3.5-dinitrophenyl)propanoylamidopropyl silica (98) 
0 "r_NO2 
02 N 
Benzoic acid (0.218 g, 1.80 mmol, 5 eq.) and HOBt (0.24 g, 1.80 mmol, 5 eq.) 
were dissolved in DCMIDMF (8:2, 10 mL). After gentle shaking of the resulting 
mixture for 10 mm, DIC (350 j.tL, 1.80 mmol, 5 eq.) was added. After a further 10 
min shaking, the reaction was charged with (S)-2-Amino-3-(3,5-
dinitrophenyl)propanoylamidopropyl silica (97). (0.8 g, 0.36 mmol, 1 eq.) and the 
reaction was heated to reflux (50°C) for 6h. After cooling the beads were filtered 
and washed with DMF (2 x 20 mL), DCM (2 x 20 mL) and Et20 (2 x 20 mL), 
followed by drying under high vacuum. A negative TNBS test indicated complete 
coupling giving (S)-2-(Benzoylamido)-3 -(3,5 -dinitrophenyl)propanoylamidopropyl 
silica (98). 
7.6.2 	Solid-phase loading from Elemental analysis 
CSP Formula C/%  H/% N/% C* H* N* Average * 
Silica- 
94 
C19H17N6010 8.79 0.84 2.94 0.39 0.49 0.35 0.41 
Silica- 
96 
C28H24N9015 11.29 1.12 3.74 0.34 0.47 0.30 0.37 
Silica- 
98 
C19H19N406 10.51 0.94 2.09 0.46 0.49 0.37 0.44 
* = loading / mmolg 1 
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